WO2023224464A1

WO2023224464A1 - Insect fat for use in the treatment or prophylaxis of intestinal inflammation

Info

Publication number: WO2023224464A1
Application number: PCT/NL2022/050268
Authority: WO
Inventors: Aman PAUL
Original assignee: Protix B.V.
Priority date: 2022-05-19
Filing date: 2022-05-19
Publication date: 2023-11-23

Abstract

The invention is in the field of health promoting or health restoring capabilities of insect fat. The invention relates to an insect composition for use as a medicament, and for use in a method for the prophylaxis or treatment of (intestinal) inflammation in a subject. The composition comprises lauric acid. Furthermore, the invention relates to a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, comprising the insect fat composition. The invention also relates to the use of the insect fat composition in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product. In addition, the invention relates to animal feed supplement, ingredient or product or use of the insect fat composition in the preparation of an animal feed supplement, ingredient or product. Finally, the invention relates to a (non-)therapeutic method of prophylaxis, maintaining or treatment of (intestinal) inflammation in a subject. Preferably, the insect is larvae of black soldier fly (BSF).

Description

INSECT FAT FOR USE IN THE TREATMENT OR PROPHYLAXIS OF INTESTINAL INFLAMMATION TECHNICAL FIELD The invention is in the field of health promoting or health restoring capabilities of insect fat. The invention relates to an insect composition for use as a medicament, and for use in a method for the prophylaxis or treatment of intestinal inflammation in a subject. The composition comprises lauric acid. Furthermore, the invention relates to a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, comprising the insect fat composition. The invention also relates to the use of the insect fat composition in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product. In addition, the invention relates to animal feed supplement, ingredient or product or use of the insect fat composition in the preparation of an animal feed supplement, ingredient or product. Finally, the invention relates to a (non-)therapeutic method of prophylaxis, maintaining or treatment of intestinal inflammation in a subject. Preferably, the insect is larvae of black soldier fly (BSF). BACKGROUND Inflammatory intestinal disease is a group of acute and/or chronic inflammatory conditions of the colon and small intestine. Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, and chronic enteropathy are among the most prevalent inflammatory intestinal diseases seen in humans and (companion) animals, such as dogs. They typically present with any of the following symptoms: abdominal pain, diarrhoea, rectal bleeding, severe internal cramps/muscle spasms in the region of the pelvis, weight loss and anaemia These diseases have a rather complex aetiology, generally believed to involve a combination of host genetics, intestinal microenvironment, environmental components and the immune system. The intestine is the primary organ for food digestion, absorption and metabolism, which also acts as essential physical and immunological barrier. Its physiological functions include nutrient absorption, pathogen sensing and intestinal homeostasis. Its integrity is based on a fine coordination of cell events: proliferation, migration, differentiation, and apoptosis. It has been established, both in humans and in animal models, that in various acute and chronic intestinal pathologies the mechanisms responsible for cell turnover are mainly subverted, leading to different degrees of mucosal barrier damage and to clinical manifestations of GI disease. Reactive oxygen species (‘ROS’) have been implicated in the pathogenesis of a variety of acute and chronic inflammatory intestinal diseases. The (chronically) inflamed intestine is subjected to substantial oxidative stress. ROS, under normal conditions, are protective for the body, but their excessive production is harmful for the tissue. Under oxidative stress conditions, glutathione and glutathione disulphide redox status affect the growth cycle of intestinal epithelial cells. Abnormal proliferation, growth stagnation, differentiation and apoptosis cause intestinal damage to cells and injury of gut barrier. In active ulcerative colitis, numerous polymorphonuclear cells (neutrophils) are present, along with macrophages, in the colonic mucosa. Macrophages and neutrophils infiltrating the intestine can produce reactive oxygen species, which leads to more severe oxidative stress and inflammation. This is the reason for the positive feedback of macrophages and the main reason for the difficulty in alleviating intestinal inflammation. Increases in ROS, due to neutrophil- or monocyte-derived oxidants such as superoxide, hydrogen peroxide, hydroxyl radicals, and hypochlorite, because an administration of radical scavengers (oxypurinol), antioxidant enzymes (superoxide dismutase, catalase), and enzyme inhibitors (sodium azide) decreased ROS-related chemiluminescence, can directly cause reversible and irreversible damage to any oxidizable biomolecule. Consequently, they have been implicated in cell or tissue damage of practically every disease, including acute and chronic enteropathies. For instance, elevated levels of ROS have been detected in humans affected by inflammatory bowel disease (IBD) and ulcerative colitis (UC), as well as in murine models with acute and chronic colitis. Oxidative markers have also been investigated in veterinary medicine by analysing faecal samples, both in healthy hunting dogs during exercise and in dogs with IBD, suggesting different degrees of oxidative stress. Mucosal damage caused by high levels of ROS may also play a key role in the pathogenesis of acute and chronic enteropathies in dogs. To maintain ROS balance, the human body is equipped with a basic antioxidant defence system against ROS imbalance, which consists of endogenous enzymatic antioxidants and endogenous non- enzymatic antioxidants. The endogenous enzymatic antioxidants, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), etc. Endogenous non-enzymatic antioxidants include glutathione, thioredoxin (Trx), and irisin. The features of patients with UC are a depletion of endogenous oxidant defence substances and glutathione (GSH) as well as the regulatory, suppressive T cells. As exogenous antioxidants, essential nutrients and nutritional supplements play an important role in antioxidant system. As most of them cannot be synthesized by human body, they need to be taken from foods. Essential nutrients consist of proteins, fats, vitamins and minerals. Over the years there have been reports of promising dietary approaches for the treat inflammatory intestinal diseases, e.g. based on antioxidant supplementation, but few strategies with proven efficacy have eventually emerged. Pharmacological interventions so far have neither shown real promise, due to low efficacy and/or because of side effects. Especially with a view to long-term or chronic treatments and/or with a view to the treatment of animals, such as horses and/or pets, it would be highly desirable to provide therapeutic strategies based on dietary components or nutrients that can help restore and/or maintain oxidative balance and reduce and suppress inflammation, while being amenable for long-term administration, without giving rise to (concerns about) side effects. SUMMARY The inventors have demonstrated the ability of black soldier fly (BSF), preferably BSF larvae, fat compositions to protect (animal) cells against the neutrophil mediated oxidative damage. Without wishing to be bound by any theory, it appears that due to the ability of the BSF fat compositions comprising BSF medium size fatty acids to alter cell-signalling pathways and/or to alter (dis)order dynamics in plasma membranes, such fat compositions are of use in prophylaxis or treatment of (intestinal) inflammation, therewith for the treatment or prevention of inflammatory intestinal diseases. In addition, the inventors demonstrated the ability of BSF fat compositions to inhibit macrophage activation and/or prevent macrophage activation, and/or prevent or inhibit macrophage-induced intestinal damage; inhibit and/or prevent reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; and inhibit activated innate and/or adaptive immune system of the subject or prevent activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes. Without wishing to be bound by any theory, it is proposed that due to these activities of the BSF fat compositions, innate and/or adaptive immunity of the subject to whom the composition is (orally) administered, is maintained, restored or improved. Therewith, diseases and health problems relating to intestinal inflammation, such as those diseases and health problems caused by or relating to (over)activated intestinal immune system, are prevented or treated upon administering the BSF fat composition to a subject such as a human subject or an animal. A first aspect of the invention relates to an insect fat composition for use as a medicament. A second aspect of the invention relates to an insect fat composition for use in a method for the prophylaxis or treatment of inflammation in a human or animal subject. A third aspect of the invention relates to a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, comprising the insect fat composition according to the invention. A fourth aspect of the invention relates to use of the insect fat composition according to the invention in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product. A fifth aspect of the invention relates to use of the insect fat composition according to the invention in the manufacture of a product selected from a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, for use as a medicament. A sixth aspect of the invention relates to use of the insect fat composition according to the invention in the manufacture of a product selected from a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, for use in a method for the prophylaxis or treatment of inflammation in a human or animal subject. A seventh aspect of the invention relates to a therapeutic or non-therapeutic method for the prophylaxis or treatment of inflammation in a human or animal subject, the method comprising orally administering to the human or animal subject, the insect fat composition according to the invention or the human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product according to the invention. In preferred embodiments, the insect fat composition comprises 10wt% - 60wt% saturated fatty acids comprising a chain with 6-12 carbon atoms (medium-chain fatty acids) based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, preferably 15wt% - 57wt%, more preferably 20wt% - 55wt%, such as 25wt% - 53wt%, 30wt% - 50wt% and 35wt% - 47wt% saturated fatty acids comprising a chain with 6-12 carbon atoms, wherein preferably the saturated fatty acids comprised by the insect fat composition are selected from caproic acid, caprylic acid, capric acid and lauric acid, more preferably selected from capric acid and lauric acid, most preferably the saturated fatty acids are lauric acid. The insect fat composition comprises free fatty acids and/or mono-, di- and/or tri- glycerides, preferably comprises mono-, di- and/or tri-glycerides, more preferably tri-glycerides. In preferred embodiments, the insect fat composition, comprises at least 0,2% insect fat based on the total weight of the insect fat composition, preferably at least 1%, at least 2%, at least 3%, at least 5%, at least 10%, at least 20%, at least 30% or at least 35%, and/or wherein the composition comprises at most 99,9% insect fat based on the total weight of the insect fat composition, preferably at most 99%, at most 97%, at most 92%, at most 80%, at most 70%, at most 60%, or at most 55%. In embodiments of the invention, the insect fat composition comprises glucosamine and/or glucosamine-sulphate. Preferred are insect fat compositions, wherein the insect is black soldier fly, preferably black soldier fly larvae. In a preferred embodiment the insect fat composition is any one of: (a) a pharmaceutical composition, optionally comprising a pharmaceutically acceptable diluent and/or a pharmaceutically acceptable excipient; (b) a food product for human consumption or a feed product for animal consumption; (c) a food ingredient or a feed ingredient; (d) a food supplement or a feed supplement; or (e) a nutraceutical or nutraceutical ingredient. In preferred embodiments of the invention, the methods for the prophylaxis or treatment according to the invention, comprise oral administration of the insect fat composition or the product comprising the insect fat composition. In preferred embodiments of the invention, the animal subject to be treated is any one or more of a pet, for example a cat or a dog, or such as livestock for example a cow or a horse or a goat or a sheep, or monogastric livestock such as a pig, preferably a dog or a cat, more preferably a dog. In preferred embodiments of the invention, the human subject to be treated is any one or more of: a human subject such as a human patient, preferably a healthy human subject or a human patient suffering from any one or more of the diseases or health problems as outlined here-above before. In preferred embodiments, the prophylaxis or treatment of inflammation in the subject is any one or more of: (a) inhibiting macrophage activation and/or preventing macrophage activation, and/or preventing or inhibiting macrophage-induced intestinal damage; (b) inhibiting and/or preventing reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; and (c) inhibiting activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes. In preferred embodiments, the prophylaxis or treatment of inflammation is in the gastrointestinal tract of the subject, preferably in any one or more of the small intestine, bowel and colon of the subject. In embodiments of the invention, the prophylaxis or treatment of inflammation comprises any one or more of: (a) prophylaxis or treatment of intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) prophylaxis or treatment of chronic or acute inflammatory intestinal disease; (c) prophylaxis or treatment of chronic enteropathy, and/or alleviation of one or more symptoms thereof; (d) prophylaxis or treatment of inflammatory bowel disease, and/or alleviation of one or more symptoms thereof; (e) prophylaxis or treatment of ulcerative colitis, and/or alleviation of one or more symptoms thereof; (f) prophylaxis or treatment of any one or more of Crohn’s disease, and/or alleviation of one or more symptoms thereof; (g) prophylaxis or treatment of any one or more of irritable bowel syndrome, and/or alleviation of one or more symptoms thereof; (h) prophylaxis or treatment of chronic or acute enteritis, and/or alleviation of one or more symptoms thereof; (i) prophylaxis or treatment of intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and (j) prophylaxis or treatment of low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon; (k) restoration, maintenance or improvement of the adaptive immune system of the subject; and/or (i) restoration, maintenance or improvement of the innate immune system of the subject, therewith restoring, maintaining or improving any one or more of the intestinal immunity, the intestinal homeostasis and the intestinal tolerance against food-related antigens, of the subject. The present invention will be described with respect to particular embodiments but the invention is not limited thereto but only by the claims. The embodiments of the invention described herein can operate in combination and cooperation, unless specified otherwise. DEFINITIONS The term “insects” as used herein refers to insects in any development stage, such as adult insects, insect larvae, insect prepupae and pupae. The term “fresh insects” as used herein has its conventional meaning and refers to living insects or insects that have been killed shortly before being provided in step a) of the method of the invention, such as killed within 1 minute – 3 hours before being subjected to step a). Fresh insects for example differ from stored insects that have been killed at a certain moment and stored at for example room temperature, 0 ^C - 8 ^C or at a temperature below 0 ^C for over 3 hours such as for days to weeks to months to years, before such stored insects are processed. Typically, fresh insects are living black soldier fly larvae. The term “hatching” as used herein has its conventional meaning and refers to the process of young larvae emerging from the egg. The term “larvae” as used herein has its conventional meaning and refers to the juvenile stadium of holometabolous insects, such as black soldier flies larvae. The term “hatchling” or “neonate” as used herein has its conventional meaning and refers to larvae that have just hatched from the eggs. The term “prepupae” as used herein refers to the last larval stage wherein the chitin content of the larvae has increased significantly. The term “pupae” as used herein has its conventional meaning and refers to the stage of the insects life wherein the metamorphosis from larva to adult insect, such as black soldier flies The term “pulp” or “insect pulp” or “puree” or “larvae puree” or “insect puree” as used herein all have the same meaning and refers to the product obtained after mechanical size reduction of the insects to a size of less than 0.5 mm. The term “nutrient stream” as used herein has its conventional meaning and refers to streams that contain nutrients, such as fats, protein and protein-derived material, carbohydrates, minerals and/or chitin. Within the context of the present invention, chitin is also considered a nutrient. Within the context of the present invention, the insect puree or insect pulp obtained with the method of the invention is also considered a nutrient. The term “anti-oxidant activity” has its regular scientific meaning and here refers to a compound or a composition, such as the puree and the hydrolysed puree of the invention and obtainable with the method of the invention, that consists of or comprises an antioxidant with antioxidant activity, such as an anti-inflammatory response. Typically, such an anti-inflammatory response is a response to the inflammatory response induced by for example reactive oxygen species, e.g. in the cells of a mammal such as a pet or a human subject, or in the cells of a fish. Reference is made to for example book chapters 1, 5 and 6 of “Antioxidants in Food: Practical Applications” (Jan Pokorny, Nedyalka Yanishlieva and Michael Gordon (editors), 2001, Cambridge: CRC Press, Woodhead Publishing Ltd. ISBN 185573 463 X, CRC Press, ISBN 0-8493-1221-1). An anti-oxidant is a compound with anti-oxidant activity or a composition with anti-oxidant activity or a composition comprising a compound with anti-oxidant activity, such as activity against the oxidative damage resulting from host immune response. An anti-oxidant for example inhibits oxidation. Oxidation, e.g. reactive oxygen species, in a subject for example induces cellular (oxidative) damage. The term “health promoting”, such as in ‘health promoting food’, ‘health promoting activity’, ‘health promoting property’, and ‘health promoting potential’, has its regular scientific meaning and here refers to the effect of a compound or a composition, such as the hydrolysed puree or the puree of the invention or obtainable with the method of the invention, on the health of an animal such as a mammal such as a pet animal or a human subject, when such compound or composition is consumed by the animal. Consumption of the compound or composition with health promoting potential contributes to or supports or promotes or increases or maintains the health status of the animal such as a mammal such as a pet animal or a human subject. Reference is made to for example book chapters 1, 5 and 6 of “Antioxidants in Food: Practical Applications” (Jan Pokorny, Nedyalka Yanishlieva and Michael Gordon (editors), 2001, Cambridge: CRC Press, Woodhead Publishing Ltd. ISBN 185573463 X, CRC Press, ISBN 0- 8493-1221-1). The term “medium chain fatty acid”, or “MCFA”, has its general scientific meaning and here refers to aliphatic fatty acids with a saturated hydrocarbon chain of 6-12 carbon atoms in length. These include the naturally occurring MCFA caproic acid, caprylic acid, capric acid and lauric acid. The term refers to both the free fatty acid form and the fatty acids when part of a glyceride (mono-glyceride, di-glyceride, tri-glyceride), unless specified otherwise. Thus, a phrase such as ‘insect fat composition comprising saturated fatty acids comprising a chain with 6-12 carbon atoms (medium-chain fatty acids) based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition’, refers to the fat composition comprising the MCFA as free fatty acids and/or as glycerides, unless specified otherwise. With the term “drying” or “dried” in the context of the invention, it is meant that the product obtained upon the drying and the dried product have a moisture content that is 20% or less based on the total weight of the product obtained upon the drying or the dried product, preferably 15% or less, more preferably 10% or less, most preferably 5% or less, such as 0,5% - 20%, 1% - 18%, 2% - 16%, 3% - 14%, 4% - 12% or 6% - 8%. Typically, the product that is dried, e.g. the insect pulp, the aqueous protein fraction, the combination of the solid containing fraction and the aqueous protein fraction, has a moisture content before drying of at least 20% based on the total weight of the product before drying, such as at least 25%, at least 30%, at least 40% or at least 45%. The terms first, second, third and the like in the description and in the claims, are used for distinguishing between similar elements and not necessarily for describing a sequential or chronological order. The terms are interchangeable under appropriate circumstances. The embodiments of the invention can operate in other sequences than described or illustrated herein, unless specified otherwise. The embodiments of the invention described herein can operate in combination and cooperation, unless specified otherwise. Furthermore, the various embodiments, although referred to as “preferred” or “e.g.” or “for example” or “in particular” are to be construed as exemplary manners in which the invention may be implemented rather than as limiting the scope of the invention. The term “comprising”, used in the claims, should not be interpreted as being restricted to the elements or steps listed thereafter; it does not exclude other elements or steps. It needs to be interpreted as specifying the presence of the stated features, integers, steps or components as referred to, but does not preclude the presence or addition of one or more other features, integers, steps or components, or groups thereof. Thus, the scope of the expression “a composition comprising A and B” should not be limited to a composition consisting only of components A and B, rather with respect to the present invention, the only enumerated components of the composition are A and B, and further the claim should be interpreted as including equivalents of those components. Similarly, the scope of the expression “a method comprising step A and step B” should not be limited to a method consisting only of steps A and B, rather with respect to the present invention, the only enumerated steps of the method are A and B, and further the claim should be interpreted as including equivalents of those steps. In addition, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that more than one of the element are present, unless the context clearly requires that there is one and only one of the elements. The indefinite article "a" or "an" thus usually means "at least one". BRIEF DESCRIPTION OF THE DRAWINGS The present invention will be discussed in more detail below, with reference to the attached drawings, in which Figure 1A: Free amino-acid content in BSF larvae puree and in BSF larvae puree that was subjected to 0.1 wt% or 0.5 wt% peptidase based on the total weight of the puree. Figure 1B: Pepsin digestibility of BSF larvae puree and of BSF larvae puree that was subjected to 0.1 wt% or 0.5 wt% peptidase based on the total weight of the puree. Figure 1C: Content of lipids (fat) in protein meal isolated from BSF larvae puree and from BSF larvae puree that was subjected to 0.1 wt% or 0.5 wt% peptidase based on the total weight of the puree. Figure 2: DPPH radical scavenging activity of BSF PureeX^TM (BSF-P; puree of BSF larvae), BSF hydrolyzed puree (BSF-HP), Chicken meal (CM) and Fish meal (FM) after 30 min incubation (n=3). Figure 3: DPPH radical scavenging activity of BSF PureeX^TM (BSF-P), BSF hydrolyzed puree (BSF-HP), Chicken meal (CM) and Fish meal (FM) after 60 min incubation (n=3). Figure 4: ABTS cation radical scavenging activity of BSF PureeX^TM (BSF-P), BSF hydrolyzed puree (BSF-HP), Chiken meal (CM) and Fish meal (FM) after 30 min incubation (n=3). Figure 5: MPO response modulation activity of BSF PureeX^TM (BSF-P), BSF hydrolyzed puree (BSF-HP), Chicken meal (CM) and Fish meal (FM) using SIEFED assay (n=3). Figure 6: MPO response modulation activity of BSF PureeX^TM (BSF-P), BSF hydrolyzed puree (BSF-HP), Chicken meal (CM) and Fish meal (FM) using classical measurement (n=3). Figure 7: Neutrophil response modulation activity of BSF PureeX^TM (BSF-P), BSF hydrolyzed puree (BSF-HP), Chicken meal (CM) and Fish meal (FM) (n=3). Figure 8: ABTS radical scavenging activity of WSEP performed in methanol. Results are mean ± SD of three independent assays in triplicate. Figure 9. (FIG.9) displays a production flow chart for producing protein hydrolysate from an aqueous water-soluble protein composition derived from black solider fly larvae. Figure 10. Glucosamine content of P (pasteurized minced meat (puree) of BSF larvae), HP (hydrolyzed and pasteurized minced meat of BSF), APH (hydrolysate of water-soluble BSF proteins), CM (chicken meal). Results expressed as mean ± standard deviation (n = 3). Letter ‘a’ above the bars represent significant differences (p < 0.05). Figure 11. Percentage cellular toxicity of P (water-soluble extract of pasteurized minced meat of BSF), HP (water-soluble extract of hydrolyzed and pasteurized minced meat of BSF), APH (hydrolysate of water-soluble BSF proteins), CM (water-soluble extract of chicken meal). Results expressed as mean ± standard deviation (n = 3). Letter a-d above the bars represent significant differences (p < 0.05). Figure 12. Reduction in ROS production from macrophages by P (water-soluble extract of pasteurized minced meat of BSF), HP (water-soluble extract of hydrolyzed and pasteurized minced meat of BSF), APH (hydrolysate of water-soluble BSF proteins), CM (water-soluble extract of chicken meal). Results expressed as mean ± standard deviation (n = 3). Letter a-c above the bars represent significant differences (p < 0.05). Figure 13. Reduction in ROS production from PMA activated HL-60 cells by P (water-soluble extract of pasteurized minced meat of BSF), HP (water-soluble extract of hydrolyzed and pasteurized minced meat of BSF), APH (hydrolysate of water-soluble BSF proteins), CM (water-soluble extract of chicken meal). Results expressed as mean ± standard deviation (n = 3). Letter a or b above the bars represent significant differences (p < 0.05). Figure 14. Cellular toxicity of P (water-soluble extract of pasteurized minced meat of BSF), HP (water-soluble extract of hydrolyzed and pasteurized minced meat of BSF), APH (hydrolysate of water- soluble BSF proteins), CM (water-soluble extract of chicken meal). Results expressed as mean ± standard deviation (n = 3). Figure 15. shows the melting temperature of triglycerides, diglycerides and monoglycerides from different fatty acids (glycerides containing same fatty acids). DETAILED DESCRIPTION It is a first goal of the present invention to provide an improved composition, and/or improved method, for the prophylaxis or treatment of inflammation in a subject, in particular in the gastrointestinal tract of the subject, preferably in any one or more of the small intestine, bowel and colon of the subject.. It is a second goal of the present invention to provide an improved compound or composition or food or feed ingredient or product or food or feed supplement or pharmaceutical composition, for administration to a mammal suffering from or at risk of developing an inflammatory condition or disease, in particular an inflammatory condition or disease of the the gastrointestinal tract, preferably in any one or more of the small intestine, bowel and colon. It is an objective of the current invention to provide a prophylactic composition and/or a composition for treating a disease or health problem, such as inflammation, in particular an inflammatory condition or disease of the the gastrointestinal tract, preferably in any one or more of the small intestine, bowel and colon. Maintaining or restoring intestinal homeostasis is a further objective of the current invention. It is a further objective of the current invention to provide an improved compound or composition or food or feed ingredient or product or food or feed supplement or pharmaceutical composition, for convenient intake, preferably suitable for oral administration, and/or which addresses, reverses, inhibits, silences, etc., at least one and preferably more than one of the factors involved, causing and contributing to the multifactorial disease, i.e. inflammatory intestinal disease. At least one of the above objectives is achieved by providing an black soldier fly (BSF) fat composition of the invention, e.g. an insect fat composition comprising a relatively high content of medium size fatty acid(s) (saturated chains of 6, 8, 10 and/or 12 hydrocarbons), such as 25 – 50wt% lauric acid based on the total weight of the fatty acids comprised by the insect fat in the insect fat composition. The present invention will be described with respect to particular embodiments but the invention is not limited thereto but only by the claims. The embodiments of the invention described herein can operate in combination and cooperation, unless specified otherwise. Inflammatory intestinal disease is a group of acute and/or chronic inflammatory conditions of the colon and small intestine. Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, and chronic enteropathy are among the most prevalent inflammatory intestinal diseases seen in humans and (companion) animals, such as dogs. They typically present with any of the following symptoms: abdominal pain, diarrhea, rectal bleeding, severe internal cramps/muscle spasms in the region of the pelvis, weight loss and anemia These diseases have a rather complex aetiology, generally believed to involve a combination of host genetics, intestinal microenvironment, environmental components and the immune system. The intestine is the primary organ for food digestion, absorption and metabolism, which also acts as essential physical and immunological barriers. Its physiological functions include nutrient absorption, pathogen sensing and intestinal homeostasis. Its integrity is based on a fine coordination of cell events: proliferation, migration, differentiation, and apoptosis. It has been established, both in humans and in animal models, that in various acute and chronic intestinal pathologies the mechanisms responsible of cell turnover are mainly subverted, leading to different degrees of mucosal barrier damage and to clinical manifestations of GI disease. A healthy GI tract is thought to be in a constant state of “controlled” inflammation as a result of the proximity of a dense population of bacteria in the GI lumen, dietary antigens, and toxins. The intestine of (mammalian) subjects display constant up- regulated expression of pro-inflammatory cytokines, infiltration of immune cells, and organization of lymphoid follicles and Peyer’s patches. Herewith, GI immune system activation associated with a “normal” commensal microbiota has significant effects on intestinal morphology and the ability to digest and absorb nutrients. When overt intestinal infections occur, inflammatory responses are amplified, and intestinal morphology and function are further impaired. Thus, the innate immune system and the adaptive immune system, and therewith a certain degree of constant state of intestinal inflammation, are constantly activated to a certain degree to control and conquer exposures to non-self antigens. Reactive oxygen species (‘ROS’) have been implicated in the pathogenesis of a variety of acute and chronic inflammatory intestinal diseases. The chronically inflamed intestine is subjected to substantial oxidative stress. ROS under normal conditions are protective for the body, but their excessive production is harmful for the tissue. Under oxidative stress conditions, glutathione and glutathione disulfide redox status affect the growth cycle of intestinal epithelial cells. Abnormal proliferation, growth stagnation, differentiation and apoptosis cause intestinal damage to cells and injury of gut barrier. In active ulcerative colitis, numerous polymorphonuclear cells (neutrophils) are present, along with macrophages, in the colonic mucosa. Macrophages and neutrophils infiltrating the intestine can produce reactive oxygen species, which leads to more severe oxidative stress and inflammation. This is the reason for the positive feedback of macrophages and the main reason for the difficulty in alleviating intestinal inflammation. Increases in ROS, due to neutrophil- or monocyte-derived oxidants such as superoxide, hydrogen peroxide, hydroxyl radicals, and hypochlorite, because an administration of radical scavengers (oxypurinol), antioxidant enzymes (superoxide dismutase, catalase), and enzyme inhibitors (sodium azide) decreased ROS-related chemiluminescence, can directly cause reversible and irreversible damage to any oxidizable biomolecule. Consequently, they have been implicated in cell or tissue damage of practically every disease, including acute and chronic enteropathies. For instance, elevated levels of ROS have been detected in humans affected by inflammatory bowel disease (IBD) and ulcerative colitis (UC), as well as in murine models with acute and chronic colitis. Oxidative markers have also been investigated in veterinary medicine by analyzing fecal samples, both in healthy hunting dogs during exercise and in dogs with IBD, suggesting different degrees of oxidative stress. Mucosal damage caused by high levels of ROS may also play a key role in the pathogenesis of acute and chronic enteropathies in dogs. To maintain ROS balance, the human body is equipped with a basic antioxidant defense system against ROS imbalance, which consists of endogenous enzymatic antioxidants and endogenous non- enzymatic antioxidants. The endogenous enzymatic antioxidants, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), etc. Endogenous non-enzymatic antioxidants include glutathione, thioredoxin (Trx), and irisin. The features of patients with UC are a depletion of endogenous oxidant defense substances and glutathione (GSH) as well as the regulatory, suppressive T cells. As exogenous antioxidants, essential nutrients and nutritional supplements play an important role in antioxidant system. As most of them cannot be synthesized by human body, they need to be taken from foods. Essential nutrients consist of proteins, fats, vitamins and minerals. Over the years there have been reports of promising dietary approaches for the treat inflammatory intestinal diseases, e.g. based on antioxidant supplementation, but few strategies with proven efficacy have eventually emerged. Pharmacological interventions so far have neither shown real promise, due to low efficacy and/or because of side effects. Especially with a view to long-term or chronic treatments and/or with a view to the treatment of animals, such as horses, monogastric livestock such as pigs, and/or pets such as cats and dogs, it would be highly desirable to provide therapeutic strategies based on dietary components or nutrients that can help restore and/or maintain oxidative balance and reduce and suppress inflammation, while being amenable for long-term administration without giving rise to (concerns about) side effects. A first aspect of the invention relates to an insect fat composition for use as a medicament. To the knowledge of the inventors, this is the first time that an insect fat composition such as a fat composition derived from minced BSF larvae such as a water-insoluble fraction and/or enzymatically hydrolysed fraction, is applied for conquering at least one and preferably several aspects of an inflammatory disease, here amongst others onset and progression of inflammatory intestinal disease, e.g. due to (increased) activation of the immune system, i.e. the innate immune system and/or the adaptive immune system in the intestine. The insect fat composition, such as BSF larvae fat composition, e.g. derived from minced and pasteurized (heated) BSF larvae, is suitable for preventing and/or reversing or inhibiting causes and consequences of inflammatory intestinal disease, e.g. relating to activated intestinal immune system, being it either the innate intestinal immune system or the adaptive intestinal immune system, or both. That is to say, administering the fat composition to a healthy subject suffering from or at risk of developing inflammatory intestinal disease, e.g. a human subject, an animal such as a pet or a horse, pig, cow, sheep, goat, preferably a dog, inhibits pathways such as cellular pathways contributing to ROS formation, innate immune system activation, cell lysis, macrophage activation, therewith treating or preventing intestinal inflammation, tissue damage, etc. A second aspect of the invention relates to an insect fat composition for use in a method for the prophylaxis or treatment of inflammation in a subject, in particular of an inflammatory condition or disease affecting the gastrointestinal tract of the subject, preferably one or more of the small intestine, bowel and colon of the subject . The inventors established that the BSF larvae fat composition inhibits macrophage activation, inhibits ROS formation and reduces the extent of activated of intestinal immune system activation, e.g. by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes. Herewith, administering the insect fat composition to an otherwise healthy subject or to a human subject or animal suffering from an inflammatory disease or condition, e.g. relating to increased intestinal immune system activation (expressed for example by an intestinal inflammation related disorder as hereunder detailed), results in prophylaxis of (over)activation of the innate and/or adaptive intestinal immune system or results in silencing or lowering the extent of the (over)activation of the innate and/or adaptive immune response of the subject. That is to say, silencing, lowering, inhibiting and decreasing extent of activation of the immune system is part of the invention, by administering a suitable amount of the insect fat composition to the subject in need thereof, e.g. a subject at risk for activation of intestinal immunity to a too large extent or a subject suffering from a disease or health problem relating to inflammation (in the intestine) due to activated innate and/or adaptive intestinal immune system. An embodiment is the insect fat composition for use according to the invention, comprising 10wt% - 60wt% saturated fatty acids comprising a chain with 6-12 carbon atoms (medium-chain fatty acids) based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, preferably 15wt% - 57wt%, more preferably 20wt% - 55wt%, such as 25wt% - 53wt%, 30wt% - 50wt% and 35wt% - 47wt% saturated fatty acids comprising a chain with 6-12 carbon atoms, and wherein preferably the saturated fatty acids comprised by the insect fat composition are selected from caproic acid, caprylic acid, capric acid and lauric acid, more preferably selected from capric acid and lauric acid, most preferably the saturated fatty acids are lauric acid. The inventors established that insect fat compositions comprising at least 10wt% MCFA based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, in particular capric acid and lauric acid, more in particular lauric acid, reduce the extent of macrophage activation, decrease ROS production by macrophages and EC and inhibit the activated innate and/or adaptive immune system of the subject or prevents activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes. An embodiment is the insect fat composition for use according to the invention, wherein the intestinal immunity, intestinal homeostasis and/or intestinal tolerance against food-related antigens is restored, maintained or improved in the gastrointestinal tract, preferably in any one or more of the small intestine, bowel and colon. As said, the GI is harboring the largest immune system of a human or animal body. Developed and equipped to protect and restore the GI and the body from microbial invasion, e.g. though intake of the diet, and exposure to (foreign, self) antigens such as food-born antigens and microbes (e.g. pathogens such as viruses, bacteria). Activation of the intestinal immune system to an extent harmful to the subject, for example immune activation resulting in or accompanied by (excessive) inflammation such as inflammation of the intestine, is effectively reduced or lowered by inactivation of macrophages, reduction of ROS production by macrophages and endothelial cells and/or by inhibiting the activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, under influence of (dietary) intake (administration) of insect fat composition, comprising the MCFA, by the subject. Homeostasis can be restored upon exposure of the intestinal immune system to the insect fat composition, after administering the insect fat composition to the subject, e.g. by providing a diet comprising the insect fat composition, e.g. comprising 30-50wt% lauric acid based on the total weight of the fatty acids comprised by the insect fat composition. BSF larvae fat is a suitable source of such insect fat comprised by the insect fat composition. Such BSF larvae fat comprises triglycerides comprising such an amount of the MCFA, in particular lauric acid. Oral uptake of the insect fat composition results in exposure of the intestinal immune system, e.g. macrophages, monocytes as part of the innate intestinal immune system, to the MCFA, and therewith the silencing or lowering of the extent of immune activation, suitable for reducing or halting the inflammatory response relating to for example intestinal inflammation. An embodiment is the insect fat composition for use according to the invention, wherein the adaptive immune system of the subject is restored, maintained or improved, and/or the innate immune system of the subject is restored, maintained or improved, therewith restoring, maintaining or improving any one or more of the intestinal immunity, the intestinal homeostasis and the intestinal tolerance against food-related antigens, of the subject. The inventors established that the insect fat composition, such as a composition comprising BSF larvae fat (about 35-45wt% lauric acid based on the total weight of the fatty acids in the insect fat, for example), reduces activation of several aspects of the innate immune system, including reduction of macrophage activation, reduction of the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, reduction of ROS production by macrophages. These activities of the insect fat composition on the intestinal immune system are beneficial in restoration, maintenance or improvement of intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food-related antigens, of the subject. The subject being a human subject such as a healthy human subject or a human subject suffering from an intestinal inflammation related disorder (BD, Crohn’s disease, etc., as described elsewhere in the description), or the subject being an animal such as an animal suffering from intestinal inflammation due to (excessive) intestinal immune system activation. An embodiment is the insect fat composition for use according to the invention, wherein the restoration, maintenance and improvement of any one or more of the intestinal immunity, the intestinal homeostasis and the intestinal tolerance against food-related antigens, of the subject, is any one or more of: (a) inhibiting macrophage activation and/or preventing macrophage activation, and/or preventing or inhibiting macrophage-induced intestinal damage; (b) inhibiting and/or preventing reactive oxygen species formation by a cell such as an endothelial cell (EC) or a macrophage; and (c) inhibiting activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes. Under influence of administered insect fat composition, the intestinal immunity, the intestinal homeostasis and/or the intestinal tolerance against food-related antigens, of the subject, is improved, maintained or restored to a level of intestinal immune system activation beneficial to the subject. Activation of the intestinal immune system to an extent resulting in e.g. intestinal inflammation relating disorders and diseases, is reduced to a level of activation that is not cumbersome (anymore) to the subject, accompanied by a level of intestinal inflammation that is not (anymore) hampering e.g. well-being, growth, daily activities, etc. of the subject. Administering the insect fat composition to the subject for days to weeks, or longer, or months to years, such as for 7 days to several years such as the rest of the lifespan of the subject, results in prophylaxis and treatment of disease or health problems related to activation of the (innate) immune system by exposure to e.g. food antigens or microbes, by maintaining, increasing or decreasing the level of intestinal immune system activation to an extent not accompanied (anymore) by intestinal inflammation at a level harmful to the subject. That is to say, administering the insect fat composition for example for weeks to years, prevents the subject from, or treats the subject suffering from any one or more of intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; chronic or acute inflammatory intestinal disease; chronic enteropathy, and/or alleviation of one or more symptoms thereof; inflammatory bowel disease, and/or alleviation of one or more symptoms thereof; chronic enteropathy, and/or alleviation of one or more symptoms thereof; inflammatory bowel disease, and/or alleviation of one or more symptoms thereof; ulcerative colitis, and/or alleviation of one or more symptoms thereof; Crohn’s disease, and/or alleviation of one or more symptoms thereof; irritable bowel syndrome, and/or alleviation of one or more symptoms thereof; chronic or acute enteritis, and/or alleviation of one or more symptoms thereof; intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon. An embodiment is the insect fat composition for use according to the invention, wherein the prophylaxis or treatment of inflammation comprises any one or more of:: (a) prophylaxis or treatment of intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) prophylaxis or treatment of chronic or acute inflammatory intestinal disease; (c) prophylaxis or treatment of chronic enteropathy, and/or alleviation of one or more symptoms thereof; (d) prophylaxis or treatment of inflammatory bowel disease, and/or alleviation of one or more symptoms thereof; (e) prophylaxis or treatment of ulcerative colitis, and/or alleviation of one or more symptoms thereof; (f) prophylaxis or treatment of any one or more of Crohn’s disease, and/or alleviation of one or more symptoms thereof; (g) prophylaxis or treatment of any one or more of irritable bowel syndrome, and/or alleviation of one or more symptoms thereof; (h) prophylaxis or treatment of chronic or acute enteritis, and/or alleviation of one or more symptoms thereof; (i) prophylaxis or treatment of intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; (j) prophylaxis or treatment of low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon; (k) restoration, maintenance or improvement of the adaptive immune system of the subject; and/or (l) restoration, maintenance or improvement of the innate immune system of the subject, therewith restoring, maintaining or improving any one or more of the intestinal immunity, the intestinal homeostasis and the intestinal tolerance against food-related antigens, of the subject. An embodiment is the insect fat composition for use according to the invention, wherein the composition comprises at least 0,2% insect fat based on the total weight of the insect fat composition, preferably at least 1%, at least 2%, at least 3%, at least 5%, at least 10%, at least 20%, at least 30% or at least 35%, and/or wherein the composition comprises at most 99,9% insect fat based on the total weight of the insect fat composition, preferably at most 99%, at most 97%, at most 92%, at most 80%, at most 70%, at most 60%, or at most 55%. Preferably, the insect fat composition comprises BSF larvae fat. Such BSF larvae fat comprises at least 10wt%, typically at least 30wt%, MCFA, in particular lauric acid, based on the total weight of the fatty acids comprised by the BSF larvae fat. Since BSF larvae comprise lauric acid in such a high relative extent, already 0,2% insect fat in the insect fat composition can be sufficient and efficacious in arriving at the prophylactic or treatment effects obtainable with administering the insect fat composition, when maintaining or restoring or lowering activity of the intestinal immune system is considered, preferably the innate intestinal immune system. The inventors established for example that insect fat compositions comprising 0,3wt% BSF larvae fat or about 13wt% BSF larvae fat based on the total weight of the insect fat composition, exerts beneficial effects on e.g. reducing macrophage activation, reducing ROS production by e.g. macrophages, lowering the relative or absolute number of phagocytic monocytes. An embodiment is the insect fat composition for use according to the invention, wherein the composition comprises insect protein, wherein preferably the mass ratio between the insect fat and the insect protein in the composition is selected from 1:200 to 500:1, such as selected from 1:100 to 200:1, or from 1:10 to 10:1, or from 1:3 to 3:1, or from 1:2 to 2:1, or wherein the insect fat composition is essentially free from insect protein, defined as less than 0,2% insect protein based on the total weight of the insect fat composition. For example, the ratio between insect fat such as BSF larvae fat, and insect protein, such as BSF larvae protein, in an insect fat composition, is about 1,2 : 1 or 1 : 1,2, or about 1 : 1. For example, BSF larvae puree (minced and heated BSF larvae) comprises about 42wt% BSF larvae protein and about 37wt% BSF larvae fat based on the total dry weight of the BSF larvae fat composition (puree). Such BSF larvae puree is a typical example of an insect fat composition for use in the prophylaxis or treatment of (intestinal) inflammation, including the diseases and health problems as here-above outlined. An embodiment is the insect fat composition for use according to the invention, wherein at least part of the insect fat is hydrolysed fat, preferably enzymatically hydrolysed fat, such as at least 50%, 60%, 70%, 80%, 90% or 95% hydrolysed fat. Without wishing to be bound by any theory, the relatively high content of lauric acid in the MCFA fraction of BSF larvae fat, is at the basis of the beneficial effects seen on reducing extent of or silencing of or maintaining of the intestinal immunity. Administering the insect fat composition, preferably an insect fat composition comprising the BSF larvae fat, to a subject results in the beneficial effects on activation of the (innate) immune system. The MCFA, preferably lauric acid, are provided and administered as mono-, di-, and tri-glycerides, and/or are administered wholly or in part, preferably in part, as free fatty acids. After enzymatic hydrolysis, the content of free lauric acid in the insect fat comprised by the insect fat composition is for example 0,5-40% based on the total weight of the fatty acids comprised by the insect fat, preferably 1-35%, such as about 2%, 5%, 8%, 10%, 15%, 20%, 25% or 30%. MCFA provided as free fatty acids or provided as glycerides are readily passively absorbed in the GI. Therefore, application and administration of the MCFA comprised by the insect fat, preferably BSF larvae fat, comprised by the insect fat composition, can equally established by applying composition comprising free fatty acids, glycerides or mixtures of free fatty acids and glycerides, wherein preferably the MCFA is lauric acid or a mixture of lauric acid and capric acid. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat comprises 10wt% - 60wt% lauric acid based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, preferably 15wt% - 57wt%, more preferably 20wt% - 55wt%, such as 25wt% - 53wt%, 30wt% - 50wt% and 35wt% - 47wt% lauric acid. In addition, the insect fat composition comprises insect fat, preferably BSF larvae fat, comprising 0,05 – 4wt% capric acid based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition. The BSF larvae fat comprises MCFA, predominantly lauric acid, and in addition to a lesser extent (0-3%) capric acid. Therefore, BSF larvae fat is a suitable source of fat for the insect fat composition for use according to the invention. An example is an insect fat composition comprising 5-50% BSF larvae fat based on the total dry weight of the insect fat composition, wherein for example the insect fat comprises 25 – 45wt% lauric acid and 0 – 3wt% capric acid based on the total weight of the fatty acids in the BSF larvae fat comprised by such an insect fat composition. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition comprises glucosamine and/or glucosamine-sulphate. Optionally, the insect fat composition, e.g. insect fat composition derived from black soldier fly larvae or insect fat composition comprising BSF larvae fat, comprises glucosamine. Glucosamine and chondroitin are important components of intestinal mucin, acting as a barrier between gut flora and the intestinal wall, potentially affecting gut permeability and intestinal immune mediation. Chitin, a large hydrophobic homo-polymer of β-(1-4)-linked N-acetyl-D-glucosamine, of the BSF larvae is the dominant source of glucosamine in the BSF larvae fat composition. If present in the insect fat composition, the amount of glucosamine is typically 0,05 – 5 wt% glucosamine based on the dry weight of the insect fat composition, preferably 0,1 – 2,5 wt%, more preferably 0,2 – 1,25 wt%, such as 0,25 – 1,0 wt%. An aspect of the invention relates to use of the insect fat composition according to the invention in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product. Optionally, the insect fat composition, e.g. insect fat composition derived from black soldier fly larvae or insect fat composition comprising BSF larvae fat, comprises glucosamine. If present in the insect fat composition, the amount of glucosamine is typically 0,05 –5 wt% glucosamine based on the dry weight of the insect fat composition, preferably 0,1 – 2,5 wt%, more preferably 0,2 – 1,25 wt%, such as 0,25 – 1,0 wt%. An embodiment is the insect fat composition for use according to the invention, wherein the insect is black soldier fly, preferably black soldier fly larvae. The inventors established that the larvae of the BSF are a source of MCFA as part of the BSF larvae fat derivable from minced and heated larvae. All of minced and heated BSF larvae (puree), BSF larvae protein fraction and BSF larvae fat fraction, the latter two obtainable from the puree, are suitable insect fats for incorporation in the insect fat composition as constituent of the composition, or such puree, insect protein or insect fat are itself the insect fat composition for use according to the invention. BSF puree and BSF protein can comprise 0,5- 50% BSF larvae fat based on the total weight of the puree or protein fraction, or based on the total dry weight of the BSF puree of BSF larvae protein fraction, whereas BSF larvae fat fraction can comprise up to 99,8wt% fat based on the total weight of the BSF larvae fat fraction derived from BSF larvae puree. BSF larvae fat is rich in MCFA, especially lauric acid (glycerides such as tri-glycerides containing the lauric acid moieties). That is to say, BSF larvae fat contains up to 50% lauric acid based on the total weight of the fatty acids comprised by the fat. This makes the BSF larvae fat a suitable source of fat for the insect fat composition for use in the method for the restoration, maintenance or improvement of intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food-related antigens, of the subject. The inventors indeed established the macrophage activation lowering effect, reduction of ROS production by macrophages and endothelial cells, etc., as outlined here above and in the Examples section, with insect fat compositions comprising BSF larvae fat. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition comprises or consists of minced and heated insects, preferably minced and heated black soldier fly, more preferably minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises or consists of enzymatically hydrolyzed minced and heated insects, preferably enzymatically hydrolyzed minced and heated black soldier fly, more preferably enzymatically hydrolyzed minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises enzymatically hydrolyzed insect protein, preferably enzymatically hydrolyzed protein of black soldier fly, more preferably enzymatically hydrolyzed protein of larvae of black soldier fly. Such minced and heated BSF larvae, also referred to as BSF larvae puree, is an insect fat composition according to the invention and an insect fat composition for use according to the invention. Such puree of BSF larvae comprises BSF larvae fat and BSF larvae protein, in a ratio selected from the range 2:1 – 1:2, such as about 30-40wt% fat and 35-50% protein based on the dry weight of the puree. The puree for example comprises 15-30% fat and protein based on the total weight of the puree (65-82% moisture). The fat fraction of the BSF larvae fat (comprising at least 90% fat, such as at least 95%, at least 97%, at least 99%, at least 99,5%, based on the total weight of the fat fraction) and the BSF larvae protein, which are both insect fat compositions of the invention, as well as a constituent comprised by certain insect fat compositions, comprise at least 10% such as at least 20% or at least 30% or at least 35%, and less than 60%, such as less than 55% or less than 52%, MCFA, preferably capric acid and lauric acid, more preferably lauric acid, based on the total weight of the fatty acids comprised by the insect fat comprised by the insect fat composition. Here the insect is only BSF, or in separate embodiments, the insect comprises BSF larvae. That is to say, the insect fat composition may comprise insect fat originating from BSF, preferably BSF larvae, and in addition, or solely, may comprise insect fat originating (also) from another insect species (mealworm, house fly, cricket, grasshopper, etc.). Preferred is an insect fat composition comprising BSF larvae puree, comprising 5 – 15% BSF larvae fat based on the total weight of the puree. Such an insect fat composition comprises 1-100% of such puree, based on the total weight of the insect fat composition. Examples are 2-90% puree, 3-80% puree, 4-70% puree, 5-60% puree, 7- 50% puree, 10-45% puree, 15%-40% puree, 20-35% puree, based on the total weight of the insect fat composition. In embodiments, the BSF larvae fat in the puree is (enzymatically) hydrolysed fat, comprising free fatty acids, mono-, di- and tri-glycerides, or any combination thereof. For example, all triglycerides are hydrolyzed, or 5-50% of the fat is present as triglycerides, and/or the free fatty acid content is 2-40%, based on the total weight of the fatty acids comprised by the fat in the puree. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition comprises or consists of: (a) the water-soluble extract of minced and heated insects, preferably the water-soluble extract of minced and heated black soldier fly, more preferably the water-soluble extract of minced and heated larvae of black soldier fly; or (b) the water-soluble extract of enzymatically hydrolyzed minced and heated insects, preferably the water-soluble extract of enzymatically hydrolyzed minced and heated black soldier fly, more preferably the water-soluble extract of enzymatically hydrolyzed minced and heated larvae of black soldier fly; or (c) the enzymatically hydrolyzed water-soluble extract of minced and heated insects, preferably the enzymatically hydrolyzed water-soluble extract of minced and heated black soldier fly, more preferably the enzymatically hydrolyzed water-soluble extract of minced and heated larvae of black soldier fly. The enzymatical hydrolyzation is the hydrolyzation of the protein fraction of such minced and heated BSF or insects. In contrast to fat (lipid) enzymatic hydrolyzation, providing free fatty acids, mono- and di-glycerides. Protein hydrolyzation provides free amino-acid residues and short-peptide chain peptides, comprising of for example 2-10 amino-acid residues. Such insect fat composition comprises (or consists of) 5-100%, or 10-99,5%, or 20-60% of such extract (a), (b) and/or (c) as here-above outlined. Extraction of the water-soluble fraction, before or following protein hydrolyzation by enzymatic protein hydrolyzation (according to established procedures known to the skilled person, applying established protein hydrolysing enzymes known in the art (also see the Examples section for examples)), results in a decreased insect fat content in the water fraction comprising the water-soluble part of the minced and heated insect, preferably BSF larvae, compared to minced and heated insect, preferably minced and heated BSF larvae, i.e. puree. The fat content of such fraction (a), (b) or (c), as defined here above, comprises 5% or less, such as 4% or less, 3% or less, 2% or less, 1% or less, or 0,5% or less, insect fat, preferably BSF larvae fat, based on the total weight of the dry matter of such fraction (a), (b), or (c). The content of MCFA, preferably lauric acid, is 10-55%, such as 30-50%, based on the total weight of the fatty acids comprised by the fat comprised by such fraction (a), (b) or (c). An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition comprises or consists of a fat fraction obtained from minced and heated insects, preferably minced and heated black soldier fly, more preferably minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises or consists of a fat fraction obtained from enzymatically hydrolyzed minced and heated insects, preferably enzymatically hydrolyzed minced and heated black soldier fly, more preferably enzymatically hydrolyzed minced and heated larvae of black soldier fly. Such a fat fraction obtained from minced and heated insect, preferably BSF larvae, is a preferred insect fat composition and is a preferred constituent of an insect fat composition, and is a preferred constituent of the insect fat composition for use in a method according to the invention, or is a preferred insect fat composition for use in a method according to the invention. The fat fraction, preferably the BSF larvae fat, for example comprises at least 90%, such as at least 95%, at least 97%, at least 98%, at least 99%, at least 99,5%, at least 99,7%, at least 99.8%, or at least 99,9% fat (lipids) based on the total weight of the fat fraction. Such fat comprises 10wt% - 60wt% saturated fatty acids comprising a chain with 6-12 carbon atoms (medium-chain fatty acids) based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, preferably 15wt% - 57wt%, more preferably 20wt% - 55wt%, such as 25wt% - 53wt%, 30wt% - 50wt% and 35wt% - 47wt% saturated fatty acids comprising a chain with 6-12 carbon atoms, and wherein preferably the saturated fatty acids comprised by the insect fat composition are selected from caproic acid, caprylic acid, capric acid and lauric acid, more preferably selected from capric acid and lauric acid, most preferably the saturated fatty acids are lauric acid. It is preferred that the MCFA are naturally occurring MCFA (C6, C8, C10 and C12 comprising MCFA). Typically, the MCFA is present as a mixture of mono-, di- and triglycerides and free fatty acids. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition is any one of: (a) a pharmaceutical composition, optionally comprising a pharmaceutically acceptable diluent and/or a pharmaceutically acceptable excipient; (b) a food product for human consumption or a feed product for animal consumption; (c) a food ingredient or a feed ingredient; (d) a food supplement or a feed supplement; or (e) a nutraceutical or nutraceutical ingredient. An aspect of the present invention features a pharmaceutical composition comprising a BSF larvae fat composition according to the invention and a physiologically acceptable carrier. A "pharmacological composition" refers to a composition in a form suitable for administration into a mammal, preferably a human, a horse, a pet such as a dog or a cat, preferably a human subject or a dog. Preferably, the pharmaceutical composition contains a sufficient amount of the insect fat composition according to the invention in a proper pharmaceutical form to exert a therapeutic effect on a human or on an animal such as a horse, pet, such as a dog or a cat, preferably a dog. Considerations concerning forms suitable for administration are known in the art and include toxic effects, solubility, route of administration, and maintaining activity. For example, pharmacological compositions injected into the blood stream should be soluble. However, preferred is the oral route of administration. For example, the pharmaceutical composition is provided as a powder, tablet, capsule. Suitable dosage forms, in part depend upon the use or the route of entry, for example oral, transdermal or by injection. Such dosage forms should allow a pharmaceutically active compound to reach a target cell whether the target cell is present in a multicellular host or in a culture. Factors are known in the art, and include considerations such as toxicity and dosage form which retard the compound or composition from exerting its effect. The food product for human consumption or the feed product for animal consumption or the food ingredient or the feed ingredient or the food supplement or the feed supplement or the nutraceutical or nutraceutical ingredient comprises for example 1-45% insect fat such as BSF larvae fat, preferably BSF larvae fat. Such products and ingredients preferably comprises further constituents such as any one or more of vitamins, minerals, a buffering salt, a filler, a matrix, water, carbohydrates, a source of protein (e.g. of vegetable and/or animal origin), a further source of fat such as vegetable and/or animal fat. In addition, such products and ingredients may comprise any one or more of an emulsifier, a preservative, a flavor. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition is comprised by any one of: (a) a pharmaceutical composition, optionally comprising a pharmaceutically acceptable diluent and/or a pharmaceutically acceptable excipient; (b) a food product for human consumption or a feed product for animal consumption; (c) a food ingredient or a feed ingredient; (d) a food supplement or a feed supplement; or (e) a nutraceutical or nutraceutical ingredient. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition is orally administered to the subject. Although MCFA comprised by the insect fat composition are readily absorbed by the cells and organs of the body of a subject to whom the insect fat composition is administered for example via e.g. the nasal route, via inhalation, transdermal administration, rectal administration, or otherwise, oral administration of the insect fat composition to a subject is preferred. Via oral administration, for example as a daily part of the diet of the subject or as (part of) a pharmaceutical composition, the insect fat composition is most efficiently delivered at the site of the body of the subject where health-stabilizing, health-promoting, homeostasis, or disease and disorder conquering effects are desired: the GI for e.g. the treatment of (over-)activated innate and/or adaptive intestinal immune system, maintaining the beneficial state of the intestinal immune system, such as a state of transiently activated intestinal immune system. That is to say, via oral administration, e.g. as part of a food or feed product or a pharmaceutical composition, the insect fat, for example the MCFA comprised by the insect fat, are directly contacted with the parts of the GI where restoration, maintenance or improvement of intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food-related antigens, of the subject, is desired. The subject being a healthy human subject or healthy animal, or the subject being an ill subject in need of for example treatment of activated intestinal immune system resulting in devastating symptoms, such as intestinal inflammation and/or any one or more of the diseases or health problems (c) – (l) as here-under detailed. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition is administered to a mammal, such as a human subject, a monogastric animal and/or livestock. The insect fat composition is beneficial for restoration, maintenance or improvement of intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food-related antigens, of the subject, the subject preferably being a (healthy or ill) human subject or an (healthy or ill) animal, wherein ‘ill’ here refers to a subject suffering from any one or more of the diseases or health problems (a) – (l) as here-under detailed. The insect fat composition is suitable for prophylaxis of the desired state of the intestinal immune system and is suitable for restoring the desired state of the intestinal immune system. In the mammal, such as a human subject, a monogastric animal such as a pet such as a cat or a dog and/or livestock such as a pig, cow, horse, goat, sheep, either the innate intestinal immune system, or the adaptive immune system, or both systems, are maintained, restored, strengthened, therewith restoring, maintaining or improving intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food-related antigens, of the subject. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition is administered to a human subject such as a human patient, preferably a healthy human subject or a human patient suffering from any one or more of the diseases or health problems: (a) intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) chronic or acute inflammatory intestinal disease; (c) chronic enteropathy; (d) inflammatory bowel disease; (e) ulcerative colitis; (f) Crohn’s disease; (g) irritable bowel syndrome; (h) chronic or acute enteritis; (i) intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and/or (j) low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition is administered to an animal, such as a pet, for example a cat or a dog, or such as livestock for example a cow or a horse or a goat or a sheep, or monogastric livestock such as a pig, preferably a dog or a cat, more preferably a dog, and wherein the animal optionally is suffering from any one or more of the diseases or health problems: (a) intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) chronic or acute inflammatory intestinal disease; (c) chronic enteropathy; (d) inflammatory bowel disease; (e) ulcerative colitis; (f) Crohn’s disease; (g) irritable bowel syndrome; (h) chronic or acute enteritis; (i) intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and/or (j) low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition has one, two or three of the following activities: (a) inhibiting macrophage activation and/or preventing macrophage activation, and/or preventing or inhibiting macrophage-induced intestinal damage; (b) inhibiting and/or preventing reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; and (c) inhibiting activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, and/or wherein the insect fat composition comprises glucosamine and/or glucosamine-sulphate. An embodiment is the insect fat composition for use according to the invention, wherein the insect fat composition inhibits and/or prevents macrophage activation and/or prevents or inhibits macrophage-induced intestinal damage; prevents and/or inhibits reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; inhibits activated innate and/or adaptive immune system of the subject or prevents activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, and wherein the insect fat composition comprises glucosamine. Optionally, the insect fat composition, e.g. fat composition derived from black soldier fly larvae or insect fat composition comprising BSF larvae fat, comprises glucosamine. Glucosamine and chondroitin are important components of intestinal mucin, acting as a barrier between gut flora and the intestinal wall, potentially affecting gut permeability and intestinal immune mediation. Chitin, a large hydrophobic homo-polymer of β-(1-4)-linked N-acetyl-D- glucosamine, of the BSF larvae is the dominant source of glucosamine in the BSF fat composition. If present in the insect fat composition, the amount of glucosamine is typically 0,05 – 5 wt% glucosamine based on the dry weight of the insect fat composition, preferably 0,1 – 2,5 wt%, more preferably 0,2 – 1,25 wt%, such as 0,25 – 1,0 wt%. An aspect of the invention relates to use of the insect fat composition according to the invention in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product. Optionally, the insect fat composition, e.g. fat composition derived from black soldier fly larvae, comprises glucosamine. If present in the insect fat composition, the amount of glucosamine is typically 0,05 –5 wt% glucosamine based on the dry weight of the insect fat composition, preferably 0,1 – 2,5 wt%, more preferably 0,2 – 1,25 wt%, such as 0,25 – 1,0 wt%. A third aspect of the invention relates to a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, comprising the insect fat composition according to the invention. Preferably, the insect is BSF larvae. Preferably, the composition comprises at least 30wt% lauric acid based on the total weight of the fatty acids comprised by the insect fat in the insect fat composition. For example, the lauric acid content is 30-60%, or 35-45%, based on the total weight of the fatty acids comprised by the insect fat in the insect fat composition. Such contents of the MCFA is sufficient and enough for achieving the restoration, maintenance or improvement of intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food-related antigens, of the subject. For example, the restoration, maintenance or improvement of intestinal immunity and/or intestinal homeostasis and/or intestinal tolerance against food-related antigens, of the subject is at least in part achieved by the (a) inhibition of macrophage activation and/or prevention of macrophage activation, and/or prevention or inhibition of macrophage-induced intestinal damage under influence of the insect fat comprised by the insect fat composition, more in particular, the MCFA, preferably the lauric acid, comprised by the insect fat in the insect fat composition, preferably comprising or consisting of BSF larvae fat; (b) inhibition and/or prevention of reactive oxygen species formation by a cell such as an endothelial cell or a macrophage, under influence of the insect fat comprised by the insect fat composition, more in particular, the MCFA, preferably the lauric acid, comprised by the insect fat in the insect fat composition, preferably comprising or consisting of BSF larvae fat; and (c) inhibition of activated innate and/or adaptive immune system of the subject or prevention of activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, under influence of the insect fat comprised by the insect fat composition, more in particular, the MCFA, preferably the lauric acid, comprised by the insect fat in the insect fat composition, preferably comprising or consisting of BSF larvae fat. A fourth aspect of the invention relates to use of the insect fat composition according to the invention in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product. A fifth aspect of the invention relates to use of the insect fat composition according to the invention in the manufacture of a product selected from a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, for use as a medicament. A sixth aspect of the invention relates to use of the insect fat composition according to the invention in the manufacture of a product selected from a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, for use in a method for the prophylaxis or treatment of inflammation in a human or animal subject. For example, in such a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, the conventional source of fat is at least in part replaced, or wholly replaced by the insect fat, preferably BSF larvae fat, therewith providing the insect fat composition of the invention and the insect fat composition for use according to the invention. Fat of a different source, such as vegetable fat and/or animal fat, may be comprised by such an insect fat composition, in addition to the insect fat replacing the previously applied fat in part or completely. In preferred embodiments of the invention, the animal is any one or more of a pet, for example a cat or a dog, or such as livestock for example a cow or a horse or a goat or a sheep, or monogastric livestock such as a pig, preferably a dog or a cat, more preferably a dog. A fifth aspect of the invention relates to a therapeutic or non-therapeutic method for the prophylaxis or treatment of inflammation in a human or animal subject, the method comprising orally administering to the human or animal subject, the insect fat composition according to the invention or the human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product according to the invention. In preferred embodiments of the invention, the animal subject to be treated is any one or more of a pet, for example a cat or a dog, or such as livestock for example a cow or a horse or a goat or a sheep, or monogastric livestock such as a pig, preferably a dog or a cat, more preferably a dog. In preferred embodiments of the invention, the human subject to be treated is any one or more of: a human subject such as a human patient, preferably a healthy human subject or a human patient suffering from any one or more of the diseases or health problems as outlined here-above before. An embodiment is the method according to the invention, wherein the prophylaxis or treatment of inflammation in the subject is any one or more of: (a) inhibiting macrophage activation and/or preventing macrophage activation, and/or preventing or inhibiting macrophage-induced intestinal damage; (b) inhibiting and/or preventing reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; and (c) inhibiting activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes. In preferred embodiments, the prophylaxis or treatment of inflammation is in the gastrointestinal tract of the subject, preferably in any one or more of the small intestine, bowel and colon of the subject. In embodiments of the invention, the prophylaxis or treatment of inflammation comprises any one or more of: (a) prophylaxis or treatment of intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) prophylaxis or treatment of chronic or acute inflammatory intestinal disease; (c) prophylaxis or treatment of chronic enteropathy, and/or alleviation of one or more symptoms thereof; (d) prophylaxis or treatment of inflammatory bowel disease, and/or alleviation of one or more symptoms thereof; (e) prophylaxis or treatment of ulcerative colitis, and/or alleviation of one or more symptoms thereof; (f) prophylaxis or treatment of any one or more of Crohn’s disease, and/or alleviation of one or more symptoms thereof; (g) prophylaxis or treatment of any one or more of irritable bowel syndrome, and/or alleviation of one or more symptoms thereof; (h) prophylaxis or treatment of chronic or acute enteritis, and/or alleviation of one or more symptoms thereof; (i) prophylaxis or treatment of intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; (j) prophylaxis or treatment of low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon; (k) restoration, maintenance or improvement of the adaptive immune system of the subject; and/or (i) restoration, maintenance or improvement of the innate immune system of the subject, therewith restoring, maintaining or improving any one or more of the intestinal immunity, the intestinal homeostasis and the intestinal tolerance against food-related antigens, of the subject. In an embodiment, a method according to the invention is provided, wherein the insect fat composition comprises 10wt% - 60wt% saturated fatty acids comprising a chain with 6-12 carbon atoms (medium-chain fatty acids) based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, preferably 15wt% - 57wt%, more preferably 20wt% - 55wt%, such as 25wt% - 53wt%, 30wt% - 50wt% and 35wt% - 47wt% saturated fatty acids comprising a chain with 6-12 carbon atoms, and wherein preferably the saturated fatty acids comprised by the insect fat composition are selected from caproic acid, caprylic acid, capric acid and lauric acid, more preferably selected from capric acid and lauric acid, most preferably the saturated fatty acids are lauric acid. In an embodiment, a method according to the invention is provided, wherein the insect fat composition comprises at least 0,2% insect fat based on the total weight of the insect fat composition, preferably at least 1%, at least 2%, at least 3%, at least 5%, at least 10%, at least 20%, at least 30% or at least 35%, and/or wherein the composition comprises at most 99,9% insect fat based on the total weight of the insect fat composition, preferably at most 99%, at most 97%, at most 92%, at most 80%, at most 70%, at most 60%, or at most 55%. In an embodiment, a method according to the invention is provided, wherein at least part of the insect fat comprised by the insect fat composition is hydrolysed fat, preferably enzymatically hydrolysed fat, such as at least 50%, 60%, 70%, 80%, 90% or 95% hydrolysed fat. In an embodiment, a method according to the invention is provided, wherein the insect fat comprised by the insect fat composition comprises 10wt% - 60wt% lauric acid based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, preferably 15wt% - 57wt%, more preferably 20wt% - 55wt%, such as 25wt% - 53wt%, 30wt% - 50wt% and 35wt% - 47wt% lauric acid. In an embodiment, a method according to the invention is provided, wherein the insect fat composition comprises glucosamine and/or glucosamine-sulphate. In an embodiment, a method according to the invention is provided, wherein the insect is black soldier fly, preferably black soldier fly larvae. In an embodiment, a method according to the invention is provided, wherein the insect fat composition comprises or consists of minced and heated insects, preferably minced and heated black soldier fly, more preferably minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises or consists of enzymatically hydrolyzed minced and heated insects, preferably enzymatically hydrolyzed minced and heated black soldier fly, more preferably enzymatically hydrolyzed minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises enzymatically hydrolyzed insect protein, preferably enzymatically hydrolyzed protein of black soldier fly, more preferably enzymatically hydrolyzed protein of larvae of black soldier fly.In an embodiment, a method according to the invention is provided, wherein the insect fat composition comprises or consists of: (a) the water-soluble extract of minced and heated insects, preferably the water-soluble extract of minced and heated black soldier fly, more preferably the water-soluble extract of minced and heated larvae of black soldier fly; or (b) the water-soluble extract of enzymatically hydrolyzed minced and heated insects, preferably the water-soluble extract of enzymatically hydrolyzed minced and heated black soldier fly, more preferably the water-soluble extract of enzymatically hydrolyzed minced and heated larvae of black soldier fly; or (c) the enzymatically hydrolyzed water-soluble extract of minced and heated insects, preferably the enzymatically hydrolyzed water-soluble extract of minced and heated black soldier fly, more preferably the enzymatically hydrolyzed water-soluble extract of minced and heated larvae of black soldier fly. An embodiment is the method according to the invention, wherein the insect fat composition comprises or consists of a fat fraction obtained from minced and heated insects, preferably minced and heated black soldier fly, more preferably minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises or consists of a fat fraction obtained from enzymatically hydrolyzed minced and heated insects, preferably enzymatically hydrolyzed minced and heated black soldier fly, more preferably enzymatically hydrolyzed minced and heated larvae of black soldier fly. An embodiment is the method according to the invention, wherein the insect fat composition is any one of: (a) a pharmaceutical composition, optionally comprising a pharmaceutically acceptable diluent and/or a pharmaceutically acceptable excipient; (b) a food product for human consumption or a feed product for animal consumption; (c) a food ingredient or a feed ingredient; (d) a food supplement or a feed supplement; or (e) a nutraceutical or nutraceutical ingredient. An embodiment is the method according to the invention, wherein the insect fat composition is orally administered to the subject. An embodiment is the method according to the invention, wherein the insect fat composition is administered to a mammal, such as a human subject, a monogastric animal and/or livestock. An embodiment is the method according to the invention, wherein the insect fat composition is administered to a human subject such as a human patient, preferably a healthy human subject or a human patient suffering from any one or more of the diseases or health problems: (a) intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) chronic or acute inflammatory intestinal disease; (c) chronic enteropathy; (d) inflammatory bowel disease; (e) ulcerative colitis; (f) Crohn’s disease; (g) irritable bowel syndrome; (h) chronic or acute enteritis; (i) intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and/or (j) low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon. An embodiment is the method according to the invention, wherein the insect fat composition is administered to an animal, such as a pet, for example a cat or a dog, or such as livestock for example a cow or a horse or a goat or a sheep, or monogastric livestock such as a pig, preferably a dog or a cat, more preferably a dog, and wherein the animal optionally is suffering from any one or more of the diseases or health problems: (a) intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) chronic or acute inflammatory intestinal disease; (c) chronic enteropathy; (d) inflammatory bowel disease; (e) ulcerative colitis; (f) Crohn’s disease; (g) irritable bowel syndrome; (h) chronic or acute enteritis; (i) intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and/or (j) low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon. An embodiment is the method according to the invention, wherein the insect fat composition has one, two or three of the following activities: (a) inhibiting macrophage activation and/or preventing macrophage activation, and/or preventing or inhibiting macrophage-induced intestinal damage; (b) inhibiting and/or preventing reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; and (c) inhibiting activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, and/or wherein the insect fat composition comprises glucosamine and/or glucosamine-sulphate. An embodiment is the method according to the invention, wherein the insect fat composition inhibits and/or prevents macrophage activation and/or prevents or inhibits macrophage-induced intestinal damage; prevents and/or inhibits reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; inhibits activated innate and/or adaptive immune system of the subject or prevents activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, and wherein the insect fat composition comprises glucosamine. An aspect of the invention relates to a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, comprising the insect fat composition of the invention. Optionally, the insect fat composition, e.g. fat composition derived from black soldier fly larvae or insect fat composition comprising BSF larvae fat, comprises glucosamine. Glucosamine and chondroitin are important components of intestinal mucin, acting as a barrier between gut flora and the intestinal wall, potentially affecting gut permeability and intestinal immune mediation. Chitin, a large hydrophobic homo-polymer of β-(1-4)-linked N-acetyl-D- glucosamine, of the BSF larvae is the dominant source of glucosamine in the BSF fat composition. If present in the insect fat composition, the amount of glucosamine is typically 0,05 – 5 wt% glucosamine based on the dry weight of the insect fat composition, preferably 0,1 – 2,5 wt%, more preferably 0,2 – 1,25 wt%, such as 0,25 – 1,0 wt%. An aspect of the invention relates to use of the insect fat composition according to the invention in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product. Optionally, the insect fat composition, e.g. fat composition derived from black soldier fly larvae, comprises glucosamine. If present in the insect fat composition, the amount of glucosamine is typically 0,05 –5 wt% glucosamine based on the dry weight of the insect fat composition, preferably 0,1 – 2,5 wt%, more preferably 0,2 – 1,25 wt%, such as 0,25 – 1,0 wt%. An aspect of the present invention features a pharmaceutical composition comprising a compound according to the invention and a physiologically acceptable carrier. A "pharmacological composition" refers to a composition in a form suitable for administration into a mammal, such as a pet, for example a cat or a dog, livestock such as a cow, pig, horse, goat, sheep, a human, preferably a human or a pet, such as a patient, e.g. a human patient or ill dog. Preferably, the pharmaceutical composition contains a sufficient amount of the insect fat composition according to the invention in a proper pharmaceutical form to exert a therapeutic effect on a human or on a mammal such as a pet (dog, cat). Preferably, the pharmaceutical composition is the insect fat composition. Black soldier fly larvae (BSF; Hermetia illucens) derived fat is gaining popularity as sustainable pet food and animal feed ingredient. These ingredients are nutritious, highly digestible and promote health of consuming mammals such as animals. Currently, pet food is the biggest market for insect proteins in Europe. Globally, 50% of households own a cat or dog. These two companion animals are together responsible for 95% of the global pet food sales. Health and wellbeing of these companion animals are of prime importance to their owners. The inventors established the preventive activity of BSF larvae fat compositions and BSF fat derivatives (hydrolysate of BSF fat), isolates and extracts in various pathways of the innate and/or adaptive immune system of the intestine, involved in developing inflammation and/or arthritis and pathways leading to intestinal inflammation formation and developing health issues and diseases relating to activated intestinal immune system such as Crohn’s disease. In vitro assays were applied to establish the treating of activated intestinal immune system and prophylaxis of activated intestinal immune system with BSF larvae fat, compositions, isolates and extracts. To the best of the knowledge of the inventors, this is for the first time that the anti-inflammatory potential of insect fats such as BSF larvae fat and extracts and hydrolysates thereof has been established. Chick meal is commonly used in pet food formulations as a protein and fat source and hence was used as an industrial benchmark in the examples with BSF larvae fat and extracts and hydrolysates thereof. Surprisingly, BSF larvae fat compositions and hydrolysates are suitable for use in a method for the prophylaxis and/or treatment of inflammation. Typically, the fat is derived from BSF larvae, such as minced and pasteurized larvae. According to the invention, a suitable source of fat for use in a method for maintaining, improving, restoring intestinal innate and/or adaptive immune system, therewith preventing or treating inflammation or symptoms and health problems occurring as a consequence of inflammation, is fat derived from BSF larvae that are 5-25 days of age post hatching and/or that are 1-3 days before pre-pupation phase (instar 7). Moreover, and more specifically, the inventors demonstrate that such fat isolated from BSF larvae and hydrolysates and water-insoluble isolates or extracts thereof, are suitable for use in a method for treating and/or preventing inflammatory intestinal disease. Moreover, such compositions are effective in relief of symptoms, accompanying inflammatory intestinal disease. The inventors are now the first to establish that since insects such as in particular Black soldier fly, contain glucosamine, the presence of this glucosamine in e.g. BSF, BSF fat isolates or extracts or compositions derived therefrom or isolated therefrom, etc., provides these insects such as BSF or extracts or compositions derived therefrom or isolated therefrom, etc. with relevant bioactivity as an anti- inflammatory composition based on said presence of glucosamine. That is to say, presence of glucosamine in BSF fat compositions endows such compositions with anti-inflammatory activity. Other aspects of the invention concern the pharmaceutical composition, the food product for human consumption or the feed product for animal consumption, the food ingredient or the feed ingredient, the food supplement or the feed supplement, or the nutraceutical or nutraceutical ingredient, preferably in unit dosage form, comprising the insect fat composition, preferably comprising or consisting of BSF larvae fat; and a kit comprising a package containing a plurality of such pharmaceutical unit dosage forms, food product unit dosage forms, feed product unit dosage forms, food ingredient unit dosage forms, feed ingredient unit dosage forms, food supplement unit dosage forms, feed supplement unit dosage forms, nutraceutical unit dosage forms or nutraceutical ingredient unit dosage forms, preferably pharmaceutical unit dosage forms, as well as a leaflet containing printed instructions to repeatedly (self-)administer said unit dosage forms in order to treat and/or prevent (intestinal) inflammation in the subject such as any one or more of: (a) prophylaxis or treatment of intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) prophylaxis or treatment of chronic or acute inflammatory intestinal disease; (c) prophylaxis or treatment of chronic enteropathy, and/or alleviation of one or more symptoms thereof; (d) prophylaxis or treatment of inflammatory bowel disease, and/or alleviation of one or more symptoms thereof; (e) prophylaxis or treatment of ulcerative colitis, and/or alleviation of one or more symptoms thereof; (f) prophylaxis or treatment of Crohn’s disease, and/or alleviation of one or more symptoms thereof; (g) prophylaxis or treatment of irritable bowel syndrome, and/or alleviation of one or more symptoms thereof; (h) prophylaxis or treatment of chronic or acute enteritis, and/or alleviation of one or more symptoms thereof; (i) prophylaxis or treatment of intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and (j) prophylaxis or treatment of low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon; (k) restoration, maintenance or improvement of the adaptive immune system of the subject; (l) restoration, maintenance or improvement of the innate immune system of the subject, therewith restoring, maintaining or improving any one or more of intestinal immunity, intestinal homeostasis and intestinal tolerance against food-related antigens, of the subject. For example, the kit, preferably the pharmaceutical kit, comprises a package containing a plurality of unit dosage forms and a leaflet, wherein said unit dosage forms contain the insect fat composition according to the invention and wherein said leaflet contains printed instructions to repeatedly self-administer said unit dosage forms in order to accomplish any of the prophylactic or therapeutic objectives as defined herein, such as to treat and/or prevent an inflammation as defined herein. In accordance with embodiments of the invention, the (pharmaceutical) kit comprises a container, such as a cardboard box, holding one or more blister packs, said one or more blister packs containing a plurality of solid unit dosage forms, preferably a plurality of tablets. In particularly preferred embodiments of the invention, the (pharmaceutical) kit comprises at least 5, at least 8, at least 10, at least 12 or at least 15 of said unit dosage forms, e.g.4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 of said unit dosage forms. In accordance with the invention, the (pharmaceutical) kit comprises a leaflet inserted into the container, typically a patient information leaflet containing printed information, which information may include a description of the form and composition of the unit dosage forms contained in the kit, an indication of the (therapeutic) indications for which the product is intended, instructions as to how the product is to be used and information and warnings concerning adverse effects and contraindications associated with the use. It will be understood by those of average skill in the art, based on the information presented herein, that the leaflet that is part of the kit according to the invention, will typically contain the information concerning the therapeutic indications, uses, treatment regimens, etc. as described here above in relation to the methods of prophylaxis or treatment of the present invention. It will be understood that these aspects of the invention all involve the same insect fat compositions, the same methods of treatment, the same subjects, etc. unless specifically stated otherwise. Specific details and preferred embodiments of the afore-mentioned methods as well as of the insect fat compositions will become evident to those skilled in the art on the basis of the preceding detailed description and the appended experimental part. Considerations concerning forms suitable for administration are known in the art and include toxic effects, solubility, route of administration, and maintaining activity. For example, pharmacological compositions for oral administration should be tolerated in the intestine of the subject to whom a dose of the insect fat composition is orally administered. Suitable dosage forms, in part depend upon the use or the route of entry, for example oral. Such dosage forms should allow the compound or composition to reach a target cell whether the target cell is present in a multicellular host or in a culture. For example, pharmacological compounds or compositions for oral administration should be tolerated in the intestine of the subject to whom a dose of the composition is orally administered, and should reach the aimed location in the intestine. Other factors are known in the art, and include considerations such as toxicity and dosage form which retard the compound or composition from exerting its effect. The fat fraction and a protein fraction are for example obtained from for example and preferably BSF larvae according the following method comprising the steps of: a) providing insects and preparing a pulp thereof, b) heating the insect pulp for 50-100 seconds at a temperature of 60 ^C-95 ^C, c) cooling the heated insect pulp of step b), therewith providing the nutrient stream consisting of cooled heated insect pulp, wherein the method after step b) comprises step c2): c2) subjecting the heated insect pulp of step b) to a physical separation step thereby obtaining a nutrient stream consisting of the fat fraction (‘BSF larvae fat fraction’, i.e. an example of an insect fat composition, comprising 90-99,9% BSF larvae fat, based on the total weight of the BSF larvae fat fraction), an aqueous protein fraction (‘BSF larvae protein fraction’, i.e. an example of an insect fat composition comprising 5-20% BSF larvae fat based on the total weight of the fraction) and a solid- containing fraction. For example, in the method, in step b) the insect pulp is heated for 60-90 seconds at a temperature of 60 ^C-95 ^C, particularly for 75-85 seconds at a temperature of 90 ^C ± 2 ^C, or for example in the method, in step b) the insect pulp is heated at a temperature of 75 ^C-95 ^C, particularly at a temperature of 80 ^C-93 ^C, preferably 85 ^C-90 ^C. Preferred is the method wherein in step b) the insect pulp is heated for 60-95 seconds, particularly for 70-90 seconds, preferably 75-85 seconds such as 78 – 82 seconds. For example, in the method, the physical separation step comprises decanting and/or centrifugation. Herewith, the fat fraction is obtained. In the method, the insect pulp is for example not enzymatically treated prior to heating in step b), or the method further comprises a step a1) of treating the insect pulp by an enzyme prior to the step b). For example in said step a1), the pulp is treated by the enzyme for 0,5 to 3 hours, preferably 1 to 2 hours at a temperature of 40 ^C to 70 ^C, preferably at 45 ^C to 65 ^C, more preferably at a temperature of 50 ^C ± 2 ^C. For example, the enzyme is a protease such as a peptidase, preferably a mixture of at least one protease and at least one peptidase, such as Flavourzyme. The fat fraction and a protein fraction are for example obtained from for example and preferably BSF larvae according the following method comprising the steps of: (a) squashing insects thereby obtaining a pulp, (b) subjecting the pulp to enzymatic hydrolysis obtaining thereby a hydrolysed mixture, (c) heating the hydrolysed mixture to a temperature of 70-100°C and (d) subjecting the mixture to a physical separation step thereby obtaining the fat fraction (‘BSF larvae fat fraction’, i.e. an example of an insect fat composition, comprising 90-99,9% BSF larvae fat, based on the total weight of the BSF larvae fat fraction), the aqueous proteinaceous fraction (‘BSF larvae protein fraction’, i.e. an example of an insect fat composition comprising 5-20% BSF larvae fat based on the total weight of the fraction) and a solid- containing fraction. For example, the fat fraction is obtained by said method, wherein the physical separation encompasses decanting and/or centrifuging. Preferred is the insect fat composition and the insect fat composition for use in a method according to the invention and the non-medical use of the invention, wherein the insect fat is derived from BSF larvae. Other sources of insect fat comprised by the insect fat composition are house fly, morio worm, mealworm or cricket, but black soldier fly is preferred. According to the method for the provision of the insect fat composition or the insect fat comprised by the insect fat composition, the pulp is for example hydrolysed using a protease at a temperature of 35-65°C, and for example, the protease is an acidic protease and the pulp is acidified to a pH of 3-6, or for example the protease is used at a pH 6-8. Preferably, the black soldier fly larvae are between 12 and 30 days of age, preferably between 14 and 28 days, more preferably 14-26 days, most preferably 12 hours-3 days before the larvae transform into prepupae, such as 1-2 days before transformation. A suitable source of insect fat comprised by the insect fat composition is BSF larvae fat, referred to as LipidX, here-under in the Examples section. Specifications of such LipidX are provided. A suitable insect fat composition is the BSF larvae fat, referred to as LipidX. A suitable source of insect fat comprised by the insect fat composition is BSF larvae fat in a composition also comprising BSF larvae protein, referred to as ProteinX, here-under in the Examples section. Specifications of such ProteinX are provided. A suitable insect fat composition is the BSF larvae fat in the composition also comprising BSF larvae protein, referred to as ProteinX. A suitable source of insect fat comprised by the insect fat composition is puree of heated and minced BSF larvae, referred to as ‘puree’ or as PureeX, here-under in the Examples section. Specifications of such puree, here PureeX, are provided. A suitable insect fat composition is the puree of the minced and heated BSF larvae, also referred to as PureeX. While the invention has been described in terms of several embodiments, it is contemplated that alternatives, modifications, permutations and equivalents thereof will become apparent to one having ordinary skill in the art upon reading the specification and upon study of the drawings. The invention is not limited in any way to the illustrated embodiments. Changes can be made without departing from the scope which is defined by the appended claims. The invention is further illustrated by the following non-limiting examples and embodiments, which should not be interpreted as limiting the present invention in any way. EXAMPLES & EMBODIMENTS EXAMPLE 1 – fat & lipid compositions derived from Black Soldier Fly (Hermetia illucens) larvae In the following examples, lauric acid comprising compositions and oil, or fat, comprising compositions were applied. These compositions were derived from processed Black Soldier Fly (BSF; Hermetia illucens) larvae, and these compositions were prepared by Protix B.V. (Dongen, The Netherlands), according to established manufacturing procedures, as hereunder outlined and as published. Such lauric acid comprising compositions, or insect oil comprising compositions, are referred to with respective identifiers as hereunder explained in the Method sections, Tables and Figures. If the main component of a composition is the insect oil, compositions are for example referred to as ‘lipid composition’, ‘oil composition’, “LipidX”, or ‘fat composition’. If (one of the) the main component(s) of a composition is insect protein, the composition also comprising insect fat (lauryl comprising composition), such composition is for example referred to as “ProteinX”, “protein”, “hydrolysed protein”, in the examples here below. The terms “fat” and “oil” are used as synonyms throughout the description and claims and figures, including in the Examples, and the terms have their regular scientific meaning. The term “lauric acid” refers to dodecanoic acid. The term “lauric acid comprising fat composition” refers to a fat composition wherein at least part of the fat molecules is based on lauric acid fatty acid chains, i.e. (mono/di/tri-)glycerides comprising at least one laurate moiety. Throughout the specification, including the examples and the claims, the terms “lauric acid” and “laurate” can be used both, referring to either the free lauric acid (for example as obtained after enzymatic hydrolysis of insect fat), or laurate as part of the insect fat molecules, unless specified otherwise. Thus, a phrase like “lauric acid comprising fat composition” refers to fat molecules in the composition, comprising laurate bound to the glyceride, and/or refers to free fatty acid molecules derived from the insect fat, unless specified differently in an embodiment or claim. The same considerations and meanings apply for the naturally occurring medium chain fatty acids caproic acid, caprylic acid and capric acid, in addition to lauric acid. Heated and minces insects, here BSF larvae, is referred to as “pulp”, “paste” or “puree”. The puree comprises 10-20 wt%, such as 8,3wt%, 12,3 wt% and 15wt%, BSF larvae fat based on the total weight of the puree. The puree comprises 30-50wt% fat such as 40,8wt% fat or 37wt% BSF larvae fat based on the total weight of the dry matter of the puree. The fat comprises 30-50wt% laurate (lauric acid) based on the total weight of the fatty acids in the fat, such as for example 36,2wt%, 40,0wt% and 43,2wt% lauric acid. The capric acid content is for example 0,2 – 2wt%. The puree may be enzymatically hydrolysed (protein hydrolysis), as described in the Examples here below. The water soluble fraction of the puree or the hydrolysed puree may be retrieved upon adding water to the puree or hydrolysed puree. The water soluble hydrolysed protein fraction of the puree typically comprises 2,7 wt% fat based on the total weight of the dry matter of such fraction. The fat comprises 30-50wt% laurate (lauric acid) based on the total weight of the fatty acids in the fat, such as for example 36,2wt%, 40,0wt% and 43,2wt% lauric acid. The capric acid content is for example 0,2 – 2wt%. Such water soluble hydrolysed protein fraction comprises free amino-acid residues and peptides with a molecular mass of 1.000 Dalton or less. Alternatively, the water soluble fraction (mainly protein) of the puree can be retrieved, and subsequently, the soluble fraction can be subjected to enzymatic protein hydrolysis. The protein fraction (BSF larvae protein composition) derived from the puree comprises 10 – 20wt% fat, such as 15wt%, fat based on the total weight of the dry matter of the protein fraction, wherein the fat comprises 30-50wt% laurate (lauric acid) based on the total weight of the fatty acids in the fat, such as for example 36,2wt%, 40,0wt% and 43,2wt% lauric acid. The capric acid content is for example 0,2 – 2wt%. The non-water soluble BSF larvae oil (fat) fraction of the puree is for example retrieved by pouring the top layer of the puree, i.e. the oil fraction, in a separate container. The oil (or fat) can be enzymatically hydrolysed, obtaining hydrolysed fat, as described in the Examples hereunder. The fat fraction comprises 98-99,75wt% fat based on the total weight of the fat fraction, such as 99wt%, 99,75wt%. The free fatty acid content of the fat fraction is 0-4wt% such as 0%, 1,5%, 3%. The lauric acid content of the fat is 30-50wt% of the total weight of the fatty acids in the fat fraction, such as for example 36,2wt%, 40,0wt% and 43,2wt% lauric acid. The BSF larvae fat fraction is also referred to as “LipidX”. Hydrolysed fat comprises free fatty acids such as the lauric acid and capric acid. The fat as derived from the insect larvae puree comprises glycerides comprising the laurate moiety. As said, the terms lauric acid and laurate are used interchangeably, unless specified otherwise. The same for capric acid and caprate, or decanoate. The BSF larvae derived fat comprises 0,2 – 2wt% capric acid, such as for example 0,75wt% and 1,0wt%. The term “medium chain fatty acid”, or “MCFA”, has its regular scientific meaning and here refers to unsaturated fatty acids with an acyl chain length of from and including 6 to and including 12 C-atoms (6, 8, 10 or 12 C-atoms). Such MCFA encompass caproic acid (C-6), caprylic acid (C-8), capric acid (C- 10) and lauric acid (C-12). MCFA are thus defined as saturated fatty acids with C-6 to C-12 hydrocarbon chains, i.e.: CH3-CH2-CH2-CH2-CH2-COOH, CH3-CH2-CH2-CH2-CH2-CH2-CH2-COOH, CH3-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-COOH and CH3-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-COOH. Provision of the compositions comprising BSF larvae fat and comprising lauric acid is outlined in more detail here below. Example 1A Live and washed larvae (black soldier fly) of 14 days old post hatching (5 kg) were collected just before being subjected to mincing by using the mincer and stored at 4 ^C until used. For each experiment 100 g larvae were minced freshly. Hundred g of minced larvae were heated to 90°C (using a hot plate and with continuously stirring) and the product was kept at this temperature for 0, 40, 80, 120, 300, 600 and 1800 s. The insect pulp (puree) obtained was left cooling till ambient temperature (room temperature). Alternatively, the insect pulp (puree) obtained was left cooling to a temperature of 3 ^C - 7 ^C. Approximate 30 g of heated larvae were collected in 3 centrifugable tubes and centrifuged at 3200G for 5 minutes. The fat fraction (BSF larvae fat, ‘LipidX’) was extracted after centrifugation and were collected using a Pasteur pipette and weighed to calculate the % fat separation (of total puree weight on wet basis). The specifications for BSF larvae puree are: 77,7 wt% moisture, 22,3wt% dry matter, 9,3wt% crude protein, 8,3wt% crude fat, 1,8wt% crude fiber, based on the total weight of the BSF larvae puree. This relates to 37,2wt% fat and 41,7wt% protein based on the total weight of the dry matter content of the BSF larvae puree. The specifications for BSF larvae protein composition comprising 10 – 20wt% BSF larvae fat based on the total weight of the protein, are: 5 wt% moisture, 56wt% protein, 15wt% fat, 9,1wt% crude fiber, based on the total weight of the BSF larvae protein. This relates to 15,8wt% fat and 58,9wt% protein based on the total weight of the dry matter content of the BSF larvae protein. Solubility was 20,8 g/ml. pH was 7.2. The lipid content and fatty acid compositions of the BSF larvae protein was as depicted in the following Table:

The specifications for BSF larvae fat are: 99wt%% total lipid content based on the total weight of the fat fraction. 1,5wt% free fatty acids based on the total weight of the fat fraction. Density was 9,1 g/ml Melting point was 29 ^C The lipid content and fatty acid compositions of the BSF larvae fat was as depicted in the following Table:

Example 1B Raw material Similar as the procedure applied for Example 1A, live and washed larvae (black soldier fly) of 14 days old post hatching were used as starting point for the different treatments, i.e. applying the conventional method according to WO2014123420. Methods Sample generation Insect pulp was provided using the conventional method according to WO2014123420, wherein in step b) the pulp was heated for 30 minutes. Each treatment was performed in duplicates (n=4), according to the two methods. Step a) was the same as in the method of the invention, in Example 1B. Providing insect pulp according to the conventional method of WO2014123420 or according to the method of the invention Fourteen days old BSFL (black soldier fly larvae) were washed with tap water and then immediately minced using a blender (common step a) of the two compared methods). Then, samples were pasteurized using the micro-cooker for either 30 minutes at 90°C (according to the conventional method, step b); sample 1) or for 80 seconds at 90°C; sample 2). Samples were placed in the fridge (4°C), therewith providing cooled heated insect pulp. Dry matter & moisture content To determine the dry matter content, first, the moisture content was determined in accordance with EC- 152/2009. Then, dry matter was calculated by subtracting the moisture content from the initial mass of the sample. The dry matter content for both samples 1 and 2 was similar and was about 29% based on the total weight of the insect pulp after subjecting step b) of the two methods. Water holding capacity (WHC) The weight of the sample was measured at the beginning of the test. Next, all samples were further heat treated at 121°C for 80 minutes. Then, samples boxes were kept tilted at 30° angle from an horizontal reference for 2 minutes. Then, the water release from the samples was drained and the weight of the residual insect pulp product after water removal was recorded. The percentage of water loss is used as a representation of the WHC of the sample. Data analysis Average and standard deviation was performed for each of the four replications (n=4) using Microsoft Excel. Statistical analysis T-test was used to compare the different treatment according to the different parameters. The test setting used was tail = 2 and type = 3. Microsoft Excel was used to perform this analysis. P-value <0.05 were considered significantly different. RESULTS The moisture content for the insect pulp obtained with the method of the invention (sample 2) and for the insect pulp obtained with the conventional method (sample 1) was essentially the same: 71,7% and 70,6%, respectively, with standard deviations of 0,7% and 1,6%, respectively, based on the total weight of the insect pulp. For the insect pulp obtained by pasteurization for 80 seconds at 90°C, the water holding capacity (WHC) expressed as the water weight loss after heat treatment, compared with the product before heat treatment for assessing WHC, was about 40% lower than the WHC of insect pulp obtained by subjecting the pulp of step a) to a heating at 90 ^C for 30 minutes according to the method of WO2014123420. The WHC expressed as the water weight loss after heat treatment, of the insect pulp obtained with the method involving the shorter pasteurization is about 11%, whereas the WHC of the insect pulp obtained with the method comprising longer pasteurization, is about 18%. That is to say, the weight of the insect pulp obtained with the method comprising the shorter pasteurizations, was about 89% after heat treatment at 121 ^C for 80 minutes, compared to the weight of the insect pulp before the start of the heating. In contrast, the weight of the insect pulp obtained with the method comprising 30 minutes pasteurization, decreased to about 82% after heat treatment at 121 ^C for 80 minutes, compared to the weight of the insect pulp before the start of the heating. Thus, the WHC of the insect pulp obtained with the method comprising 80 seconds pasteurization improved with 7%. Example 2 A puree of BSF larvae, also referred to as BSF PureeX^TM (BSF-P), and hydrolyzed puree (BSF-HP) obtained by enzymatic hydrolysis of the puree of BSF larvae, were prepared by Protix B.V. (Dongen, The Netherlands) in October 2019. The puree and the enzymatically digested puree were obtained according to the following method. Live and washed Black Soldier Fly larvae of 14 days old (after hatching) were collected just before being subjected to the mincer for mincing the larvae (therewith providing larvae pulp (also referred to as puree)), and subsequently stored at 4 ^C until used. For each experiment, larvae were minced freshly. The minced larvae was treated with 0.1% or 0.5% Flavourzyme, based on the mass of the minced larvae, for 0,5 – 3 hours, for example 1 to 2 hours, at 45 ^C to 65 ^C (± 2 ^C) under continuous stirring. The batch of hydrolysed BSF larvae puree applied in Example 2 was obtained by enzymatic hydrolysis for 1 hr at 50 ^C (± 2 ^C). Flavourzyme (Novozymes, Denmark) is a combination of aminopeptidases which have endopeptidase and exopeptidase activities. The enzyme- treated minced larvae, and control larvae without enzyme treatment, were heated to 90°C and the product was kept at this temperature for 80 seconds. The obtained insect puree were used for measuring free amino acid content (Figure 1A: Free amino acid content (n=1) Tested in puree) and pepsin digestibility (Figure 1B: Digestibility (n=1)- Tested in puree). Protein meal was obtained from the heated BSF larvae pulp, and from the two batches of heated BSF larvae pulp that was first subjected to enzymatic hydrolysis of proteins using either 0.1 wt%, or 0.5 wt% Flavourzyme prior to the heating step at 90 ^C, e.g. by steps of protein separation from the pulp, evaporation, drying and grinding. The percentage of fat separation was measured during the separation step (Figure 1C: % fat separation (n=3)- Tested during separation step to make protein meal). In all experiments performed, a dose dependent effect was observed, when the amount of applied enzyme is considered. Thus, enzymatic treatment of minced larvae using Flavourzyme prior to the heating step increases the free amino acid content and increases pepsin digestibility of the obtained hydrolysed larvae puree, and as a result, the obtained puree comprising hydrolysed protein has a better taste (free amino-acid content relates to attractive, appealable taste when animals and humans consume a product comprising free amino- acids), is highly digestible and has anti-oxidant properties (see test results, here below). In addition, enzymatic treatment of BSF larvae pulp improves the fat separation in the following separation step after enzymatic hydrolysis and heat-treatment of the enzymatically digested pulp, which increases the fat extraction from the protein meal, when compared to fat separation from the protein fraction obtained with larvae puree that was not subjected to an enzymatic hydrolysis step prior to heating at 90 ^C. The fat content and the content of MCFA and the content of lauric acid in the puree and in the hydrolysed puree are detailed in Example 1. Example 3 2. Materials and Methods 2.1. Reagents All the reagents were of analytical grade. Dimethylsulfoxide, methanol, ethanol, calcium chloride, potassium chloride, sodium chloride, hydrogen peroxide and Tween-20 were purchased from Merck (VWR, Leuven, Belgium). Sodium nitrite, bovine serum albumin, phorbol 12-myristate 13-acetate and Percoll^TM were purchased from Sigma (Bornem, Belgium). Aqueous extracts and solutions were made in Milli-Q water obtained using Milli-Q water system (Millipore, Bedford, USA). Bicinchoninic acid and copper (II) sulfate solutions were purchased from Sigma (Steinheim, Germany). Whatman filter paper grade 4 (270 mm) was purchased from Amersham (Buckinghamshire, UK). Sterlip 30 ml disposable vacuum filter system was purchased from Millipore (Bedford, USA).2,2-Diphenyl-1-picrylhydrazyl and 2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) were purchased from Aldrich (Darmstadt, Germany). 8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4(2H,3H)dione (L-012) was purchased from Wako Chemicals (Neuss, Germany). 2.2. Raw materials Chicken meal (CM) and fish meal (FM) were purchased from an online webshop in September 2019. The chemical composition of both ingredients as declared by the supplier is indicated in table 2. Table 2. Chemical composition of chicken meal and fish meal (as in basis, provided by supplier).

BSF-P and hydrolyzed puree BSF-HP were prepared by Protix B.V. (Dongen, The Netherlands) in October 2019. (1). BSF-P was pasteurized BSF minced ‘meat’ (puree, pulp) supplied frozen at -20 ^C. BSF-P is also the raw material to produce BSF protein meal (ProteinX^TM). (2). BSF-HP was hydrolyzed and pasteurized BSF meat (puree) also supplied frozen at -20 ^C. (3). The chemical composition of the two ingredients BSF-P and BSF-HP were as is indicated in table 3. Table 3. Chemical composition of BSF protein derivatives heated puree and heated hydrolysed puree (as in basis, provided by supplier).

1BSF-P: BSF PureeX^TM; ²BSF-HP: BSF hydrolyzed puree; ^aMean values based on the range established at Protix. Water soluble extracts were prepared for CM, FM, BSF-P and BSF-HP. These products (100 g each) were dissolved with six times volumes of Milli-Q water based on their respective dry matter contents (e.g. BSF-P had dry matter content of 33.3% and was diluted 200 ml Milli-Q water) and stirred for 2 h on a magnetic stirrer. Post centrifugation (1000 x g for 30 min at 4 ^C), the top fat layer was removed and the supernatant was filtered using Whatman Filter (grade 4). The centrifugation and filtration step was repeated again to remove all non-soluble residues. Finally the supernatant was filtered using a Sterlip Filter (50 mL, 0.22 µm) and freeze dried over a period of two days to obtain respective water soluble extract powders. All four water soluble extract were stored in a desiccator (at 18 ^C) until further use. 2.3. Protein quantification Total protein content of the four water soluble extracts was analysed using Bicinchoninic acid (BCA) protein assay [5]. The calibration curve was obtained using bovine serum albumin (BSA) as standard at concentrations: 0, 0.125, 0.25, 0.5 and 1 mg/ml. Stock solutions of 3 mg/ml water soluble extracts were used for analysis. A test solution was made by dissolving 4900 µl BCA (49/50) and 100 µl copper (II) sulfate (1/50). Sample stock solutions (10 µl) and test solution (200 µl) were added in wells of 96-well plate. This plate was incubated at 37 ˚C for 30 min and absorbance was measured at 450 nm using a Multiscan Ascent (Fisher Scientific, Asse, Belgium). 2.4. DPPH assay DPPH radical scavenging activity was analysed according to protocol of Brand-Willams et al. [6], with some modifications. DPPH test solution was made by dissolving 10.5 mg DPPH in 40 ml ethanol. Test solution was made fresh and stored in dark until further use. DPPH working solution was made by diluting test solution with 10 times ethanol (to obtain absorbance of 0.6 to 0.8 at 517 nm). DPPH working solution (1920 µl) was mixed with 20 µl of samples dilutions (four water soluble extracts in Milli-Q water) to obtain final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml. The decrease in absorbance after 30 and 60 min of incubation in dark was recorded at 510 nm using HP 8453 UV-vis spectrophotometer (Agilent Technologies, Waldbronn, Germany). Instead of sample dilutions only Milli- Q water was used in case of control. 2.5. ABTS assay ABTS cation radical scavenging activity was analysed according to protocol of Arnao et al. [7], with some modifications. ABTS test solution was made by dissolving 7.0 mmol/l ABTS and 2.45 mmol/l potassium persulfate in Milli-Q water. The test solution was kept overnight in dark at room temperature. ABTS working solution was made by diluting with methanol to obtain the absorbance between 0.7 and 0.8 at 734 nm. ABTS working solution (1920 µl) was mixed with 20 µl of samples dilutions (four water soluble extracts in Milli-Q water) to obtain final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml. The decrease in absorbance after 30 min of incubation in dark was recorded at 734 nm using HP 8453 UV-vis spectrophotometer (Agilent Technologies, Waldbronn, Germany). Instead of sample dilutions only Milli-Q water was used in case of control. 2.6. Myeloperoxidase (MPO) activity using Specific Immunological Extraction Followed by Enzymatic Detection (SIEFED) assay SIEFED assay is a licensed method developed by Franck et al. [8] for specific detection of animal origin MPO. MPO solution was made by diluting human MPO in 20 mM phosphate buffer saline (at pH 7.4), 5 g/l BSA and 0.1% Tween-20. Sample dilutions at final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml were incubated for 10 min (at 37 ˚C) with MPO solution at a final concentration of 25 ng/ml. After incubation, the mixtures were loaded into the wells of a 96 wells microtitre plate coated with rabbit polyclonal antibodies (3 µl/ml) against equine MPO and incubated for 2 h at 37 ˚C in darkness. After washing up the wells, the activity of the enzymes captured by the antibodies was measured by adding hydrogen peroxide (10 µM), NO2- (10 mM) and Amplex^TM Red (40 µM). The oxidation of Amplex^TM Red into the fluorescent adduct resorufin was monitored for 30 min at 37 ˚C with Fluorosckan Ascent (Fisher Scientific, Asse, Belgium). Instead of sample dilutions only Milli-Q water was used in case of control. 2.7. Myeloperoxidase (MPO) activity using classical measurement MPO solution was prepared as mention in section 2.6. Sample dilutions at final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml were incubated for 10 min (at 37 ˚C) with MPO solution at a final concentration of 25 ng/ml. After incubation, the mixture (100 µl) was immediately transferred into 96- well microtitre plate. This was followed by addition of 10 µl NO2- (10 mM) and 100 µl of Amplex^TM Red and hydrogen peroxide mixture (at concentrations mentioned in section 2.6). The oxidation of Amplex^TM Red into the fluorescent adduct resorufin was monitored for 30 min at 37 ˚C with Fluorosckan Ascent (Fisher Scientific, Asse, Belgium) immediately after addition of relevation mixture. Instead of sample dilutions only Milli-Q water was used in case of control. 2.8. Cellular antioxidant activity Preparation of the neutrophil and phorbol 12-myristate 13-acetate (PMA) solutions were made according to Paul et al. [2]. Neutrophil response modulation activity of samples was analysed using the protocol of Tsumbu et al. [1]. Neutrophil suspension (1 million cells/143 µl PBS) was loaded in wells of 96-wells microtite plate and incubated for 10 min (at 37˚C in dark) with phospahte buffer saline solution of samples at final concentrations of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml. After incubation, 25 µl calcium chloride (10 µM) and 20 µl L-012 (100 µM) were added in wells. The neutrophils were activated with 10 µl PMA (16 µM) immediately before monitoring the chemiluminesence response of neutrophils during 30 min at 37˚C using Fluorosckan Ascent (Fisher Scientific, Asse, Belgium). Instead of sample dilutions only phosphate buffer saline was used in case of control. 2.9. Statistical analyses All the analyses were performed in triplicates. For protein quantification, the equation of a fitted line and R-square value were calculated using linear regression. The relationships between concentration and inhibition obtained for antioxidant assays were non-monotonic in nature. To address this, the locally estimated scatterpot smoothing (LOESS) regression technique was used to model the relationship [9]. Models were fitted using the R statistical software [10]. These models require a span parameter that defines the smoothing sensitivity of the local regressions. By visual inspection a span parameter value of 0.4 was found to be suitable for all concentration and inhibition relationship curves. Concentrations with a predicted inhibition percentrage of interest, such as IC50 (concentration at which 50 % inhibition is reached), were found using the fitted models in combination with a numerical search routine. 3. Results 3.1. Protein quantification The calibration curve obtained using BSA, equation of the line and R-square value are established. The optical density of samples and relative concentration of proteins (calculated using equation of line) are mentioned in table 4. BSF-P extract solution (3 mg/ml) exhibits the highest, on the other hand BSF-HP solution exhibits the lowest protein concentrations amongst the tested solutions using Bichinchoninic acid assay. Table 4. Protein quantification using Bichinchoninic acid assay

¹BSF-P: BSF PureeX^TM; ²BSF-HP: BSF hydrolyzed puree;³FM: Fish meal; ⁴CM: Chicken meal. 3.2. DPPH assay DPPH radical scavenging activity of all five samples after 30 and 60 minutes of incubation is indicated in figure 2 and figure 3, respectively. The plot shows the measured values as well as fitted curves obtained from LOESS. CM exhibited pro-oxidant behavior at all tested concentrations after 30 as well as 60 minutes of incubation. Whereas, FM exhibited pro-oxidant behavior at four out of five tested concentrations after 30 min of incubation and at all tested concentrations after 60 min of incubation. The IC50 of BSF-HP after 60 min of incubation is indicated in table 5. It was not possible to calculate IC50 for other samples (after 30 or 60 min of incubation) because the samples either exhibited pro-oxidant activity or 50% inhibition was not achieved during the assay. The Emax (maximum inhibition achieved during the assay) of all the samples are also indicated in table 6 and are in following order: BSF-HP> BSF-P> FM and BSF-HP> BSF-P after 30 and 60 minutes of incubation, respectively. Table 5. Antioxidant activity IC50 (mg/ml) of samples obtained using different assays

¹BSF-P: BSF PureeX^TM; ²BSF-HP: BSF hydrolyzed puree; ³FM: Fish meal; ⁴CM: Chicken meal; ^aMPO: Myeloperoxidase; ^bCAA: Cellular antioxidant activity using neutrophil model; ^cNE: Not estimated because 50% inhibition was not achieved in tested concentrations; ^dPO: Not estimated because sample exhibited pro-oxidant activity on tested concentrations. Table 6. Antioxidant activity Emax (% inhibition) of samples obtained using different assays

*C: Concentration at which Emax is achieved; ¹BSF-P: BSF PureeX^TM; ²BSF-HP: BSF hydrolyzed puree; ³FM: Fish meal; ⁴CM: Chicken meal; ^aMPO: Myeloperoxidase; ^bCAA: Cellular antioxidant activity using neutrophil model; ^CPO: Not estimated because sample exhibited pro-oxidant activity on tested concentrations. 3.3. ABTS assay ABTS cation radical scavenging activity of samples after 30 minutes of incubation is shown in figure 4 (measured values as well as fitted curves obtained from LOESS). All the samples exhibited a similar inhibition pattern i.e., % inhibition increased as a function of increasing concentration. The IC50 of samples are mentioned in table 5 and are in following order: FM> CM> BSF-HP > BSF-P. Lower the IC50, higher is the ABTS cation radical scavenging activity. The Emax (maximum inhibition achieved during the assay) of all the samples are indicated in table 6 and are in following order: BSF-P> BSF- HP> FM> CM. 3.4. Myeloperoxidase (MPO) activity using Specific Immunological Extraction Followed by Enzymatic Detection (SIEFED) assay MPO response modulation activity of samples obtained using SIEFED assay is shown in figure 5 (measured values as well as fitted curves obtained from LOESS). BSF-HP exhibited strong inhibition behavior, with >75 % inhibition at 0.20 mg/ml concentration. The IC50 of samples are mentioned in table 5 and are in following order: BSF-HP. The Emax of samples are shown in table 6, and are in following order: BSF-HP> BSF-P. FM and CM show pro-oxidant behavior at all tested concentrations. On the other hand Emaz for BSF-P was < 50 %. 3.5. Myeloperoxidase (MPO) activity using classical assay MPO response modulation activity of samples obtained using classical assay is indicated in figure 6 (measured values as well as fitted curves obtained from LOESS). CM and FM exhibited pro-oxidant behavior at all tested concentrations. The Emax of all the samples tested are indicated in table 6. BSF-P and BSF-HP exhibited Emax > 75 %. The IC50 of samples are mentioned in table 5 and are in following order: BSF-P> BSF-HP. 3.6. Cellular antioxidant activity Neutrophil response modulation activity (measured values as well as fitted curves obtained from LOESS) and Emax of samples are shown in figure 7 and table 6, respectively. All the tested samples exhibited Emax > 0%. FM and CM exhibited Emax < 40%. CM exhibited pro-oxidant behavior at 3 out of 5 tested concentration. The IC50 of samples are mentioned in table 5. BSF-P and BSF-HP have the same numerical IC50 values. 4. Discussion 4.1. Protein quantification The protein concentration of the four water soluble extracts estimated using Bichinchoninic acid assay are displayed in table 4. Considering the amino acid pattern similarities between black soldier fly proteins, FM and CM, the protein content of four water soluble extracts are in following order: BSF-P> CM> FM> 45.5 %> BSF-HP. 4.2. DPPH radical scavenging activity DPPH and ABTS assays are commonly used to analyze antioxidant potential of food and feed products. DPPH radical scavenging activity represents the ability of a sample to donate hydrogen atom (referred as hydrogen atom transfer) or electrons (referred as single electron transfer) to stabilize free radicals. DPPH assay IC50 and Emax for all tested samples are mentioned in table 5 and table 6, respectively. Post 30 min of incubation, all the tested samples exhibit Emax < 50 % (with BSF-HP exhibiting highest Emax). On the other hand, after 60 min of incubation only BSF-HP exhibit Emax > 50 %. BSF-HP is manufactured by controlled hydrolysis of black soldier fly proteins and contains at least 24 % of proteins <1000 Da (see table 3). On the other hand BSF-P contains at least 6 % proteins <1000 Da. The inventors were not able to find any representative literature for molecular weight distribution of FM and CM. However, according to the literature, FM and CM contain 2.2 % and 1.1 % free amino acid (of total proteins), respectively [Li, P.; Wu, G. Composition of amino acids and related nitrogenous nutrients in feedstuffs for animal diets. Amino Acids 2020, 1–20, doi:10.1007/s00726-020-02833-4.]. Which translates into FM and CM containing at least 2.2 % and 1.1 % proteins <1000 Da respectively. The capacity of proteinaceous materials to scavenge free radicals depends on the protein molecular weight distribution. Proteins with low molecular weight peptides could scavenge free radicals more efficiently. Free radical scavenging activity of proteinaceous molecules is also influenced by: (1). Amino acid composition: hydrophobic amino acids (for e.g. Tyr, Phe, Pro, Ala, His and Leu) have superior radical scavenging activity in comparison to hydrophilic amino acids; (2). Amino acid sequence: Peptides with amphiphilic nature could enhance radical scavenging activity of a sample. Chemical analyses have indicated that Tyr exhibit antioxidant behavior via hydrogen atom transfer mechanism. On the other hand, amino acids such as Cys, Trp and His exhibit antioxidant behavior via single electron transfer mechanism. FM and CM exhibit pro-oxidant behavior at most concentrations tested after 30 min as well as 60 min of incubation (see Figure 2 and Figure 3). This behavior mainly arises from the thermal processing. For both FM and CM, thermal processing commonly involves heating the raw product at high temperatures for 15 to 20 min. In Norway, during fishmeal production, wild caught fishes are subjected to heating at temperatures ≥70 ^C for time ≥20 min in order to achieve 100 log10 reductions of Enterobacteriaceae and Salmonella counts. Such strict thermal processing conditions may result in oxidation of fats and proteins. Fish meal contains lipids rich in polyunsaturated fatty acids that are more susceptible to thermal oxidation. Antioxidant are commonly added in fish meal to prevent the oxidation of polyunsaturated fatty acids (also visible in table 1). Heat induced oxidation of amino acids lead to development of wide range oxidation products. The pro-oxidant behavior of amino acid oxidation by products is already known. They can result in a wide range of health conditions in animal body. All the black soldier fly protein derivatives (puree, hydrolysed puree) used and analyzed by the inventors were thermally processed at temperatures <100 ^C for time <.1.5 min (e.g. at 90 ^C for 80 seconds). These thermal processing time-temperature combinations of the current invention were adopted to ensure minimum damage to nutrients (proteins and fat) and adequate inactivation of pathogenic microbiota. This implies that pro-oxidant behavior of FM and CM arises mainly due to stringent production method. In one of the recent studies [3], researchers made BSF protein hydrolysate using bromelain enzyme. Bromelain derived protein hydrolysate was also tested for DPPH radical scavenging activity, which resulted into the IC50 of 8.4 mg/ml. The DPPH radical scavenging activity of this bromelain derived protein hydrolysate was much lower when compared to the activity of products such as BSF-HP (IC50 0.18 mg/ml after 60 min of incubation). The higher activity of BSF-HP as found by the inventors could arise from compositional attributes (as previously discussed in this section) and quality of raw material itself. Protix is reportedly producing insect proteins in GMP+ and SecureFeed certified facilities, under HACCP conditions. 4.3. ABTS cation radical scavening activity ABTS cation radical scavenging denotes the ability of sample to donate electron and stabilize free radicals. ABTS assay IC50 of all samples are indicated in table 5. They are in following order: FM> CM> BSF-HP> BSF-P. The higher the IC50, the lower the antioxidant activity. In this assay even FM and CM exhibit antioxidant activity. It appears that FM and CM extracts may be efficient where free radical(s) could be stabilized using single electron transfer mechanism. However, they still exhibit lower scavenging activity in comparison to the surprisingly high scavenging activity of BSF derivatives BSF larvae puree and hydrolysed BSF larvae puree. Dependence of radical scavenging activity on protein molecular weight is already explained in section 4.2. At Protix the inventors established that BSF-P and BSF-HP have exactly the same amino acids composition. However, due to protein hydrolysis, the amount of proteins <1000 Da is higher in BSF-HP than in BSF-P. It is therefore somewhat surprising that the BSF-P IC50 value was slightly lower in comparison to BSF-HP. This could be explained by the mechanism of hydrolysis. Enzymatic hydrolysis is achieved through exo- and endo- peptidase. Exopeptidase cleaves the terminal peptide bond, on the other hand endopeptidase cleaves the non-terminal peptide bond. In both cases the sequence of amino acids is altered. The radical scavenging ability of resulting peptides via single electron transfer is also dependent on the amphiphilic nature of proteinaceous molecules. It is possible that peptides in BSF-HP are less amphiphilic in nature that results into lower ABTS cation radical scavenging activity of BSF-HP compared to BSF-P. Zhu et al. [4] developed BSF protein hydrolysate using wide range of commercial enzymes. The hydrolysates were further fractionated into following group: group 1 (<3000 Da), group 2 (3000 to 10,000 Da) and group 3 (>10,000 Da) using ultrafiltration. The activity of these hydrolyzed fractionates were also investigated for ABTS cation radical scavenging activity. Ascorbic acid was used as the reference molecule in the example. Interestingly the best performing fractionate and ascorbic acid were able to inhibit 85.67 % and 92.11 % of ABTS cation radical at 0.05 mg/ml concentration, respectively. The current inventors now surprisingly established that BSF-P already exhibits ABTS cation radical scavenging Emax of as high as 89, (at 0.2 mg/ml). This shows that fractioning BSF-P reveals fractions that have very strong antioxidant potential. 4.4. Neutrophil response modulation activity Strong free radical scavenging activities of BSF derivatives are evident from section 4.2 and 4.3. Furthermore, all the samples were also tested for neutrophil response modulation activity. Neutrophils are white blood cells present in animal body (including humans, pets, fishes and swine). They are involved in the primary defense against pathogens. When pathogenic microbes enter the animal body, neutrophils rush to the site of infestation and initiate defense. During granulation, neutrophil release a wide range of oxidative enzymes including NADPH oxidase, which is responsible for production of superoxide anion and by product (e.g. hydrogen peroxide). Superoxide anion can further react with nitric oxide radical to produce peroxynitrite. This process also generates hydroxyl radical (by reaction of hydrogen peroxide with metal ion). This battery of oxidative reactions are crucial to the defense of the host animal. However, these ROS generated during host defense can react with enzymes, proteins, lipids, etc. of body cells and result in the development of different health conditions (for e.g. cellular ageing, cancer, etc.). The neutrophil assay conducted in this research determines the ability of proteinaceous molecules to scavenge ROS produced as a result of neutrophil activity. PMA was used to activate protein kinase C present in neutrophils, which results in production of NADPH oxidase responsible for catalyzing ROS production. ROS production in system is coupled with lucigenin amplified chemi-luminescence. Ability of proteinaceous sample to scavenge ROS (particularly superoxide anion) is marked by decreased chemi-luminescence. To the inventors knowledge, this is the first analysis of in vitro neutrophil response modulation activity of BSF derivatives BSF larvae puree and hydrolysed BSF larvae puree. CM exhibited pro-oxidant behavior at 3 out of 5 tested concentrations, and Emax of only 5% at 0.2 mg/ml (see figure 7 and table 6). CM is commonly used in pet food preparations. However, the comparative test results in the examples and embodiments of the invention indicate that CM inclusion offers little or no benefits relating to scavenging the ROS produced by neutrophils. Moreover, CM inclusion could even result in inflammatory damage to host cells. Repetitive inflammatory damage of canine or feline cells could translate into conditions such as accelerated aging, slow cognitive function, etc. On the other hand, FM exhibits mild anti-oxidant behavior in this assay, with Emax of 22% (see table 6). At 0.2 mg/ml, FM exhibits inhibition of 5%. Aquaculture rearing media (i.e. water) offers a continuous buffer of pathogenic bacteria. Therefore, aquaculture organisms are at constant risk of pathogenic bacterial invasions. This results in wide range of health conditions, including reduced immunity, aging, etc. The comparative examples of the current inventors highlight the inadequacy of FM to suppress the inflammatory damage from repetitive neutrophil activity. This often translates into incremental cost occurring as a result of antibiotics and nutritional supplement usage. BSF-P exhibits Emax and IC50 of 59.57% and 0.15 mg/ml, respectively (see table 6). Moreover, BSF-HP also exhibits neutrophil response modulation activity comparable to BSF-P (see table 5). 4.5. MPO response modulation activity (SIEFED and classical assay) The general mechanism of neutrophil response is known. The neutrophil extracellular trap contains several molecules required to inactivate pathogenic microbes. MPO enzyme present in neutrophil extracellular trap can produce hypochlorous acid from hydrogen peroxide and chloride ion. Additionally, MPO is capable of oxidizing tyrosine into the tyrosyl free radical. Both products of MPO oxidation (hypochlorous acid and tyrosyl free radical) are crucial to inactivate pathogens. Again, repetitive interaction of these molecules with animal cells result in inflammatory damage. In an animal body, MPO- Fe(III) (active form) reacts with hydrogen peroxide to form oxoferryl π cation radical (CpI form). CpI form converts back into MPO-Fe(III) coupled with chloride ion transforming into hypochlorous acid. However, in the present experiment, back reduction of the Cp I form to MPO-Fe(III) was achieved in 2 stages. First reduction of CpI to MPO-Fe(IV)=O via electron transfer through nitrite ions. Then, electron provisioning was done (via Amplex^TM Red oxidation to resorufin reaction) which converts MPO-Fe(IV)=O to MPO-Fe(III) form. Proteinaceous molecules could prevent the oxidative damage resulting from MPO either by directly reacting with CpI form and terminating the halogenation, or by donating hydrogen (hydrogen atom transfer) to ROS produced as a consequence of MPO activity. MPO response modulation activity was analyzed using the classical and SIEFED assay. The classical assay measures ability of sample to complex with CpI form and stabilize ROS. Whereas in SIEFED assay, MPO is bound to rabbit polyclonal antibodies (and rest of the compounds are washed away), so it purely measures the ability of samples to complex with CpI form. As with neutrophil response modulation activity, MPO response modulation activity of BSF derivatives BSF larvae puree and hydrolysed BSF larvae puree is also being established by the inventors for the first time, after provision of the puree according to the method of the invention. FM and CM exhibit pro-oxidant behavior in both the assays (see figure 5 and 6). Presence of oxidative reaction products in FM and CM (as a consequence of production process) that are capable of initiating pro- oxidative response has been already discussed in section 4.2. Detailed in vitro investigations realized by the inventors indicate that inclusion of FM and CM in animal diets may result in inflammatory damage. In classical assay, BSF derivatives exhibit surprisingly strong antioxidant potential, with IC50 in following order: BSF-P> BSF-HP. In the SIEFED assay, BSF-P did not reach 50% inhibition (even at highest concentration tested). Thus while, BSF-P is more effective in stabilizing ROS, BSF-HP has higher efficacy in complexing with CpI form of MPO. These observations show that the two BSF derivatives are suitable for use as an ingredient in pet food and aquaculture formulations to effectively suppress inflammatory damages resulting from MPO activity. BSF protein derivatives offer anti-oxidative advantage over FM and CM. EXAMPLE 4 Fat oxidation as a consequence of puree heating times Introduction Pasteurization is crucial for production of processed insect protein. Optimal heating time and optimal heating temperature combinations is important for: (1). inactivation of pathogens; and (2). preserving the nutritional quality of food. With respect to fat quality (of insect proteins), pasteurization time x temperature combination is significant for: (1). inactivation of intestinal SN-1,3- lipase: If not inactivated, this enzyme could hydrolyze triglycerides into free fatty acids (present at SN-1,3 position of triglycerides) and 2-monoglycerides. (2). Lipid oxidation: Heating could result in the (non-enzymatic) oxidation of polyunsaturated fatty acids. The free fatty acids formed due to lipase activity could also undergo (enzymatic) oxidation via lipoxygenases. These two oxidation processes result in the formation of primary (e.g. hydroperoxides) and secondary oxidation products (e.g. aldehydes and ketones). These reactions have adverse effect on the sensory quality of food and also the health of consuming animals. In this current Example 4 the extent of FFA formation in pasteurized puree (to analyze lipase inactivation) and development of hydroperoxides as a consequence of heating times, is established. Materials and Methods Approximately 5 kg live black soldier fly larvae were harvested from a rearing unit (Protix, The Netherlands). These larvae were washed thoroughly to remove all visible impurities.300 g of washed larvae were used per treatments. Larvae were minced to obtain a smooth slurry (puree) and pasteurized according to treatments indicated in Table 7. The pasteurized larvae puree was immediately frozen (to - 20°C). These frozen samples were later thawed and analysed for free fatty acid content and peroxide values. All the experiments were performed in duplicates. Table 7. Description of pasteurization treatments used in Example 4.

Results The free fatty acid contents and peroxide values obtained for respective treatments are mentioned in Table 8. Table 8. Free fatty acid and peroxide values obtained for respective treatments

¹Results expressed at mean ± S.D. (n=2) As visible from Table 8, that insect puree heated at 90°C for 40 s has relatively high amounts for free fatty acids (approx.70%). Heating puree just for 40 s is ineffective in the deactivation of lipase. Whereas, low amounts of free fatty acids are observed when puree is heated for 80 s, indicating the sufficiency of this time for enzyme inactivation at 90°C. At heating times of over 80 seconds (treatment 4 and 5 in Table 7 and Table 8), the fatty acid content increases when compared to the low fatty acid content obtained when the black soldier fly larvae puree is heated for 80 seconds. Therefore, for obtaining a protein fraction which comprises a relatively low free fatty acid content, the heating time in the method of the invention should be longer than 40 seconds and shorter than 300 seconds, such as 50 – 100 seconds, or a heating time selected from 60 – 90 seconds, or 70 – 85 seconds, such as about 80 seconds. Preferred heating time is about 90 ^C or 90 ^C ^ 2 ^C. Also higher peroxide value is observed for heating duration of 40 s. This could be explained by high amounts of free fatty acids that could participate in enzyme oxidation leading to the production of hydroperoxides. However, in case of 80 s treatment, lower peroxide value is obtained. Heating the product further has an effect on fat oxidation in that the peroxide value for Treatment 4 and Treatment 5 is increased compared to the peroxide value for Treatment 3, i.e. a heating time of 80 seconds. Therefore, for obtaining a protein fraction which comprises a relatively low peroxide value, the heating time in the method of the invention should be longer than 40 seconds and shorter than 300 seconds, such as 50 – 100 seconds, or a heating time selected from 60 – 90 seconds, or 70 – 85 seconds, such as about 80 seconds. Preferred heating time is about 90 ^C or 90 ^C ^ 2 ^C. Conclusion Heating the minced insect larvae at 90°C for 80 s is sufficient for enzyme inactivation, prevents free fatty acid formation, and prevents peroxide formation. EXAMPLE 5 Antioxidant activity of Fish samples after feeding fish with feed supplement Antioxidant activity of Fish fillet samples was investigated using anti-radical (ABTS) technique. Water soluble black soldier fly larvae protein extracts, referred to as HI-0, HI-25, HI-50 and HI-100, were prepared in distilled water and used at different concentrations. In the ABTS assay, the percentage inhibition at maximum tested concentration was in following order: HI-25 > HI-100 > HI-50 > HI-0. In the ABTS assay, the HI-25 filet sample reached the IC50 ≥50%. In conclusion, within the concentration series tested, the HI-25 sample had the maximum ABTS radical scavenging activity among all the tested Fish fillet samples. Using the ABTS assay, activity of fish flesh samples was assessed with regard to radical lowering activity of black soldier fly protein obtained with the method of the invention. Materials and Methods Diets ProteinX (high protein meal of Hermetia illucens) used in this study was produced according to the method of the invention and was provided by Protix (The Netherlands). Two iso-nitrogenous, iso-lipidic and iso-energetic diets where formulated with either fish meal (20.6%) or ProteinX (32%) as the main protein source. Both diets where produced by Research Diet Services (the Netherlands). Diamol was added to both diets as inert marker for digestibility measurements. Four treatments where formed by feeding either one of both feeds, or mixing both feeds to a determined ratio. The dietary treatments where referred to as: HI0 (100% fish meal based feed); HI25 (75% fish meal based feed mixed with 25% ProteinX based feed); HI50 (both feeds mixed in equal ratio; 50% fish meal based feed mixed with 50% ProteinX based feed); and HI100 (100% ProteinX based feed). The proximate composition of all four dietary treatments is presented in Table 9. The proximate composition of ProteinX and of the four experimental dietary treatments was determined by DISAFA laboratories and is presented in Table 9. Feed samples were ground using a cutting mill (MLI 204; Bühler AG, Uzwil, Switzerland) and analysed for dry matter content (AOAC #934.01), crude protein content (AOAC #984.13), ash content (AOAC #942.05), and ether extract (AOAC #2003.05) were analysed according to AOAC International. Crude protein content was calculated as: ^^^^^^^^ ∗ 6.25 Fish and rearing conditions The animal feeding trial was conducted at the Experimental Facility of the Department of Agricultural, Forest, and Food Sciences of the University of Torino (Italy). The experimental protocol was designed according to the guidelines of the current European and Italian laws on the care and use of experimental animals (European directive 86609/EEC, put into law in Italy with D.L. 116/92). The experimental protocol was approved by the Ethical Committee of the University of Turin (protocol n° 143811). Juvenile rainbow trout were obtained from a private hatchery (Troticoltura Bassignana, Cuneo, Italy) and randomly distributed over 12 fiberglass tanks (n = 3) (50 fish per tank). Tanks were supplied artesian well water (13 ±1°C) in a flow-through system at a flow rate of 8 L/min. Dissolved oxygen was measured every fortnight and ranged between 7.6 and 8.7 mg / L. Fish were acclimatized to the experimental set up for four weeks during which a commercial diet was fed at 1.6% of the total body weight per tank. After acclimatization, fish were restrictively fed a dietary treatment for 133 days of which 113 days at a fixed ratio of 1.4% followed by 20 days at a fixed ratio of 1.1%. Feed intake was monitored at each administration. Feed was distributed by hand twice a day, 6 days per week. The biomass of each tank was weighed in bulk every 14 days to correct the daily feeding rate. Mortality was checked daily.

Sampling: At the end of the trial, fish were fasted for one day, and 9 fish/treatment (3 fish/tank) fish per treatment where killed by overdose of anaesthesia (MS-222 - PHARMAQ Ltd, UK; 500 mg/L) and individually weighed. The right fillets were collected of each fish and vacuum-sealed, frozen (-20°) and subsequently freeze dried. Sample preparation: Fish samples (in powdered form) were received. The samples were kept in a freezer (-20 ^C) until further processing. Water soluble extract powders (WSEP) of respective samples were made according to the protocol of Mouithys-Mickalad et al. (2020). WSEP were stored in a desiccator (at 18 ^C) until further experimentations. The stock solutions of the WSEP were made by dissolving to a final concentration of 20 mg/mL in Milli-Q water, which stock solution will be then diluted by half to obtain 10, 5, 2.5 and 1.25 mg/mL, successively. ABTS radical scavenging activity: The radical scavenging activity of WSEP samples toward ABTS radical cation were analysed according to the method of Arnao et al. (2001). ABTS stock solution was made by completely dissolving 7.0 mmol/L ABTS and 1.35 mmol/L potassium persulfate in Milli-Q water. The test solution was kept overnight in dark (at 18 ^C) for reaction to complete. ABTS working solution was made by diluting stock solution with methyl alcohol to obtain absorbance between 0.7 to 0.8 mm at 734 nm. ABTS working solution (1920 µL) was mixed with 20 µL of WSEP solutions (obtained by dissolving WSEP in Milli-Q water) to obtain a final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml. Decrease in absorbance post 30 min of incubation in dark was measured at 734 nm using an HP 8453 UV-vis spectrophotometer. Instead of WSEP dilution, only Milli-Q water was used in case of control. The repetitions with increasing concentrations of different samples was performed as described by Paul (2007) and transferred into a multi-well device (96-well plate) with a final volume of 200 µL (198 µL of solvent and 2 µL of WSEP). Likewise, after a 30-min incubation period, the absorbance was read at 740 nm using a Multiskan Ascent reader (Thermo Fisher Scientific). Results ABTS radical scavenging activity of WSEP samples is indicated in Figure 8: displayed is the ABTS radical scavenging activity of WSEP performed in methanol. Results are mean ± SD of three independent assays in triplicate. For all the samples increase in concentration resulted into an increase of mean inhibition values (indicating anti-oxidant behaviour). Emax (maximum inhibition obtained during the test) were in the following order: HI-25 > HI-100 > HI-50 > HI-0 (all obtained at 0.2 mg/ml, final concentration). This result indicates that HI-25 samples exhibit highest ABTS radical scavenging activity. On the other hand, HI-0 samples exhibit least ABTS radical scavenging activity. Eventually, HI-25 samples exhibited mean inhibition values ≥ 50% (IC50 was achieved). Concluding remark As assessed by using the ABTS assay, all the protein samples obtained by applying the method of the invention with black soldier fly larvae, exhibit anti-oxidant activity in a dose-dependent manner. HI-25 samples show the highest anti-oxidant activity. Example 6 An aqueous water-soluble protein composition or a dried water-soluble protein composition wherein the water-soluble proteins are substantially completely dissolvable in an aqueous solution such as water, is provided by isolating a proteinaceous fraction from black soldier fly larvae according to the method as described in European patent application EP2953487, in the Examples section, Example 1, page 12, line 8-13 and page 13, line 3-5. In brief, larvae of black soldier fly were provided and subjected to the method to convert insects or worms into nutrient streams, as substantially outlined here below: Method to convert insects or worms into nutrient streams, comprising the steps of: (a1) providing insects or worms, here larvae of black soldier fly (a2) reducing the insects or worms in size, (a3) obtaining a pulp from insects or worms, then (b) heating the pulp to a temperature of 70-100°C, and then (c) subjecting the heated pulp to a physical separation step thereby obtaining a fat fraction, an aqueous protein fraction (referred to as “larvae water”) and a solid- containing fraction. The aqueous protein fraction is an aqueous water-soluble protein fraction when black soldier fly larvae are subjected to the method to convert insects into nutrient streams. The aqueous water-soluble protein fraction is in some embodiments dried after step (c) using spray-drying, therewith providing dried black soldier fly larvae proteins. The method does not comprise enzymatic treatment of the pulp in any of the steps of the method. Optionally, the method does comprise enzymatic treatment of the larvae pulp, though for the current example, no enzymatic digestion steps were applied in the method to convert black soldier fly larvae into nutrient streams. In step (b) of the method, the minced black soldier fly larvae are pasteurized by heating the pulp (or ‘puree’) at 90 ^C for 80 seconds, therewith providing pasteurized ‘meat’ of larvae. The pasteurized meat is subsequently in step (c) mechanically separated to obtain the liquid protein fraction (larvae water). The aqueous protein fraction is either used directly ‘as is’ without further treatment steps (for example drying or concentration) before provided as aqueous insect- or worm protein composition comprising at least one protein in step (a) of the method of the invention for the provision of enzymatically hydrolysed insect- or worm proteins and for the provision of Maillard reaction products of enzymatically hydrolysed insect- or worm proteins, or the aqueous protein fraction (larvae water) is first concentrated, for example three to twelve times, such as 5-10 times, or first dried for example using spray-drying, before being subjected to dissolving in an aqueous solution such as water, and then provided in step (a) of the method of the invention as aqueous insect- or worm protein composition comprising at least one protein. The crude protein content of the larvae water obtained with step (c) of the here above outlined method to convert insects or worms into nutrient streams, was 3,8% by weight based on the total weight of the larvae water. The crude fat content was 0,3% by weight based on the total weight of the larvae water. For the obtained larvae water, the total plate count assessed as the aerobic mesophilic count at 30 ^C (ISO 4833) was 26000 cfu/g; the Bacillus cereus count at 30 ^C (ISO 7932) was < 40 cfu/g; the Clostridium perfringens count at 37°C (ISO 7937) was < 10 cfu/g; the Escherichia coli count at 44°C was < 10 cfu/g; and Salmonella was not detected in 25 g of the product, using PCR fast method (ISO 6579). Thus, in the larvae water, the microbial count was less than 40 cfu / g protein for Bacillus cereus; less than 10 cfu / g protein for Clostridium perfringens; less than 10 cfu / g protein for Escherichia coli; and the Salmonella count was 0 cfu / g protein when 25 g of the larvae water was assessed. Herewith, the microbial count was within value boundaries that should be reached for application of the larvae water in food products or food ingredients. The aqueous water-soluble protein fraction (larvae water), either or not concentrated, or first dried and then dissolved again, is applied as the substrate for enzymatic hydrolysis of the at least one protein in black soldier fly larvae water-soluble protein fraction. The liquid aqueous water-soluble protein fraction contains approximately 91% moisture content by weight, about 4% proteins by weight based on the total weight of the aqueous protein fraction (larvae water), and the liquid aqueous protein fraction had low fat content (<1% by weight based on the total weight of the aqueous protein fraction, i.e. 0,3% for the current preparation). The larvae water is a stock solution of dissolved water-soluble proteins that does not need any dilution step before enzymatic hydrolysis of the water-soluble proteins. The aqueous water- soluble protein fraction (larvae water) does not comprise water-insoluble chitin. Enzymatic hydrolysis The aqueous water-soluble protein fraction (larvae water) was subjected to enzymatic hydrolysis in a bioreactor with temperature control (30°C to 100°C), pH control (pH is between 4 and 9) and with continuous stirring (up to 1250 rpm). The proteins were enzymatically hydrolysed in some examples using a single amino-peptidase and in further examples using a combination of aminopeptidases which have endopeptidase and exopeptidase activities. The enzyme concentration was 0.1% to 2% by weight based on the total weight of the aqueous water-soluble protein fraction comprising the enzyme(s), for the one or more amino-peptidases. For example, Flavourzyme (Novozymes, Denmark) was used at 1% by weight based on the total weight of the aqueous protein fraction comprising the enzyme(s). Reaction conditions During enzymatic hydrolysis, the pH (typically between 4 to 8), the reaction temperature (typically from 35 ^C to 60°C) and the enzymatic hydrolysis time (typically from 2 hours to 12 hours) of the reaction depended on the type of selected enzyme(s). With the Flavourzyme, the aqueous water-soluble protein fraction was hydrolysed at pH 7 (which was also the pH of the larvae water), at a temperature of 50°C during 6 hours. Heating to induce enzyme deactivation The enzymatic hydrolysis reactions were terminated by heat deactivation of enzyme(s) at 75 ^C to 110°C for 1 minute to 10 minutes. Commonly, the enzymatic hydrolysis reaction was terminated by heating the reaction mixture of the aqueous water-soluble protein fraction comprising the enzyme(s), at 100°C for 2 minutes, providing enzymatically hydrolysed black soldier fly larvae water-soluble proteins. When the Flavourzyme enzymes were applied, the enzymatically hydrolysed proteins are referred to as Hydrolysed Insect Extract 1 (“HIE1”, or “HIE 1”). Final product The composition HIE 1 is subsequently subjected to experiments, by using the solution provided with the method of the invention for providing the enzymatically hydrolysed water-soluble insect protein or HIE 1 are first subjected to a concentration step by evaporating the aqueous solution such that the dry matter content is for example at least 30% by weight such as for example at least 50% by weight of the total weight of the concentrated HIE 1. Alternatively, the HIE 1 is applied as dried hydrolysed protein, for example as a powder, by an evaporation step executed with HIE 1, and a drying step for example using a fluidized bed dryer and/or using a spray dryer, such that the dry matter (DM) content of the dried HIE 1 is at least 92% by weight DM based on the total weight of the dried HIE 1. Composition The chemical compositions of the enzymatically hydrolysed black soldier fly larvae water-soluble proteins HIE 1 are outlined in Table 10. In addition, the chemical composition of the aqueous water- soluble protein fraction of black soldier fly larvae (larvae water) is provided in Table 1. The free amino acid compositions of the aqueous water-soluble protein fraction of black soldier fly larvae (larvae water) and HIE 1 are outlined in Table 11. While counts of some pathogenic microbes is mentioned in table 12. Table 10: Chemical compositions of the aqueous water-soluble protein fraction of black soldier fly larvae (larvae water), the enzymatically hydrolysed black soldier fly larvae proteins HIE 1

Table 11: Free amino acid composition of the enzymatically hydrolysed black soldier fly larvae proteins HIE 1. The amounts of the free amino acids is determined by applying the DJA75 test (ISO 13903:2005/IC-UV).

More than fifty percent by weight of the hydrolysed proteins, based on the total weight of protein present in HIE 1 (i.e.100%), are detected as very short chain peptides. “Very short chain peptides” is herein defined as peptides having an amino-acid residues chain length of between about 6 amino acid residues and about 20 amino acid residues. Table 12: Counts of pathogenic bacteria in the enzymatically hydrolysed black soldier fly larvae proteins HIE 1

The total plate count, also referred to as ‘Aerobic Mesophylic Count 30°C’ (equivalent to ISO 4833), was determined by Nutrilab (Rijswijk, NL); the Bacillus cereus count was assessed at 30 ^C (equivalent to ISO 7932); the Clostridium perfringens count was determined at 37°C (equivalent to ISO 7937); the Escherichia coli plate count was assessed at 44°C; The Salmonella count was assessed using PCR fast method (equivalent to ISO 6579). Thus, in the two products HIE 1, the microbial count was less than 10 cfu / g protein for Bacillus cereus; less than 10 cfu / g protein for Clostridium perfringens; less than 10 cfu / g protein for Escherichia coli; and the Salmonella count was 0 cfu / g protein when 25 g of the HIE 1 was assessed. Herewith, the microbial count for HIE 1 was within value boundaries that should be reached for application of the larvae water in food products or food ingredients. That is to say, according to the European Commission, in “OECD issue paper on microbial contaminants limits for microbial pest control products”, the detected plate counts for the indicated microbes was within acceptable limits according to the European Commission guidelines. Example 7 2. Materials and Methods 2.1. Reagents All the reagents were of analytical grade. Dimethylsulfoxide, methanol, ethanol, calcium chloride, potassium chloride, sodium chloride, hydrogen peroxide and Tween-20 were purchased from Merck (VWR, Leuven, Belgium). Sodium nitrite, bovine serum albumin, phorbol 12-myristate 13-acetate and Percoll^TM were purchased from Sigma (Bornem, Belgium). Aqueous extracts and solutions were made in Milli-Q water obtained using Milli-Q water system (Millipore, Bedford, USA). Bicinchoninic acid and copper (II) sulfate solutions were purchased from Sigma (Steinheim, Germany). Whatman filter paper grade 4 (270 mm) was purchased from Amersham (Buckinghamshire, UK). Sterlip 30 ml disposable vacuum filter system was purchased from Millipore (Bedford, USA).2,2-Diphenyl-1-picrylhydrazyl and 2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) were purchased from Aldrich (Darmstadt, Germany). 8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4(2H,3H)dione (L-012) was purchased from Wako Chemicals (Neuss, Germany). 2.2. Raw materials Chicken meal (CM) and fish meal (FM) were purchased from an online webshop in September 2019. The chemical composition of both ingredients as declared by the supplier is indicated in table 13. Table 13. Chemical composition of chicken meal and fishmeal (as in basis, provided by supplier).

A puree of BSF larvae, also referred to as BSF PureeX^TM (BSF-P), was prepared by Protix B.V. (Dongen, The Netherlands) in October 2019. The puree was obtained according to the following method. Live and washed Black Soldier Fly larvae of 14 days old were collected just before being subjected to the mincer for mincing the larvae (therewith providing larvae pulp), and subsequently stored at 4 ^C until used. For each experiment, larvae were minced freshly. The minced larvae was subjected to a separation step, obtaining water-soluble BSF larvae protein according to the invention. The water-soluble BSF larvae protein was treated with 1 wt% Flavourzyme, based on the mass of the protein, for 6 hours at 50 ^C (± 2 ^C) under continuous stirring, according to the method of the invention. Flavourzyme (Novozymes, Denmark) is a combination of aminopeptidases which have endopeptidase and exopeptidase activities. The enzyme-treated water-soluble BSF larvae protein was heated subsequently, for inactivation of the enzyme, according to the method of the invention. The aqueous protein hydrolysates (BSF-APH) obtained as here above described, was provided by Protix B.V. (Dongen, The Netherlands) in October 2019. According to Protix: BSF-APH is a hydrolysate of water soluble BSF proteins, prepared according to the method of the invention. It is established that BSF-APH has high solubility in water (>95%). The chemical composition of all three ingredients as declared by the supplier or by Protix (the inventors) is indicated in table 14. Table 14. Chemical composition of BSF protein derivative BSF-APH (as in basis, prepared by Protix).

³BSF-APH: BSF aqueous protein hydrolysate; ^aMean values based on the range determined by Protix. Water soluble extracts were prepared for CM and FM. These products (100 g each) were dissolved with six times volumes of Milli-Q water based on their respective dry matter contents and stirred for 2 h on a magnetic stirrer. Post centrifugation (1000 x g for 30 min at 4 ^C), the top fat layer was removed and the supernatant was filtered using Whatman Filter (grade 4). The centrifugation and filtration step was repeated again to remove all non-soluble residues. Finally the supernatant was filtered using a Sterlip Filter (50 mL, 0.22 µm) and freeze dried over a period of two days to obtain respective water soluble extract powders. BSF-APH was used directly because it has water solubility >95%. All four water soluble extract and BSF-APH powders were stored in a desiccator (at 18 ^C) until further use. 2.3. Protein quantification Total protein content of four water soluble extracts and BSF-APH powders was analysed using Bicinchoninic acid (BCA) protein assay [5]. The calibration curve was obtained using bovine serum albumin (BSA) as standard at concentrations: 0, 0.125, 0.25, 0.5 and 1 mg/ml. Stock solutions of 3 mg/ml water soluble extracts and BSF-APH were used for analysis. A test solution was made by dissolving 4900 µl BCA (49/50) and 100 µl copper (II) sulfate (1/50). Sample stock solutions (10 µl) and test solution (200 µl) were added in wells of 96-well plate. This plate was incubated at 37 ^C for 30 min and absorbance was measured at 450 nm using a Multiscan Ascent (Fisher Scientific, Asse, Belgium). 2.4. DPPH assay DPPH radical scavenging activity was analysed according to protocol of Brand-Willams et al. [6], with some modifications. DPPH test solution was made by dissolving 10.5 mg DPPH in 40 ml ethanol. Test solution was made fresh and stored in dark until further use. DPPH working solution was made by diluting test solution with 10 times ethanol (to obtain absorbance of 0.6 to 0.8 at 517 nm). DPPH working solution (1920 µl) was mixed with 20 µl of samples dilutions (four water soluble extracts and BSF-APH in Milli-Q water) to obtain final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml. The decrease in absorbance after 30 and 60 min of incubation in dark was recorded at 510 nm using HP 8453 UV-vis spectrophotometer (Agilent Technologies, Waldbronn, Germany). Instead of sample dilutions only Milli- Q water was used in case of control. 2.5. ABTS assay ABTS cation radical scavenging activity was analysed according to protocol of Arnao et al. [7], with some modifications. ABTS test solution was made by dissolving 7.0 mmol/l ABTS and 2.45 mmol/l potassium persulfate in Milli-Q water. The test solution was kept overnight in dark at room temperature. ABTS working solution was made by diluting with methanol to obtain the absorbance between 0.7 and 0.8 at 734 nm. ABTS working solution (1920 µl) was mixed with 20 µl of samples dilutions (four water soluble extracts and BSF-APH in Milli-Q water) to obtain final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml. The decrease in absorbance after 30 min of incubation in dark was recorded at 734 nm using HP 8453 UV-vis spectrophotometer (Agilent Technologies, Waldbronn, Germany). Instead of sample dilutions only Milli-Q water was used in case of control. 2.6. Myeloperoxidase (MPO) activity using Specific Immunological Extraction Followed by Enzymatic Detection (SIEFED) assay SIEFED assay is a licensed method developed by Franck et al. [8] for specific detection of animal origin MPO. MPO solution was made by diluting human MPO in 20 mM phosphate buffer saline (at pH 7.4), 5 g/l BSA and 0.1% Tween-20. Sample dilutions at final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml were incubated for 10 min (at 37 ^C) with MPO solution at a final concentration of 25 ng/ml. After incubation, the mixtures were loaded into the wells of a 96 wells microtitre plate coated with rabbit polyclonal antibodies (3 µl/ml) against equine MPO and incubated for 2 h at 37 ^C in darkness. After washing up the wells, the activity of the enzymes captured by the antibodies was measured by adding hydrogen peroxide (10 µM), NO2- (10 mM) and Amplex^TM Red (40 µM). The oxidation of Amplex^TM Red into the fluorescent adduct resorufin was monitored for 30 min at 37 ^C with Fluorosckan Ascent (Fisher Scientific, Asse, Belgium). Instead of sample dilutions only Milli-Q water was used in case of control. 2.7. Myeloperoxidase (MPO) activity using classical measurement MPO solution was prepared as mention in section 2.6. Sample dilutions at final concentration of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml were incubated for 10 min (at 37 ˚C) with MPO solution at a final concentration of 25 ng/ml. After incubation, the mixture (100 µl) was immediately transferred into 96- well microtitre plate. This was followed by addition of 10 µl NO2- (10 mM) and 100 µl of Amplex^TM Red and hydrogen peroxide mixture (at concentrations mentioned in section 2.6). The oxidation of Amplex^TM Red into the fluorescent adduct resorufin was monitored for 30 min at 37 ^C with Fluorosckan Ascent (Fisher Scientific, Asse, Belgium) immediately after addition of relevation mixture. Instead of sample dilutions only Milli-Q water was used in case of control. 2.8. Cellular antioxidant activity Preparation of the neutrophil and phorbol 12-myristate 13-acetate (PMA) solutions were made according to Paul et al. [2]. Neutrophil response modulation activity of samples was analysed using the protocol of Tsumbu et al. [1]. Neutrophil suspension (1 million cells/143 µl PBS) was loaded in wells of 96-wells microtite plate and incubated for 10 min (at 37 ˚C in dark) with phospahte buffer saline solution of samples at final concentrations of 0.0125, 0.025, 0.05, 0.1 and 0.2 mg/ml. After incubation, 25 µl calcium chloride (10 µM) and 20 µl L-012 (100 µM) were added in wells. The neutrophils were activated with 10 µl PMA (16 µM) immediately before monitoring the chemiluminesence response of neutrophils during 30 min at 37 ˚C using Fluorosckan Ascent (Fisher Scientific, Asse, Belgium). Instead of sample dilutions only phosphate buffer saline was used in case of control. 2.9. Statistical analyses All the analyses were performed in triplicates. For protein quantification, the equation of a fitted line and R-square value were calculated using linear regression. The relationships between concentration and inhibition obtained for antioxidant assays were non-monotonic in nature. To address this, the locally estimated scatterpot smoothing (LOESS) regression technique was used to model the relationship [9]. Models were fitted using the R statistical software [10]. These models require a span parameter that defines the smoothing sensitivity of the local regressions. By visual inspection a span parameter value of 0.4 was found to be suitable for all concentration and inhibition relationship curves. Concentrations with a predicted inhibition percentrage of interest, such as IC50 (concentration at which 50% inhibition is reached), were found using the fitted models in combination with a numerical search routine. 3. Results 3.1. Protein quantification The calibration curve obtained using BSA, equation of the line and R-square value are established. The optical density of samples and relative concentration of proteins (calculated using equation of line) are mentioned in table 15. CM extract solution (3 mg/ml) exhibits the highest, on the other hand BSF-APH solution exhibits the lowest protein concentrations amongst the tested solutions using Bichinchoninic acid assay. Table 15. Protein quantification using Bichinchoninic acid assay

³BSF-APH: BSF aqueous protein hydrolysate; ⁴FM: Fish meal; ⁵CM: Chicken meal. 3.2. DPPH assay DPPH radical scavenging activity of all five samples after 30 and 60 minutes of incubation is indicated in figure 2 and figure 3, respectively. The plot shows the measured values as well as fitted curves obtained from LOESS. CM exhibited pro-oxidant behavior at all tested concentrations after 30 as well as 60 minutes of incubation. Whereas, FM exhibited pro-oxidant behavior at four out of five tested concentrations after 30 min of incubation and at all tested concentrations after 60 min of incubation. It was not possible to calculate IC50 for all samples (after 30 or 60 min of incubation) because the samples either exhibited pro-oxidant activity or 50% inhibition was not achieved during the assay. The E_max (maximum inhibition achieved during the assay) of all the samples are also indicated in table 17 and are in following order: BSF-APH> FM after 30 minutes of incubation. Table 16. Antioxidant activity IC50 (mg/ml) of samples obtained using different assays

³BSF-APH: BSF aqueous protein hydrolysate; ⁴FM: Fish meal; ⁵CM: Chicken meal; ^aMPO: Myeloperoxidase; ^bCAA: Cellular antioxidant activity using neutrophil model; ^cNE: Not estimated because 50% inhibition was not achieved in tested concentrations; ^dPO: Not estimated because sample exhibited pro-oxidant activity on tested concentrations. Table 17. Antioxidant activity Emax (% inhibition) of samples obtained using different assays

*C: Concentration at which Emax is achieved; ³BSF-APH: BSF aqueous protein hydrolysate; ⁴FM: Fish meal; ⁵CM: Chicken meal; ^aMPO: Myeloperoxidase; ^bCAA: Cellular antioxidant activity using neutrophil model; ^CPO: Not estimated because sample exhibited pro-oxidant activity on tested concentrations. 3.3. ABTS assay ABTS cation radical scavenging activity of samples after 30 minutes of incubation is shown in figure 4 (measured values as well as fitted curves obtained from LOESS). All the samples exhibited a similar inhibition pattern i.e., % inhibition increased as a function of increasing concentration. The IC₅₀ of samples are mentioned in table 16 and are in following order: FM> CM> BSF-APH. Lower the IC50, higher is the ABTS cation radical scavenging activity. The Emax (maximum inhibition achieved during the assay) of all the samples are indicated in table 17 and are in following order: BSF-APH> FM> CM. 3.4. Myeloperoxidase (MPO) activity using Specific Immunological Extraction Followed by Enzymatic Detection (SIEFED) assay MPO response modulation activity of samples obtained using SIEFED assay is shown in figure 5 (measured values as well as fitted curves obtained from LOESS). The IC50 of samples are mentioned in table 16. The Emax of samples are shown in table 17. FM and CM show pro-oxidant behavior at all tested concentrations. 3.5. Myeloperoxidase (MPO) activity using classical assay MPO response modulation activity of samples obtained using classical assay is indicated in figure 6 (measured values as well as fitted curves obtained from LOESS). CM and FM exhibited pro-oxidant behavior at all tested concentrations. The Emax of all the samples tested are indicated in table 17. BSF- APH exhibited Emax > 75%. The IC50 of samples are mentioned in table 16. 3.5. Cellular antioxidant activity Neutrophil response modulation activity (measured values as well as fitted curves obtained from LOESS) and Emax of samples are shown in figure 7 and table 17, respectively. All the tested samples exhibited Emax > 0%. BSF-APH, FM and CM exhibited Emax < 40%. CM exhibited pro-oxidant behavior at 3 out of 5 tested concentration. The IC50 of samples are mentioned in table 16. 4. Discussion 4.1. Protein quantification The protein concentration of BSF-APH and two water soluble extracts estimated using Bichinchoninic acid assay are displayed in table 15. For BSF-APH, 3 mg/ml solution resulted in protein concentration of 0.702 mg/ml, which translates into 0.235 mg proteins per gram of BSF-APH (or 23.5% proteins). According to the inventors (Protix), the average protein content of BSF-APH is 45.5% (see table 14, analyzed using Dumas method). Differences in protein content arise due to method of analysis. Bichinchoninic acid assay is based on the detection of bonds specific to Cys, Trp and Tyr. On the other hand, Dumas assay is based on estimation of total organic nitrogen. Therefore, protein content estimated using Dumas method is always higher than that estimated using Bichinchoninic acid assay. However, comparing the two protein estimation methods is not an aspect of the current invention. Considering the amino acid pattern similarities between FM and CM, it is concluded that protein content of two water soluble extracts are in following order: CM> FM> 45.5 %. 4.2. DPPH radical scavenging activity DPPH and ABTS assays are commonly used to analyze antioxidant potential of food and feed products. DPPH radical scavenging activity represents the ability of a sample to donate hydrogen atom (referred as hydrogen atom transfer) or electrons (referred as single electron transfer) to stabilize free radicals. DPPH assay IC50 and Emax for all tested samples are mentioned in table 16 and table 17, respectively. Post 30 min of incubation, all the tested samples exhibit Emax < 50% BSF-APH contain at least 98% proteins <1000 Da. The inventors were not able to find any representative literature for molecular weight distribution of FM and CM. However, according to the literature, FM and CM contain 2.2% and 1.1% free amino acid (of total proteins), respectively [Li, P.; Wu, G. Composition of amino acids and related nitrogenous nutrients in feedstuffs for animal diets. Amino Acids 2020, 1–20, doi:10.1007/s00726-020- 02833-4.]. Which translates into FM and CM containing at least 2.2% and 1.1% proteins <1000 Da respectively. The capacity of proteinaceous materials to scavenge free radicals depends on the protein molecular weight distribution. Proteins with low molecular weight peptides could scavenge free radicals more efficiently. However, this does not explain the fact that BSF-APH contains higher amount of proteins <1000 Da and still exhibits lower inhibition of DPPH free radicals. Free radical scavenging activity of proteinaceous molecules is also influenced by: (1). Amino acid composition: hydrophobic amino acids (for e.g. Tyr, Phe, Pro, Ala, His and Leu) have superior radical scavenging activity in comparison to hydrophilic amino acids; (2). Amino acid sequence: Peptides with amphiphilic nature could enhance radical scavenging activity of a sample. Chemical analyses have indicated that Tyr exhibit antioxidant behavior via hydrogen atom transfer mechanism. On the other hand, amino acids such as Cys, Trp and His exhibit antioxidant behavior via single electron transfer mechanism. FM and CM exhibit pro-oxidant behavior at most concentrations tested after 30 min as well as 60 min of incubation (see figure 2 and 3). This behavior mainly arises from the thermal processing. For both FM and CM, thermal processing commonly involves heating the raw product at high temperatures for 15 to 20 min. In Norway, during fishmeal production, wild caught fishes are subjected to heating at temperatures ≥70 ˚C for time ≥20 min in order to achieve 100 log10 reductions of Enterobacteriaceae and Salmonella counts. Such strict thermal processing conditions may result in oxidation of fats and proteins. Fishmeal contains lipids rich in polyunsaturated fatty acids that are more susceptible to thermal oxidation. Antioxidant are commonly added in fishmeal to prevent the oxidation of polyunsaturated fatty acids (also visible in table 13). Heat induced oxidation of amino acids lead to development of wide range oxidation products. The pro-oxidant behavior of amino acid oxidation by products is already known. They can result in a wide range of health conditions in animal body. According to the supplier, all the black soldier fly protein derivatives used in this study were thermally processed at temperatures <100 ^C for time < 1.5 min. Supplier also indicated that these thermal processing time-temperature combinations were adopted to ensure minimum damage to nutrients (proteins and fat) and adequate inactivation of pathogenic microbiota. This implies that pro-oxidant behavior of FM and CM arises mainly due to stringent production method. 4.3. ABTS cation radical scavening activity ABTS cation radical scavenging denotes the ability of sample to donate electron and stabilize free radicals. ABTS assay IC50 of all samples are indicated in table 16. They are in following order: FM> CM> BSF-APH. The higher the IC50, the lower the antioxidant activity. In this assay even FM and CM exhibit antioxidant activity. It appears that FM and CM extracts may be efficient where free radical(s) could be stabilized using single electron transfer mechanism. However, they still exhibit lower scavenging activity in comparison to BSF-APH. BSF-APH has at least 98% proteins <1000 Da (the lowest protein molecular weight amongst all tested sample) and also exhibited lowest ABTS IC50. Dependence of radical scavenging activity on protein molecular weight is already explained in section 4.2. Zhu et al. [4] developed BSF protein hydrolysate using wide range of commercial enzymes. The hydrolysates were further fractionated into following group: group 1 (<3000 Da), group 2 (3000 to 10,000 Da) and group 3 (>10,000 Da) using ultrafiltration. The activity of these hydrolyzed fractionates were also investigated for ABTS cation radical scavenging activity. Ascorbic acid was used as the reference molecule in this study. Interestingly the best performing fractionate and ascorbic acid were able to inhibit 85.67% and 92.11% of ABTS cation radical at 0.05 mg/ml concentration, respectively. The inventors now established that BSF-APHs exhibit ABTS cation radical scavenging Emax of 91% (at 0.2 mg/ml). This shows that fractioning BSF-APH will result in fractions that have very strong antioxidant potential. 4.4. Neutrophil response modulation activity Strong free radical scavenging activities of BSF derivatives are evident from section 4.2 and 4.3. Furthermore, all the samples were also tested for neutrophil response modulation activity. Neutrophils are white blood cells present in animal body (including humans, pets, fishes and swine). They are involved in the primary defense against pathogens. When pathogenic microbes enter the animal body, neutrophils rush to the site of infestation and initiate defense. During granulation, neutrophil release a wide range of oxidative enzymes including NADPH oxidase, which is responsible for production of superoxide anion and by product (e.g. hydrogen peroxide). Superoxide anion can further react with nitric oxide radical to produce peroxynitrite. This process also generates hydroxyl radical (by reaction of hydrogen peroxide with metal ion). This battery of oxidative reactions are crucial to the defense of the host animal. However, these ROS generated during host defense can react with enzymes, proteins, lipids, etc. of body cells and result in the development of different health conditions (for e.g. cellular ageing, cancer, etc.). The neutrophil assay conducted in this research determines the ability of proteinaceous molecules to scavenge ROS produced as a result of neutrophil activity. PMA was used to activate protein kinase C present in neutrophils, which results in production of NADPH oxidase responsible for catalyzing ROS production. ROS production in system is coupled with lucigenin amplified chemiluminescence. Ability of proteinaceous sample to scavenge ROS (particularly superoxide anion) is marked by decreased chemiluminescence.To the inventor’s knowledge, this is the first analysis and determination of in vitro neutrophil response modulation activity of BSF derivatives. CM exhibited pro- oxidant behavior at 3 out of 5 tested concentrations, and Emax of only 5% at 0.2 mg/ml (see figure 7 and table 17). CM is commonly used in pet food preparations. However, the inventors now established that CM inclusion offers little or no benefits relating to scavenging the ROS produced by neutrophils, in contrast to the scavenging activity of the hydrolysate of the invention. Moreover, CM inclusion could even result in inflammatory damage to host cells, in contrast to the BSF larvae protein hydrolysate of the invention. Repetitive inflammatory damage of canine or feline cells could translate into conditions such as accelerated aging, slow cognitive function, etc. On the other hand, FM exhibits mild antioxidant behavior in this assay, with Emax of 22% (see table 17). At 0.2 mg/ml, FM exhibits inhibition of 5%. Aquaculture rearing media (i.e. water) offers a continuous buffer of pathogenic bacteria. Therefore, aquaculture organisms are at constant risk of pathogenic bacterial invasions. This results in wide range of health conditions, including reduced immunity, aging, etc. The inventors executed comparative tests with FM which highlights the inadequacy of FM to suppress the inflammatory damage from repetitive neutrophil activity. This often translates into incremental cost occurring as a result of antibiotics and nutritional supplement usage. Surprisingly, BSF- APH exhibits Emax of 36.62% (see table 17). Therefore, without wishing to be bound by any theory, according to the inventors, the BSF-APH of the invention offers natural and sustainable solution to suppress oxidative damage resulting from pathogenic invasion. 4.5. MPO response modulation activity (SIEFED and classical assay) The general mechanism of neutrophil response is known. The neutrophil extracellular trap contains several molecules required to inactivate pathogenic microbes. MPO enzyme present in neutrophil extracellular trap can produce hypochlorous acid from hydrogen peroxide and chloride ion. Additionally, MPO is capable of oxidizing tyrosine into the tyrosyl free radical. Both products of MPO oxidation (hypochlorous acid and tyrosyl free radical) are crucial to inactivate pathogens. Again, repetitive interaction of these molecules with animal cells result in inflammatory damage. In an animal body, MPO- Fe(III) (active form) reacts with hydrogen peroxide to form oxoferryl π cation radical (CpI form). CpI form converts back into MPO-Fe(III) coupled with chloride ion transforming into hypochlorous acid. However, in the present experiment, back reduction of the Cp I form to MPO-Fe(III) was achieved in 2 stages. First reduction of CpI to MPO-Fe(IV)=O via electron transfer through nitrite ions. Then, electron provisioning was done (via Amplex^TM Red oxidation to resorufin reaction) which converts MPO-Fe(IV)=O to MPO-Fe(III) form. Proteinaceous molecules could prevent the oxidative damage resulting from MPO either by directly reacting with CpI form and terminating the halogenation, or by donating hydrogen (hydrogen atom transfer) to ROS produced as a consequence of MPO activity. MPO response modulation activity was analyzed using the classical and SIEFED assay. The classical assay measures ability of sample to complex with CpI form and stabilize ROS. Whereas in SIEFED assay, MPO is bound to rabbit polyclonal antibodies (and rest of the compounds are washed away), so it purely measures the ability of samples to complex with CpI form. As with neutrophil response modulation activity, MPO response modulation activity of the BSF derivative hydrolysed BSF larvae protein is also found by the inventors for the first time. FM and CM exhibit pro-oxidant behavior in both the assays (see figure 5 and 6). Presence of oxidative reaction products in FM and CM (as a consequence of production process) that are capable of initiating pro- oxidative response has been already discussed in section 4.2. Detailed in vitro investigations in comparative examples realized by the inventors show that inclusion of FM and CM in animal diets may result in inflammatory damage, in contrast to the effect seen with BSF-APH. In classical assay, BSF-APH exhibits surprisingly strong antioxidant potential. BSF-APH shows strong antioxidant potential in classical assay (see table 16). These observations show that BSF-APH is very suitable for use in pet food and aquaculture formulations to effectively suppress inflammatory damages resulting from MPO activity, for example for use as a food or feed ingredient. The inventors surprisingly found that BSF protein derivatives offer anti-oxidative advantage over FM and CM. EXAMPLE 8 Materials and Methods Raw materials Chicken meal (CM) was purchased from an online webshop in October 2020. Three types of BSF protein derivatives namely: pasteurized minced meat supplied frozen at - 20°C; enzymatically hydrolyzed and pasteurized minced meat also supplied frozen at -20°C; and hydrolysate of water-soluble proteins supplied as dry powder were provided by Protix B.V. (Dongen, The Netherlands) in November 2020. Product composition, storage conditions and method employed to develop water-soluble extract were similar or the same as indicated in Mouithys-Mickalad et al. (Ange Mouithys-Mickalad, Eric Schmitt, Monika Dalim, Thierry Franck, Nuria Martin Tome, Michel van Spankeren, Didier Serteyn and Aman Paul, Black Soldier Fly (Hermetia illucens) Larvae Protein Derivatives: Potential to Promote Animal Health, Animals 2020, 10, 941; doi:10.3390/ani10060941) and in international application WO 2021/054823 A1. Live and washed larvae (black soldier fly) of 14 days old post hatching (5 kg) were collected just before being subjected to mincing by using the mincer and subsequently processed or first stored at 4 ^C until used. For each experiment 100 g larvae were minced freshly. Hundred g of minced larvae were heated to 90°C (with continuously stirring) and the product was kept at this temperature for 80-120 s. In particular, protein is obtained when minced black soldier fly larvae are heated for 80 seconds at 90 ^C. The insect pulp (puree), i.e. BSF pasteurized minced meat, obtained was cooled to 3 ^C - 7 ^C. More in detail, Fourteen days old BSFL (black soldier fly larvae) were washed with tap water and then immediately minced using a blender. Then, samples were pasteurized using the micro-cooker for 80 seconds at 90°C. Samples were placed in the fridge (4°C), therewith providing cooled heated insect pulp. Protein hydrolysis A puree of BSF larvae, also referred to as BSF PureeX^TM (BSF-P), and hydrolyzed puree (BSF-HP) obtained by enzymatic hydrolysis of the puree of BSF larvae, were prepared by Protix B.V. (Dongen, The Netherlands). The puree and the enzymatically digested puree were obtained according to the following method. Live and washed Black Soldier Fly larvae of 14 days old (after hatching) were collected just before being subjected to the mincer for mincing the larvae (therewith providing larvae pulp (also referred to as puree)), and subsequently stored at 4 ^C until used. For each experiment, larvae were minced freshly. The minced larvae was treated with 0.1% or 0.5% Flavourzyme, based on the mass of the minced larvae, for 0,5 – 3 hours, for example 1 to 2 hours, at 45 ^C to 65 ^C (± 2 ^C) under continuous stirring. The batch of hydrolysed BSF larvae puree applied was obtained by enzymatic hydrolysis for 1 hr at 50 ^C (± 2 ^C). Flavourzyme (Novozymes, Denmark) is a combination of aminopeptidases which have endopeptidase and exopeptidase activities. The enzyme-treated minced larvae, and control larvae without enzyme treatment, were heated to 90°C and the product was kept at this temperature for 80 seconds. The obtained insect puree were used for measuring free amino acid content (Free amino acid content (n = 1)- Tested in puree) and pepsin digestibility (Digestibility (n = 1)- Tested in puree). Protein meal was obtained from the heated BSF larvae pulp, and from the two batches of heated BSF larvae pulp that was first subjected to enzymatic hydrolysis of proteins using either 0.1 wt%, or 0.5 wt% Flavourzyme prior to the heating step at 90 ^C, e.g. by steps of protein separation from the pulp, evaporation, drying and grinding. In all experiments performed, a dose dependent effect was observed, when the amount of applied enzyme is considered. Thus, enzymatic treatment of minced larvae using Flavourzyme prior to the heating step increases the free amino acid content and increases pepsin digestibility of the obtained hydrolysed larvae puree, and as a result, the obtained puree comprising hydrolysed protein has a better taste (free amino-acid content relates to attractive, appealable taste when animals and humans consume a product comprising free amino-acids), is highly digestible and has anti-oxidant properties (see test results, here below). In addition, enzymatic treatment of BSF larvae pulp (pure; minced larvae) improves the fat separation in the following separation step after enzymatic hydrolysis and heat-treatment of the enzymatically digested pulp, which increases the fat extraction from the protein meal, when compared to fat separation from the protein fraction obtained with larvae puree that was not subjected to an enzymatic hydrolysis step prior to heating at 90 ^C. Glucosamine content Glucosamine content analysis of BSF protein derivatives (P, HP, AHP) and chicken meal (CM) was performed by Eurofins Food Testing B.V. (Barendrecht, The Netherlands). Samples were mixed with phenyl isothiocyanate in a pre-column derivatization reaction. Following this, samples were separated on a reverse phase ultra-liquid chromatography system equipped with an ethylene bridged hybrid column. Quantification of peaks was done against an external standard: dog food comprising insect protein (“Insect Protein All Breeds Dog Food”, Yora, Warninglid, UK). As said, glucosamine content was measured in BSF protein derivatives as well as chicken meal. For biochemical investigations, hydrolysate of water-soluble proteins (APH) was used as it is, because of high water solubility. Whereas, in case of other raw materials (other two BSF protein derivatives and chicken meal), because of limited water solubility respective water-soluble extracts were used for testing. The glucosamine contents of P, HP, APH and CM is indicated in Figure 10 and in Table 18. There were no significant differences in the glucosamine content amongst the samples (p < 0.05). Table 18. Glucosamine content of BSF protein derivatives and chicken meal

Data is presented as mean ± standard deviation (n = 3). Letter above the bars represent significant differences (p < 0.05). a: weight percentage (on dry matter basis) compared to the total mass of the (hydrolysed) protein composition. Glucosamine and its salts are commonly used as nutraceutical supplements to ease the pain in dogs suffering with OA. Glucosamine, being an amino monosaccharide, is the preferred substrate for the biosynthesis of glycosaminoglycan, which is further used for the biosynthesis of proteoglycans that form cartilage. Three insect protein samples tested contain 0.4 to 0.5% by weight glucosamine (on dry matter basis) in the monomeric form. Therefore, dry pet food containing 30% of these insect proteins can supply about 120 mg glucosamine per 100 g of formula. A popular pet food brand currently recommends feeding 250 to 340 g insect-based formula per day to dogs with body weight 20 to 30 kg. This feeding pattern will render about 300 to 400 mg glucosamine to consuming dog, which is considerable when compared to commercial glucosamine supplements available in market that contain 300 to 1600 mg glucosamine. However, there are some reports that provide evidence about limited uptake of orally administer glucosamine in dogs. For proper functioning of the activity against OA, the in vivo uptake of glucosamine present in BSF proteins is essential. Cell membrane stability assay – erythrocyte stability assay Cell membrane stability assay was realized according to the protocol of Karimi et al. Blood used for the assay was extracted from a healthy horse in 10 ml tubes containing EDTA. It was centrifuged for 10 min at 3000 rpm and plasma supernatant was discarded. Obtained erythrocytes (red blood cells) were washed two times with 5 ml PBS solution at pH 7.4. Red blood cell pellets were diluted 10 times by phosphate buffer solution. Aliquots (0.5 ml) of this cell suspension were transferred to 5 ml tubes. This was followed by addition of 0.35 ml of 0.15 M phosphate buffer, 0.1 ml water-soluble extract solution of CM, P, HP and APH (at 0.25, 0.5, 1 and 2 mg/ml) and incubation for 10 min. The red blood cells (1 ml of above solution) were challenged by addition of 0.05 ml 25 mM 2,2’-Azinobis(2-amidopropane) di- hydrochloride (97%). For control, only buffer solution was used instead of water-soluble extract solutions. The resulting mixtures were incubated for 30 min at 57°C. Finally, the mixtures were chilled to 4°C and centrifuged for 10 min at 3000 rpm. The supernatants (0.5 ml) were diluted with PBS and the absorbance was measured at 560 nm. Percentage inhibition toward lysis from 2,2’-Azinobis(2- amidopropane) di-hydrochloride (AAPH) was estimated using the formula: [(absorbance of control – absorbance of respective sample) / (absorbance of control)] x 100%. The protective effect of P, HP, APH and CM against free radical- (in this case AAPH) induced red blood cell lysis is indicated in Figure 11. During this assay P, HP and APH showed an increase in inhibition with increasing concentration from 0.25 to 1 mg/ml. At the highest concentration used, % inhibition was in following order: P> HP> CM> APH (p < 0.05). These results identified pasteurized meat of BSF larvae as a most effective composition in protecting the red blood cells against AAPH induced cell lysis with regard to all the tested samples. Erythrocyte stability is crucial during for example arthritis. Literature published during last decade has highlighted the importance of erythrocytes in osteoarthritis (OA). There is already evidence showing the increase of erythrocyte sedimentation rate during OA. The increase of erythrocyte sedimentation rate could be attributed to the assault of ROS produced during the third phase of OA process. Furthermore, if the concentration of viable erythrocytes in the joint cavity decreases, it can have severe implications to the cartilage and synovial tissues. During this assay AAPH was used to generate ROS. AAPH is commonly used in biochemical assays to investigate cyto-protective effects of amino residues. AAPH can generate free radicals via spontaneous decomposition (at body temperature i.e., 37°C, when e.g. human subjects and dogs are considered). These free radicals can react with oxygen to produce ROS, which can further react with lipids present in cellular membrane to form peroxyl radicals. This process not only results in production of peroxyl radicals that participate in inflammatory process, but also results in disintegration of cells (including erythrocytes). Molecules that can stabilize the reactive products generated by AAPH are known to have cyto-protective effects and could contribute towards prevention of OA. Surprisingly now, the inventors demonstrated that BSF protein derivatives have strong cyto- protective activity at all the concentrations ≥ 0.5 mg/ml (see figure 11). Previously, the inventors demonstrated the strong potential of BSF protein derivatives to donate hydrogens atoms and electrons in stabilizing free radicals (Mouithys-Mickalad et al., 2020). Indicating that BSF protein derivatives could instantly donate these chemical species to stabilize the intermediates of AAPH induced oxidation resulting in cyto-protective effects in e.g. a (human) patient suffering from or at risk for any one or more of: inflammation, intestinal inflammation, such as in inflammatory conditions of the small intestine and/or colon, chronic or acute inflammatory intestinal disease, damaged structural biomolecules of the intestine, such as the small intestine and/or the colon, chronic or acute enteropathy, and/or one or more symptoms thereof, chronic or acute enteritis and/or one or more symptoms thereof, inflammatory bowel disease, and/or one or more symptoms thereof, ulcerative colitis, and/or one or more symptoms thereof, Crohn’s disease, and/or one or more symptoms thereof, irritable bowel syndrome, and/or one or more symptoms thereof, intestinal damage such as induced by activated macrophages and/or of intestinal macrophage activation, such as in the small intestine and/or colon, intestinal macrophage activation and/or macrophage-induced intestinal damage, such as in the small intestine and/or colon, low-grade inflammatory disease of the intestine, such as of the small intestine and/or colon, and/or an innate immune response in an intestine, such as in the small intestine and/or colon, in a human subject or in an animal such as a horse, a pet such as a dog or a cat, preferably a human subject or a dog and/or in e.g. human OA patients and dogs suffering from OA, or even in human subjects and dogs in order to prevent any one or more of the here-above listed diseases and health problems (prophylaxis). At highest concentration, out of all tested samples BSF-P (pasteurized minced meat of insect) exhibited maximum inhibition of cell lysis. Reactive oxygen species (ROS) production of macrophages Human myeloid HL-60 cell line was purchased from American Type Culture Collection (Manassas, USA) and cultured according to the method of Boly et al. (Rainatou Boly, Thierry Franck, Stephan Kohnen, Marius Lompo, Innocent Pierre Guissou, Jacques Dubois,Didier Serteyn, and AngeMouithys-Mickalad, Evaluation of Antiradical and Anti-Inflammatory Activities of Ethyl Acetate and Butanolic Subfractions of Agelanthus dodoneifolius (DC.) Polhill & Wiens (Loranthaceae) Using Equine Myeloperoxidase and Both PMA-Activated Neutrophils and HL-60 Cells, Evidence-Based Complementary and Alternative Medicine Volume 2015, Article ID 707524, 9 pages, 1-9, dx.doi.org/10.1155/2015/707524). At the start of each assay: (1) cell count of suspension was estimated to maintain cellular density of 10⁶ cells/ml; (2). cell viability was measured using trypan blue assay to ensure the main viability >95% in all assays performed. Cultured HL-60 cells were plated in Iscove’s modified Dulbecco’s medium. Differentiation was induced by adding 10 nM phorbol myristate acetate (PMA) dissolved in dimethyl sulfoxide (DMSO) for 24 h (37°C). It was ensured that final concentration of DMSO in the culture medium was < 0.1% and DMSO addition did not impact HL-60 proliferation, viability, and differentiation. Morphological alteration (to macrophage phenotype) in HL-60 cells resulting from differentiation was verified after 24 h of culturing using light microscopy. Post differentiation, the medium was discarded, and non-adherent cells were gently washed with Hank’s balanced salt solution. Only the adherent cells were used for the assay. Reactive oxygen species (ROS) produced by macrophages was estimated by chemi- luminescence (CL) measurement. During this assay L-012 salt (8-Amino-5-chloro-2,3-dihydro-7-phenyl- Pyrido[3,4-d]pyridazine-1,4-dione, sodium salt) was used as CL enhancer using a method adapted from Ielciu et al. Macrophages were treated with 0.05 ml of water-soluble extracts of CM, P, HP and APH to reach final concentration of 0.025, 0.05, 0.1 and 0.2 mg/ml and incubated for 1 h in the presence of 0.8 ml HBSS. Then, 20 µl of Ca²⁺ (10 mM), 20 µl of L-012 salt solution (10^-4 M) were added prior to activation with 0.05 mL PMA and final volume was made up to 1 ml. The CL response of macrophages was monitored for 30 min at 37°C using a Fluoroskan Ascent (Fisher Scientific, Tournai, Belgium) and expressed as the integral value of total CL emissions. For control only HBSS was added instead of water-soluble extract solution of CM, P, HP and APH. The effect of P, HP, APH and CM on the ROS production by macrophages is displayed in Figure 12. For P, HP and APH there was a decrease in chemi-luminescence with increasing concentration (i.e., decrease in ROS production). For CM, there was no change in chemi-luminescence with increase in concentration. Indicating that all the BSF protein derivatives and compositions reduce the ROS production, whereas CM has no effect on the ROS production by macrophages. The significant differences amongst the chemi-luminescence signals at highest concentration tested are also indicated in Figure 12. Macrophages have a key role in animal body due to their ability to identify, engulf and destruct pathogenic microbes or substances during phagocytosis. During OA, the activated macrophages express NOX2 genes that trigger secretion of NADH oxidase, which results in the production of ROS including superoxide anions. These ROS are further responsible for chondrocyte senescence and cartilage breakdown. The inventors no surprisingly found that all three BSF protein derivatives were able to suppress ROS production by macrophages. At highest concentration used P and APH were able to suppress ROS production > 50% in comparison to control. Whereas no ROS suppression activity was observed in case of CM. Without wishing to be bound by any theory, ROS suppression activity could arise due to two mechanisms: (a). Scavenging of ROS produced by macrophage. The inventors have demonstrated the strong potential of BSF protein derivatives to scavenge ROS. In addition, the inventors also demonstrated that CM is ineffective in scavenging ROS (Mouithys-Mickalad et al., 2020). (b). Down regulation of NOX2 genes - There is well documented evidence regarding ability of specific food derived bioactive peptides to down regulate genes responsible for ROS production. Without wishing to be bound by any theory, it is possible that BSF protein derivatives also have specific peptides that could result in such down regulation. Results obtained with the here presented examples show that BSF protein derivatives can suppress ROS production from macrophages and herewith would help in prevention of OA in e.g. human subjects and pets such as dogs, cats, and in e.g. horses. Furthermore, without wishing to be bound by any theory, perhaps the BSF peptides and protein compositions have the capability to down regulate genes responsible for inflammation. Reactive oxygen species production of PMA activated HL-60 cells Human myeloid HL-60 cell line was purchased from American Type Culture Collection (Manassas, USA) and cultured according to the method of Boly et al. At the beginning of each assay: (1) cell count of suspension was estimated to maintain cellular density of 106 cells/ml; (2). cell viability was measured using trypan blue assay to main viability > 95 %. Cultured HL-60 cells (5x10⁵) were suspended in 143 µl HBSS and loaded in each well of a 96- well microtiter plate and were incubated at 37°C for 10 min with 2 µl of water-soluble extracts of CM, P, HP and APH to reach final concentration of 0.025, 0.05, 0.1 and 0.2 mg/ml. Post incubation, 20 µl of Ca2+ (10 mM), 20 µl of L-012 salt solution (10-4 M) were added into each well. Finally, the mixtures were activated with 10 µl PMA (16 µM). The CL measurement and control preparation was done as indicated here below in the paragraph relating to ‘Metabolic activity of HL-60 cells’. Again, chemi- luminescence was expressed as integral value of total chemi-luminescence emissions. The effect of P, HP, APH and CM on the ROS production by PMA activated HL-60 cells is indicated in Figure 13. A decrease in production of ROS was observed with increasing concentration of P, HP and APH. In case of CM, at the lowest concentration tested ROS production was 1.5 folds higher in comparison to control. The ROS production decreased with increasing concentration. However, even at the highest concentration tested CM exhibited pro-inflammatory behaviour. At final concentration % relative chemi-luminescence was in following order: CM > P = HP = APH. Oxidative stress could trigger ROS production from monocytes which may contribute in OA development. The inventors used PMA activated HL-60 cells to mimic monocytes. Surprisingly, the inventors found that BSF protein derivatives are highly effective in suppressing the ROS production by HL-60 cells. Without wishing to be bound by any theory, the ROS suppression activity could arise due to two mechanisms: (a). Scavenging of ROS produced by the cells. The inventors have demonstrated the strong potential of BSF protein derivatives to scavenge ROS. In addition, the inventors also demonstrated that CM is ineffective in scavenging ROS (Mouithys-Mickalad et al., 2020). (b). Down regulation of NOX2 genes - There is well documented evidence regarding ability of specific food derived bioactive peptides to down regulate genes responsible for ROS production. Without wishing to be bound by any theory, it is possible that BSF protein derivatives also have specific peptides that could result in such down regulation. Results obtained with the here presented examples show that BSF protein derivatives can suppress ROS production from the cells and herewith would help in prevention of OA in e.g. human subjects and pets such as dogs. Furthermore, without wishing to be bound by any theory, perhaps the BSF peptides and protein compositions have the capability to down regulate genes responsible for inflammation.. Whereas CM exhibited pro-inflammatory activity in this assay. Indicating that CM stimulates the ROS production in this assay, which may aid OA development in pets. Metabolic activity of HL-60 cells Cultured HL-60 cells were incubated with 0.025, 0.05, 0.1 and 0.2 mg/ml of each water-soluble extract of CM, P, HP and APH for 1 h at 37°C. Post incubation, treated cells were washed two times with media and the cell metabolic activity was evaluated by adding 10 µl MTS tetrazolium salt as a cytotoxicity indicator. Absorbance of mixtures were measured after every 60 min during 2 h. The outcomes of cellular toxicity analysis of P, HP, APH and CM are indicated in Figure 14. None of the tested samples exhibited toxicity in this assay. None of the tested samples had negative effect on the viability of HL-60 cells during this assay. This provides the following surprising indication: (a). BSF protein derivatives and (hydrolysed) protein compositions are not toxic to mammalian cells such as human cells and animal cells, such as cells of dogs, cats, horses; (b). ROS suppression activity seen in previous sections is not arising due to cellular mortality. Statistical analysis All the testing of the above examples was performed in triplicates. Significant differences in values obtained during glucosamine content determination, cell membrane stability, ROS production by macrophages and ROS production by PMA activated HL-60 cells analyses were examined using one- way ANOVA. Subsequently, Tukey’s Range Test was performed to identify which differences were statistically significant. Differences between means were considered significantly different if p-value was less than 0.05. This analysis was conducted in GraphPad Prism 8 (GraphPad Software, San Diego, USA). EXAMPLE 9 Modified insect fat: Characteristics and Applications Background Black soldier fly larvae (BSF) lipids are now being considered as sustainable alternative of palm kernel oil. A program was set up to investigate whether LipidX could be modified to meet the desire for a softer product with higher water dispersibility, without detriment to other chemical, physical and nutritional properties. It was hypothesized that enzymatic processing of BSF lipids leading to production of partial glycerides and free fatty acids, and also possibly the re-esterification of fatty acids back on glyceride backbone could open several new applications. During this study, BSF lipids were enzymatically hydrolyzed and the resulting fractions were analysed for: - TAG, DAG, MAG and FFA composition of all hydrolysed product - Crystallization and melting properties - Emulsion stability - Antimicrobial properties Materials and methods A preliminary study had been conducted to compare different enzymes, all obtained from Novozymes, Denmark, which resulted in the selection of Eversa Transform 2.0. This enzyme was selected for in depth analysis. The details about this enzyme are as follows:

Enzymatic hydrolysis A batch of Eversa Transform 2.0 (NS-F1036) was sourced from Novozymes. This enzyme was stored according to the guidelines provided by the supplier. LipidX was obtained from Protix’ production facility (stored according to specification) and used within 7 days of obtaining. Before hydrolysis LipidX was melted by keeping them in a water bath at 35 °C for 30 min. Following this hydrolysis was carried using following conditions:

Immediately after the hydrolysis the samples were transferred to fridge (4 °C) and stored there until further analysis. Composition analysis of LipidX and resulting hydrolysed lipid fractions Composition analysis was done at Nutrilab B.V. As a part of compositional analysis TAG, DAG, MAG and FFA content of LipidX and three hydrolysed fractions was analysed. Solid fat content (as a function of temperature) Tubes are filled with molten product for each test/temperature. All tubes are first brought to 0 ^oC (stand for 60 minutes). From here, the tubes are transferred to water baths of the temperature to be measured (stand for 30 minutes). Then the tubes are measured by means of the NMR spectrometer to determine solid fat content. Solid fat content (as a function of temperature) Analysis of the three enzyme-treated products revealed that, at each temperature, the solid fat content was below that of the LipidX product, with the following order (of solid fat content): hydrolysed lipids 10% < Hydrolysed lipids 1% < Hydrolysed lipids 0.5% < LipidX, as summarized in the table below.

Composition analysis Results obtain are summarized in the table below:

It is clearly visible that increasing the enzyme concentration results in an increase in the concentration of resulting diglycerides and free fatty acids. Another observation is that TAG, DAG, MAG and FFA content of Hydrolysed lipids 0.5% and 1% is very similar. According to Krog and Sparsø (2004, Food emulsifiers: their chemical and physical properties. Food Emuls. 45–91), monoglyceride and diglycerides have higher melting points than triglycerides. The melting point of lauric acid is 43.2 °C (PubChem, n.d.). For lauric acid containing fatty acid derivatives, the order of melting temperature is: α crystals of trilaurin < β crystals of trilaurin < free lauric acid < 1,3-dilaurin < 1-monolaurin (Figure 15). Eversa transform 2.0 also possesses interesterification activity. It is hypothesized that the higher the production of partial glycerides and free fatty acids, the higher was the extent of interesterification. It is also hypothesized that production of high levels of DAG and MAG will improve the emulsifying properties of resulting fractions. EXAMPLE 10 – Granulocyte and monocyte inactivation Materials and Methods Experimental diets Two isoenergetic and isonitrogenous diets were formulated to attend nutrient requirement of adult dogs according to FEDIAF (2020). The conventional diet with 26% of low ash poultry by-product meal (PBM), and diet with 29.5% black soldier fly larvae protein (BSFL), also referred to as ProteinX, were formulated (Table 19). Both diets were extruded using a single-screw extruder at Sao Paulo State University, Botucatu (BR). After extrusion, kibbles were dried in a crawler-type dryer. Poultry fat and palatants were sprayed on the kibbles under continuous mixing immediately after drying. The BSF larvae protein fraction comprises 15wt% fat based on the total weight of the dry matter content of the BSF larvae protein fraction. Since the diet comprises 29,50wt% BSF larvae protein, the diet comprises 4,43wt% BSF larvae fat, of which about 40wt% is lauric acid based on the total weight of the fatty acids in the fat. Animals, accommodation and food The study has been carried out at the Animal Nutrition Laboratory of the Federal University of Paraíba (UFPB) and Altos do Miramar Kennel, located in the state of Paraíba, Brazil. Kennel owner was aware of all procedures and gave a written consent for inclusion of their animals in the study. All procedures were previously approved by local ethics in the use of animals committee (CEUA nº 3149030322). Eight healthy beagle dogs, male and female, vaccinated, free of worms and ectoparasites, 3.2 ± 1.4 years old, initial body weight 10.88 ± 1.232 kg and body condition score (BCS) of 5.2 ± 1.2 (9 points scale) were used in this study. The study has been conducted in a cross-over design, with two diets and two periods. Each period will last 50 days, with half of animals eating BSFL diet and the other half PBP diet, followed by the second period, where dogs will receive the opposite diet for 50 additional days. Each animal has been fed according to dogs energy requirement for maintenance (NEM) = 110 × kg body weight 0.75. The food has been weighed daily and offered in 2 meals at 9:00 am and 4:00 pm. Food leftovers have been weighed to calculate consumption. Water is provided ad libitum. Dogs will be individually housed in kennels (8 m²) with access to an outdoor area environmentally enriched (120 m²) for socialization and physical activities, 1 hour per day (except during the feces collection period). Biochemical Parameters Blood samples for assessment of effect of diets in the biochemical parameters, were obtained through venepuncture alternating between the left and right jugular veins and using 0.8×0.25mm needles and 10mL syringes. Blood samples (4mL) collected were distributed into previously identified tubes without anticoagulant. Serum was obtained by centrifuging the samples for 10min at 1500g at 4°C. The aliquots were frozen at −80°C until needed for biomarker analyses. Evaluation of diets on organic antioxidant defense system Before start and after 60 days of diets consumption, to evaluate the effect of diets consumption on organic antioxidant capacity, will be performed blood collection for analysis of thiobarbituric acid reactive substances (TBARS), total antioxidant capacity, 2,2-diphenyl-1-picryl-hydrazyl (DPPH), Vitamin E and measurement of redox enzymes (GSH, CAT, GST, SOD e LPO). Additionally, after 50 days of diets consumption will be performed phagocytosis assay. Vitamin E Vitamin E concentrations are determined by high-performance liquid chromatography (Shimadzu Co., Kyoto, Japan), according to Arnaud (1991) [Arnaud, J., Fortis, I., Blachier, S., Kia, D., Favier, A. (1991). Simultaneous determination of retinol, alpha-tocopherol and betacarotene in serum by isocratic high- performance liquid chromatography. Journal of Chromatography, 572, 103–116. DOI: 10.1016/0378- 4347(91)80476-S.]. TBARS (MDA) Malondialdehyde (MDA). Malondialdehyde is one of the most abundant aldehydes resulting from tissue lipid peroxidation and can be considered a marker of global oxidative stress. In addition, it is related to the aging process (Fan et al., 2014) [Q. Fan, L. Chen, S. Cheng et al., “Aging aggravates nitrate- mediated ROS/RNS changes,” Oxidative Medicine and Cellular Longevity, vol.2014, Article ID 376515]. This analysis is carried out according to the method proposed by Gerard-Monnier (1998) [D. Gerard- Monnier, I. Erdelmeier, K. Regnard, N. Moze-Henry, J. C. Yadan, and J. Chaudiere, “Reactions of 1- methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation,” Chemical Research in Toxicology, vol.11, no.10, pp.1176– 1183, 1998], with some adaptations. For the determination of MDA in the plasma, 100 μl of plasma is used. To this, 300 μl of 10 mM solution of 1-methylphenylindole in acetonitrile and methanol (2 : 1, v/v) and 75 μl HCl PA (37%) is added. Soon after, the tubes are vortexed and incubated in a water bath at 45°C for 40 minutes. After the bath, the samples are cooled on ice and then the tubes are centrifuged at 4000 rpm for 10 minutes. From the supernatant, absorbance is read in an apparatus (SpectraMax M3, Molecular Devices, USA) with a wavelength of 586 nm. The concentration of MDA is calculated using a hydrolyzed 1,1,3,3-tetramethoxypropane (TMP) curve (Ekstrom et al., 1988) [Ekström, T., Garberg, P., Egestad, B., & Högberg, J. (1988). Recovery of malondialdehyde in urine as a 2, 4- dinitrophenylhydrazine derivative analyzed with high-performance liquid chromatography. Chemico- biological interactions, 66(3-4), 177-187]. TAC Antioxidant Activity. Antioxidant molecules prevent or inhibit the harmful reactions of reactive oxygen species. Plasma concentrations of different antioxidants can be measured in the laboratory separately, but the measurements are time-consuming, costly, labor-intensive, and often require complicated techniques. As the effect of these different antioxidants is additive, an alternative is to measure the total antioxidant capacity (TAC). This variable is measured using a method based on 2,2-azinobis 3- ethylbenzthiazoline-6-sulfonate (ABTS) by absorbance reading (Erel, 2004) [Erel, O. (2004). A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clinical biochemistry, 37(4), 277-285]. DPPH (2,2-diphenyl-1-picryl-hydrazyl) The hydrogen donor activity by serum antioxidants is evaluated by DPPH• quenching read by UV– visible spectrophotometry (Janaszewska A & Bartosz G, 2002) [Janaszewska A & Bartosz G (2002) Assay of total antioxidant capacity: comparison of four method as applied to human blood plasma. Scand J Clin Lab Investig 62, 231–236]. A mixture of 0·5 ml serum and 0·5 ml acetone are vortexed for 1 min and then centrifuged for 5 min at 5500 g and 4°C for deproteinisation of the sample. The supernatant is filtered with a Pasteur pipette filled with cotton cloth to remove small particles. A 0·1 mM methanolic DPPH solution (0·0039 g per 100 ml) is prepared immediately before testing and is incubated in the dark. An aliquot of 400 µl of DPPH solution is added to 360 µl of phosphate buffer (pH 7·4) and 40 µl of sample and homogenised by vortexing. Absorbance is read at 505 nm (Labquest, Labtest Diagnostica) at 0, 5, 10, 15 and 20 min after mixing. The inhibition (discoloration) of DPPH• radical is calculated as the relative percentage of absorbance of the sample at the time of the reading compared with a blank (400 µl of DPPH solution plus 400 µl of phosphate buffer) Redox Parameter Evaluation (GSH, CAT, GST, SOD and LPO) The quantification of the activity of SOD enzymes (Gao et al.1998) [Gao, R., Yuan, Z., Zhao, Z., Gao, X., 1998. Mechanism of pyrogallol autoxidation and determination of superoxide dismutase enzyme activity. Bioelectrochemistry Bioenerg. 45, 41–45. https://doi.org/10.1016/S0302-4598(98)00072-5], catalase (CAT) (Aebi, 1984) [Aebi, H., 1984. Catalase in vitro. pp. 121–26. https://doi.org/10.1016/S00766879(84)05016-3. Association of American Feed Control Officials (AAFCO). 2014] and glutathione transferase (GST) (Habig et al. 1974) [Habig, W.H., Pabst, M.J., Jakoby, W., 1974. Glutathione S-transferases. The First Enzymatic Step in Mercapturic Acid Formation. J Biol Chem], the quantification of glutathione GSH (Sedlak & Lindsay, 1968) [Sedlak, J., Lindsay, R.H., 1968. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal. Biochem. 25, 192–205 ]and lipid peroxidation (LPO) (Jiang et al. 1991) [Jiang, Z.-Y., Woollard, A.C.S., Wolff, S.P., 1991. Lipid hydroperoxide measurement by oxidation of Fe2+ in the presence of xylenol orange. Comparison with the TBA assay and an iodometric method. Lipids 26, 853– 856 ] allows us to infer and discuss the functioning of enzymatic and non-enzymatic antioxidant systems. Enzymes exist to protect organs against oxidative damage caused by the production of Reactive Oxygen Species (ROS), including hydrogen peroxide, singlet dioxygen (1O2) and the hydroxyl radical (HO). Phagocytosis assay To determine the absolute proportion and count of peripheral blood cells, 1 mL of whole blood collected with anticoagulants is used for purification of peripheral blood mononuclear cells (PBMC) by the red cell lysis method or by gradient. After purification, the PBMC are incubated for 30 minutes (RT) with 50 µL of a fluorescent particle phagocytosis conjugate (pHrodo™ Green Zymosan Bioparticles™ Conjugate for Phagocytosis, from ThermoFisher Scientific, 1mg/mL). Samples are incubated with pHrodo™ for 30 minutes at 37ºC and then fixed with 1% paraformaldehyde for 30 minutes at 4ºC. Afterwards, the already labeled and fixed cells are resuspended with 2 mL of phosphate-buffered saline (PBS) + 1% Bovine serum albumin (BSA) + 0.01% sodium azide, for storage until reading and analysis by flow cytometry. For absolute quantification of circulating leukocytes, 50 µL of absolute count microspheres (C36950, CountBright from ThermoFisher Scientific) are added. Statistical Analysis Antioxidant parameters will be evaluated by two-way analysis (Two diets: HPM, CPM) x time (two moments: 0 and 50 days of diets consumption)] with repeated measures on one factor [time] measures. Post-hoc comparisons of the data will be carried out using a Tukey-Kramer multiple comparison test. Statistical analyses will be performed using SigmaPlot v.12.0 software at 5% significance level. Results The study is on day 45 of the first period. All partial results presented were calculated considering the data obtained in the first period (4 dogs of each treatment) and the final values can suffer changes. It was possible to extrude diets on a high level of inclusion of BSFL, with acceptable density (380 g/L), proper cooking and expansion. Dogs presented good acceptance of diets with no episode of refusal, diarrhea or vomiting. During the digestibility evaluation, dogs presented similar stool scores (of 3.77 and 3.93) and consider ideal. Switching from a chicken meal comprising diet to a BSF fat comprising diet results in reduction of the relative number of circulating phagocytic monocytes in the blood of dogs fed with the diet comprising the BSF larvae protein fraction comprising 4,32wt% BSF larvae fat (of which 40wt% of the total fatty acid content is lauric acid): 9,14% phagocytic monocytes in the group of dogs fed with the chicken meal comprising diet, and 7,06% for the test group of dogs fed with the BSF fat comprising diet. In addition, also the absolute number of phagocytic monocytes decreases upon feeding the dogs a diet comprising BSF fat: the average PI (intensity of phagocytic activity; arbitrary unit) decreases from 5,51 to 4,45 when the control group and the BSF fat diet group are compared. Moreover, the number of phagocytic granulocytes (mainly neutrophils) decreases even more dramatically, i.e. to a large extent, when dogs fed with the BSF fat are compared with the dogs fed with the chicken meal comprising diet: the average PI for the phagocytic granulocytes decreases from 6,24 to 5,57 (p < 0,05) when the control group and the BSF fat diet group are compared. These results show that when dogs are fed a diet comprising BSF larvae fat, the innate immune system is less active or less activated, or activity is decreased, when compared to the extent of the innate immune response in the dogs fed with the diet comprising chicken fat. Less monocytes are present in the circulation of the dogs fed with the BSF larvae fat, relative to the total leucocyte cell count. Less phagocytic monocytes are circulating in the dogs fed with the BSF larvae fat. Less phagocytic granulocytes (mainly leucocytes) are circulating in the dogs fed with the BSF larvae fat. These data point to a more beneficial and efficient and potent innate immune response in the dogs fed with the BSF larvae fat comprising diet, resulting in less innate immune system activity after the feeding period, likely due to less microbial burden in the intestine of the treated dogs (BSF larvae fat). In other words: in the dogs fed with the regular diet comprising animal fat (less lauric acid content), the innate immune system is activated to a higher extent, reflecting an increased trigger, e.g. microbial burden. Lowering the microbial burden by an effective innate immune response results in decrease of the extent of the innate immune response, as seen in those dogs fed with the diet comprising BSF larvae fed with increased lauric acid content compared to regular control diet. Table 19. Estimated chemical and ingredients composition of experimental diets with poultry by-product meal (PBP) and BSF larvae protein fraction (ProteinX (BSFL)).

1 BSF larvae protein, ProteinX (Protix, The Netherlands). 2 Liquid palatant produced by AFB International, São Paulo, Brazil.2 PettyMeal Dog MCassab (Brazil).3 Amount per kilogram of product: vitamin A, 2.000.000 IU; vitamin B1 (thiamine mononitrate), 500 mg; vitamin B12, 6250 mcg; vitamin B2, 1000 mg; vitamin B6 (pyridoxine hydrochloride), 500 mg; vitamin D3, 200.000 IU; vitamin E (DL- alpha tocopherol), 12.000 IU; pantothenic acid (D-calcium pantothenate), 2500 mg; folic acid, 75 mg; biotin, 6 mg; copper sulphate, 1750 mg; choline, 100 g; iron (ferrous sulfate), 20 g; iodine (sodium iodide), 375 mg; manganese (manganous oxide), 1250 mg; niacin, 3750 mg; selenium (sodium selenite), 40 mg; zinc oxide, 30g. 4 VERDILOX® (Kemin®, USA). Ingredients: Silicon Dioxide, Tetrasodium Pyrophosphate, Refined Canola Oil, Tocopherol Concentrate, Rosemary Extract, Green Tea Extract, Mint Extract, Spearmint, Refined Sunflower Oil. REFERENCES 1. Tsumbu, C.N.; Deby-Dupont, G.; Tits, M.; Angenot, L.; Frederich, M.; Kohnen, S.; Mouithys- Mickalad, A.; Serteyn, D.; Franck, T. Polyphenol content and modulatory activities of some tropical dietary plant extracts on the oxidant activities of neutrophils and myeloperoxidase. Int J Mol Sci 2012, 13, 628–650, doi:10.3390/ijms13010628. 2. Paul, A. Field border flowering strips as a source of valuable compounds, Gembloux Agro-Bio Tech University of Liège, Gembloux, Belgique, 2017. 3. Firmansyah, M.; Abduh, M.Y. Production of protein hydrolysate containing antioxidant activity from Hermetia illucens. Heliyon 2019, 5, e02005, doi:10.1016/j.heliyon.2019.e02005. 4. Zhu, D.; Huang, X.; Tu, F.; Wang, C.; Yang, F. Preparation, antioxidant activity evaluation, and identification of antioxidant peptide from black soldier fly (Hermetia illucens L.) larvae. J. Food Biochem. 2020, e13186, doi:10.1111/jfbc.13186. 5. Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.K.; Gartner, F.H.; Provenzano, M.D.; Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem.1985, 150, 76–85, doi:10.1016/0003-2697(85)90442-7. 6. Brand-Williams, W.; Cuvelier, M.E.; Berset, C. Use of a free radical method to evaluate antioxidant activity. LWT - Food Science and Technology 1995, 28, 25–30, doi:10.1016/S0023- 6438(95)80008-5. 7. Arnao, M.B.; Cano, A.; Acosta, M. The hydrophilic and lipophilic contribution to total antioxidant activity. Food Chemistry 2001, 73, 239–244, doi:10.1016/S0308-8146(00)00324-1. 8. Franck, T.; Kohnen, S.; Boudjeltia, K.Z.; Van Antwerpen, P.; Bosseloir, A.; Niesten, A.; Gach, O.; Nys, M.; Deby-Dupont, G.; Serteyn, D. A new easy method for specific measurement of active myeloperoxidase in human biological fluids and tissue extracts. Talanta 2009, 80, 723–729, doi:10.1016/j.talanta.2009.07.052. 9. Zhang, H.; Holden-Wiltse, J.; Wang, J.; Liang, H. A Strategy to Model Nonmonotonic Dose- Response Curve and Estimate IC50. PLOS ONE 2013, 8, e69301, doi:10.1371/journal.pone.0069301. 10. R Core Team R: A language and environment for statistical computing; R Foundation for Statistical Computing: Vienna, Austria, 2017. 11. Mouithys-Mickalad, A., Schmitt, E., Dalim, M., Franck, T., Tome, N.M., van Spankeren, M., Serteyn, D., Paul, A., 2020. Black Soldier Fly (Hermetia illucens) Larvae Protein Derivatives: Potential to Promote Animal Health. Animals 10, 941. https://doi.org/10.3390/ani10060941

Claims

CLAIMS 1. Insect fat composition for use as a medicament.

2. Insect fat composition for use in a method for the prophylaxis or treatment of inflammation in a subject.

3. Insect fat composition for use according to claim 1 or 2, comprising 10wt% - 60wt% saturated fatty acids comprising a chain with 6-12 carbon atoms (medium-chain fatty acids) based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, preferably 15wt% - 57wt%, more preferably 20wt% - 55wt%, such as 25wt% - 53wt%, 30wt% - 50wt% and 35wt% - 47wt% saturated fatty acids comprising a chain with 6-12 carbon atoms, and wherein preferably the saturated fatty acids comprised by the insect fat composition are selected from caproic acid, caprylic acid, capric acid and lauric acid, more preferably selected from capric acid and lauric acid, most preferably the saturated fatty acids are lauric acid.

4. Insect fat composition for use according to claim 2 or 3, wherein the prophylaxis or treatment of inflammation in the subject is in the gastrointestinal tract of the subject, preferably in any one or more of the small intestine, bowel and colon of the subject.

5. Insect fat composition for use according to any one of the claims 2-4, wherein the prophylaxis or treatment of inflammation in the subject is any one or more of: (a) prophylaxis or treatment of intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) prophylaxis or treatment of chronic or acute inflammatory intestinal disease; (c) prophylaxis or treatment of chronic enteropathy, and/or alleviation of one or more symptoms thereof; (d) prophylaxis or treatment of inflammatory bowel disease, and/or alleviation of one or more symptoms thereof; (e) prophylaxis or treatment of ulcerative colitis, and/or alleviation of one or more symptoms thereof; (f) prophylaxis or treatment of Crohn’s disease, and/or alleviation of one or more symptoms thereof; (g) prophylaxis or treatment of irritable bowel syndrome, and/or alleviation of one or more symptoms thereof; (h) prophylaxis or treatment of chronic or acute enteritis, and/or alleviation of one or more symptoms thereof; (i) prophylaxis or treatment of intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and (j) prophylaxis or treatment of low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon; (k) restoration, maintenance or improvement of the adaptive immune system of the subject; (l) restoration, maintenance or improvement of the innate immune system of the subject, therewith restoring, maintaining or improving any one or more of intestinal immunity, intestinal homeostasis and intestinal tolerance against food-related antigens, of the subject.

6. Insect fat composition for use according to any one of the claims 2-5, wherein the prophylaxis or treatment of inflammation in the subject is any one or more of: (a) inhibiting macrophage activation and/or preventing macrophage activation, and/or preventing or inhibiting macrophage-induced intestinal damage; (b) inhibiting and/or preventing reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; and (c) inhibiting activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes.

7. Insect fat composition for use according to any one of the claims 1-6, wherein the composition comprises at least 0,2% insect fat based on the total weight of the insect fat composition, preferably at least 1%, at least 2%, at least 3%, at least 5%, at least 10%, at least 20%, at least 30% or at least 35%, and/or wherein the composition comprises at most 99,9% insect fat based on the total weight of the insect fat composition, preferably at most 99%, at most 97%, at most 92%, at most 80%, at most 70%, at most 60%, or at most 55%.

8. Insect fat composition for use according to any one of the claims 1-7, wherein the composition further comprises insect protein, wherein preferably the mass ratio between the insect fat and the insect protein in the composition is selected from a mass ratio in the range 1:200 to 500:1, such as selected from 1:100 to 200:1, or from 1:10 to 10:1, or from 1:3 to 3:1, or from 1:2 to 2:1, or wherein the insect fat composition is essentially free from insect protein, defined as less than 0,2% insect protein based on the total weight of the insect fat composition.

9. Insect fat composition for use according to any one of the claims 1-8, wherein at least part of the insect fat is hydrolysed fat, preferably enzymatically hydrolysed fat, such as at least 50%, 60%, 70%, 80%, 90% or 95% hydrolysed fat.

10. Insect fat composition for use according to any one of the claims 1-9, wherein the insect fat comprises 10wt% - 60wt% lauric acid based on the total weight of the fatty acids of the insect fat comprised by the insect fat composition, preferably 15wt% - 57wt%, more preferably 20wt% - 55wt%, such as 25wt% - 53wt%, 30wt% - 50wt% and 35wt% - 47wt% lauric acid.

11. Insect fat composition for use according to any one of the claims 1-10, wherein the insect fat composition comprises glucosamine and/or glucosamine-sulphate.

12. Insect fat composition for use according to any one of the claims 1-11, wherein the insect is black soldier fly, preferably black soldier fly larvae.

13. Insect fat composition for use according to any one of the claims 1-12, wherein the insect fat composition comprises or consists of minced and heated insects, preferably minced and heated black soldier fly, more preferably minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises or consists of enzymatically hydrolyzed minced and heated insects, preferably enzymatically hydrolyzed minced and heated black soldier fly, more preferably enzymatically hydrolyzed minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises enzymatically hydrolyzed insect protein, preferably enzymatically hydrolyzed protein of black soldier fly, more preferably enzymatically hydrolyzed protein of larvae of black soldier fly.

14. Insect fat composition for use according to any one of the claims 1-12, wherein the insect fat composition comprises or consists of: (a) the water-soluble extract of minced and heated insects, preferably the water-soluble extract of minced and heated black soldier fly, more preferably the water-soluble extract of minced and heated larvae of black soldier fly; or (b) the water-soluble extract of enzymatically hydrolyzed minced and heated insects, preferably the water-soluble extract of enzymatically hydrolyzed minced and heated black soldier fly, more preferably the water-soluble extract of enzymatically hydrolyzed minced and heated larvae of black soldier fly; or (c) the enzymatically hydrolyzed water-soluble extract of minced and heated insects, preferably the enzymatically hydrolyzed water-soluble extract of minced and heated black soldier fly, more preferably the enzymatically hydrolyzed water-soluble extract of minced and heated larvae of black soldier fly.

15. Insect fat composition for use according to any one of the claims 1-12, wherein the insect fat composition comprises or consists of a fat fraction obtained from minced and heated insects, preferably minced and heated black soldier fly, more preferably minced and heated larvae of black soldier fly, or wherein the insect fat composition comprises or consists of a fat fraction obtained from enzymatically hydrolyzed minced and heated insects, preferably enzymatically hydrolyzed minced and heated black soldier fly, more preferably enzymatically hydrolyzed minced and heated larvae of black soldier fly.

16. Insect fat composition for use according to any one of the claims 1-15, wherein the insect fat composition is any one of: (a) a pharmaceutical composition, optionally comprising a pharmaceutically acceptable diluent and/or a pharmaceutically acceptable excipient; (b) a food product for human consumption or a feed product for animal consumption; (c) a food ingredient or a feed ingredient; (d) a food supplement or a feed supplement; or (e) a nutraceutical or nutraceutical ingredient.

17. Insect fat composition for use according to any one of the claims 1-16, wherein the insect fat composition is orally administered to the subject.

18. Insect fat composition for use according to any one of the claims 1-17, wherein the insect fat composition is administered to a mammal, such as a human subject, a monogastric animal and/or livestock.

19. Insect fat composition for use according to any one of the claims 2-18, wherein the insect fat composition is administered to a human subject such as a human patient, preferably a healthy human subject or a human patient suffering from any one or more of the diseases or health problems of claim 5.

20. Insect fat composition for use according to any one of the claims 2-19, wherein the insect fat composition is administered to an animal, such as a pet, for example a cat or a dog, or such as livestock for example a cow or a horse or a goat or a sheep, or monogastric livestock such as a pig, preferably a dog or a cat, more preferably a dog, and wherein the animal optionally is suffering from any one or more of the diseases or health problems of claim 5.

21. Insect fat composition for use according to any one of the claims 1-20, wherein the insect fat composition has one, two or three of the following activities: (a) inhibiting macrophage activation and/or preventing macrophage activation, and/or preventing or inhibiting macrophage-induced intestinal damage; (b) inhibiting and/or preventing reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; and (c) inhibiting activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, and/or wherein the insect fat composition comprises glucosamine and/or glucosamine-sulphate.

22. Insect fat composition for use according to any one of the claims 1-21, wherein the insect fat composition inhibits and/or prevents macrophage activation and/or prevents or inhibits macrophage- induced intestinal damage; prevents and/or inhibits reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; inhibits activated innate and/or adaptive immune system of the subject or prevents activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes, and wherein the insect fat composition comprises glucosamine.

23. Human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product, comprising the insect fat composition according to any one of the claims 3, 7-15, 21 and 22.

24. Use of the insect fat composition according to any one of the claims 3, 7-15, 21 and 22 in the preparation of a human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product.

25. Animal feed supplement, ingredient or product of claim 23 or use of the insect fat composition in the preparation of an animal feed supplement, ingredient or product according to claim 24, wherein the animal is any one or more of a pet, for example a cat or a dog, or such as livestock for example a cow or a horse or a goat or a sheep, or monogastric livestock such as a pig, preferably a dog or a cat, more preferably a dog.

26. Method for the prophylaxis or treatment of inflammation in a subject, wherein the subject is any one or more of: a human subject such as a human patient, preferably a healthy human subject or a human patient suffering from any one or more of the diseases or health problems of claim 5, and/or an animal, such as a pet, for example a cat or a dog, or such as livestock for example a cow or a horse or a goat or a sheep, or monogastric livestock such as a pig, preferably a dog or a cat, more preferably a dog, and wherein the animal optionally is suffering from any one or more of the diseases or health problems of claim 5; the method comprising orally administering to the human subject or to the animal the insect fat composition of any one of the claims 3, 7-15, 21 and 22 or the human food supplement or animal feed supplement, human food ingredient or animal feed ingredient or human food product or animal feed product of claim 23 or 25.

27. Method of claim 26, wherein the prophylaxis or treatment of inflammation in the subject is any one or more of: (a) inhibiting macrophage activation and/or preventing macrophage activation, and/or preventing or inhibiting macrophage-induced intestinal damage; (b) inhibiting and/or preventing reactive oxygen species formation by a cell such as an endothelial cell or a macrophage; and (c) inhibiting activated innate and/or adaptive immune system of the subject or preventing activation of the innate and/or adaptive immune system of the subject, such as by decreasing the relative number of phagocytic monocytes, decreasing the number of phagocytic monocytes, and/or decreasing the number of phagocytic granulocytes.

28. Method of claim 26 or 27, wherein the prophylaxis or treatment of inflammation is in the gastrointestinal tract of the subject, preferably in any one or more of the small intestine, bowel and colon of the subject.

29. Method of any one of the claims 26-28, wherein the prophylaxis or treatment of inflammation is any one or more of: (a) prophylaxis or treatment of intestinal inflammation, such as in inflammatory conditions of the small intestine, bowel and/or colon; (b) prophylaxis or treatment of chronic or acute inflammatory intestinal disease; (c) prophylaxis or treatment of chronic enteropathy, and/or alleviation of one or more symptoms thereof; (d) prophylaxis or treatment of inflammatory bowel disease, and/or alleviation of one or more symptoms thereof; (e) prophylaxis or treatment of ulcerative colitis, and/or alleviation of one or more symptoms thereof; (f) prophylaxis or treatment of any one or more of Crohn’s disease, and/or alleviation of one or more symptoms thereof; (g) prophylaxis or treatment of any one or more of irritable bowel syndrome, and/or alleviation of one or more symptoms thereof; (h) prophylaxis or treatment of chronic or acute enteritis, and/or alleviation of one or more symptoms thereof; (i) prophylaxis or treatment of intestinal damage such as induced by reactive oxygen species, activated macrophages, phagocytic monocytes and/or phagocytic granulocytes, and/or by intestinal macrophage activation, monocyte activation and/or granulocyte activation, such as in the small intestine, bowel and/or colon; and (j) prophylaxis or treatment of low-grade inflammatory disease of the intestine, such as of the small intestine, bowel and/or colon; (k) restoration, maintenance or improvement of the adaptive immune system of the subject; and/or (l) restoration, maintenance or improvement of the innate immune system of the subject, therewith restoring, maintaining or improving any one or more of the intestinal immunity, the intestinal homeostasis and the intestinal tolerance against food-related antigens, of the subject.

30. Insect fat composition for use according to any one of the claims 1-22, human food or animal feed supplement, ingredient or product of claim 23 or 25 or use of the insect fat composition in the preparation of an animal feed supplement, ingredient or product according to claim 24 or 25, or the non-therapeutic method according to any one of the claims 26-29, wherein the human subject or the animal is a healthy subject or is a subject suffering from a disease of health problem of claim 5.